ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2018

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from
to

Commission file number 001-31361

BioDelivery Sciences International, Inc.

(Exact name of registrant as specified in its charter)

Delaware

35-2089858

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

4131 ParkLake Avenue, Suite #225

Raleigh, NC

27612

(Address of principal executive offices)

(Zip Code)

Registrants telephone number:
919-582-9050

Securities registered pursuant to
Section 12(b) of the Act:

Title of each class

Name of exchange on which
registered

Common stock, par value $.001

Nasdaq Capital Market

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes ☐ No ☒

Indicate by check mark if the registrant is
not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days. Yes ☒ No ☐

Indicate by check mark whether the
registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the
registrant was required to submit such files) Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is
not contained herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or
any amendment to this Form 10-K. ☐

Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company. See definition of large accelerated filer, accelerated filer
and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

☐

Accelerated filer

☒

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act). Yes ☐ No ☒

The aggregate market value of the
voting and non-voting common equity held by non-affiliates as of June 29, 2018 was approximately $113,670,574 based on the closing sale price of the companys
common stock on such date of $2.95 per share, as reported by the NASDAQ Capital Market.

As of March 14, 2019, there were
70,968,435 shares of company common stock issued and 70,952,944 shares of company common stock outstanding.

Unless we have indicated otherwise, or the context otherwise requires, references in this Report to BDSI, the
Company, we, us and our or similar terms refer to BioDelivery Sciences International, Inc., a Delaware corporation and its consolidated subsidiaries.

We own various trademark registrations and applications, and unregistered trademarks, including BioDelivery Sciences International, Inc., BEMA, BELBUCA,
BUNAVAIL, ONSOLIS and our corporate logo. All other trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective holders. Solely for convenience, the trademarks and trade names in
this prospectus may be referred to without the ® and  symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest
extent under applicable law, their rights thereto. We do not intend to use or display other companies trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

This Report and the documents we have filed with the Securities and Exchange Commission (which we refer to herein as the SEC) that are
incorporated by reference herein contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act) and Section 21E of the Securities Exchange Act of 1934, as
amended (the Exchange Act), that involve significant risks and uncertainties. Any statements contained, or incorporated by reference, in this Report that are not statements of historical fact may be forward-looking statements. When we
use the words anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will and other
similar terms and phrases, including references to assumptions, we are identifying forward-looking statements. Forward-looking statements involve risks and uncertainties which may cause our actual results, performance or achievements to be
materially different from those expressed or implied by forward-looking statements.

A variety of factors, some of which are outside our
control, may cause our operating results to fluctuate significantly. They include:

the domestic and international regulatory process and related laws, rules and regulations governing our
technologies and our approved and proposed products and formulations, including: (i) the timing, status and results of our or our commercial partners filings with the U.S. Food and Drug Administration and its foreign equivalents,
(ii) the timing, status and results of non-clinical work and clinical studies, including regulatory review thereof and (ii) the heavily regulated industry in which we operate our business generally;



our ability to enter into strategic partnerships for the development, commercialization, manufacturing and
distribution of our products and product candidates;



our ability, or the ability of our commercial partners, to actually develop, commercialize, manufacture or
distribute our products and product candidates, including for BELBUCA®and
BUNAVAIL®, which we are self-commercializing;

our ability to finance our operations on acceptable terms, either through the raising of capital, the incurrence
of convertible or other indebtedness or through strategic financing or commercialization partnerships;

the protection and control afforded by our patents or other intellectual property, and any interest patents or
other intellectual property that we license, of our or our partners ability to enforce our rights under such owned or licensed patents or other intellectual property;

the ability of our manufacturing partners to supply us or our commercial partners with clinical or commercial
supplies of our products in a safe, timely and regulatory compliant manner and the ability of such partners to address any regulatory issues that have arisen or may in the future arise;



our ability to retain members of our management team and our employees; and



competition existing today or that will likely arise in the future.

The foregoing does not represent an exhaustive list of risks that may impact the forward-looking statements used herein or in the documents
incorporated by reference herein. Please see Risk Factors for additional risks which could adversely impact our business and financial performance and related forward-looking statements.

Moreover, new risks regularly emerge and it is not possible for our management to predict all risks, nor can we assess the impact of all risks
on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this Report are based on information

available to us on the date hereof. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained
throughout this Report and the documents we have filed with the SEC.

PART I

ITEM 1.

Description of Business

Overview

BioDelivery Sciences
International, Inc., (NASDAQ: BDSI), is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. At our core is a shared passion to make every day a little bit easier for patients and help
improve the lives of people living with chronic conditions so they can experience life to the fullest. We have built a portfolio of products utilizing our novel and proprietary BioErodible MucoAdhesive (BEMA) drug-delivery technology, and other
drug-delivery technologies to develop and commercialize new applications of proven therapies aimed at addressing important unmet medical needs. We now commercialize in the United States using our own sales force while working in partnership with
third parties to commercialize our products outside the United States. We have made it a point to deeply understand the patients journeys and are driven by recognizing the full impact of their condition so we can deliver life-altering
solutions.

Our Strategy

Our
strategy is evolving with the establishment of our commercial footprint in the management of chronic pain; we seek to build a well-balanced, diversified, high-growth specialty pharmaceutical company. Through our industry-leading commercialization
infrastructure, BDSI is executing the commercialization of our existing products. As part of our corporate growth strategy, we have licensed, and will continue to explore opportunities to acquire or license additional products that meet the needs of
patients living with debilitating chronic conditions and treated primarily by therapeutic specialists. As we gain access to these drugs and technologies, we will employ our commercialization experience to bring them to the marketplace. With a strong
commitment to patient access and a focused business-development approach for transformative acquisitions or licensing opportunities, we will leverage our experience and apply it to developing new partnerships that enable us to commercialize novel
products that can change the lives of people suffering from debilitating chronic conditions.

Our historical clinical and regulatory
development strategy has focused primarily on our ability to use the U.S. Food and Drug Administration, or the FDAs, 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved, active
therapeutics incorporated into our drug-delivery technology. Because the 505(b)(2) approval process is designed to address new formulations of previously approved drugs, we believe it has the potential to be more cost efficient and expeditious, with
less regulatory approval risk than other FDA-approval approaches.

An overview of our products and
their therapeutic areas is set out below.

Our Company

We are a publicly listed company. Our common stock is listed on The Nasdaq Capital Market under the symbol BDSI. We were
incorporated in the state of Indiana in 1997 and reincorporated as a Delaware-based corporation in 2002.

Chronic Pain

Chronic pain is often defined as any pain lasting more than 12 weeks. Whereas acute pain is a normal sensation that alerts us to possible
injury, chronic pain persists  often for months or even longer. Chronic pain may arise from an initial injury, such as back sprain, or there may be an ongoing cause, such as an illness. Sometimes there is no clear cause. According to results
from the National Health Interview Survey there are over 25 million American adults experiencing daily chronic pain, with over 10 million of these experiencing severe pain.

Treatment Landscape for Chronic Pain

The pain market is well established, with many pharmaceutical companies marketing new formulations of existing molecules, as well as generic
versions of older, non-patent protected products. In 2018, according to data from Symphony Health, the market for extended release opioids in the U.S. totaled nearly $4.7 billion in annual sales with
13.8 million prescriptions dispensed. However, prescription volume of long acting opioids declined over 13% in 2018 compared to 2017 amidst wide-ranging efforts to curb misuse, abuse and over use of opioids in order to address the current
opioid crisis.

A number of products are competitors to BELBUCA, including BuTrans®, a transdermal formulation of buprenorphine which also has a generic equivalent available. Other competitors are U.S. Drug Enforcement Agency, or the DEA, Schedule II opioids such as OxyContin® from Purdue Pharma L.P., or Purdue, and Nucynta® ER from Depomed, Inc./ Collegium Pharmaceutical, Inc., or Collegium, and multiple generic
Schedule II oral opioid formulations, such as morphine, hydrocodone, and fentanyl containing products. Approximately 75% of the retail/mail order prescriptions for long-acting opioids are dispensed as a generic product.

Some manufacturers have also formulated Schedule II opioids in abuse deterrent formulations (or ADF). Embeda® from Pfizer Inc., Hysingla® ER from Purdue, Zohydro® ER from Pernix Therapeutics
Holdings Inc., MorphaBond ER from Daiichi Sankyo Company, Xtampza® ER from Collegium and Arymo ER from Egalet Corporation, as well as new formulations of OxyContin®, use a variety of technologies that aim to minimize the potential for abuse and misuse. Select abuse deterrent products are playing an increasingly important role in treating patients with
chronic pain, while others are experiencing slower than anticipated adoption, leading some manufacturers to reconsider launching an ADF product into the current market.

Other manufacturers are working to develop alternative buprenorphine formulations for treatment of acute or chronic pain. In July 2018, the
FDA issued a complete response letter for sublingual buprenorphine spray for the treatment of moderate-to-severe acute pain being developed by Insys Therapeutics, Inc.,
or Insys. Relmada Therapeutics, Inc., or Relmada, is developing an oral, enteric-coated buprenorphine (BuTab) for chronic pain and opioid dependence indications. In December 2015, Relmada announced topline results of a
proof-of-concept pharmacokinetic study in healthy volunteers which showed that the product can be delivered at therapeutic levels through the gastrointestinal route,
though the bioavailability remained low. No further development is noted.

In addition to product competition, there are other factors
that have impacted the market for pain products in general. Opioids continue to garner increased scrutiny based on the growing problem of prescription drug abuse and addiction. There have been an increasing number of actions the FDA and other
government agencies have taken to address the problem of opioid abuse and addiction.



In July 2012 the FDA approved a class-wide REMS program for the extended release and long-acting opioids. The
class-wide REMS program consists of a REMS-compliant educational program offered by an accredited provider of continuing medical education, patient counseling materials and a medication guide. BELBUCA falls within the existing class-wide REMS
program.



In August 2014, the DEA published in the Federal Register its final ruling moving hydrocodone combination
products (such as Vicodin, Lortab, Norco, etc.) from Schedule III to the more-restrictive Schedule II, as recommended by the Assistant Secretary for Health of HHS and as supported by the DEAs own evaluation of relevant data. As a result of the
ruling, hydrocodone containing products are now classified in the same category (Schedule II) as morphine and oxycodone.



In March 2016, HHSs Centers for Disease Control and Prevention ,or the CDC, issued guidelines for
prescribing opioids for chronic pain. CDC developed and published the CDC Guideline for Prescribing Opioids for Chronic Pain to provide recommendations for the prescribing of opioid pain medication for patients 18 and older
in primary care settings. Recommendations focus on the use of opioids in treating chronic pain. The guidelines advocate use of nonpharmacologic therapy and nonopioid pharmacologic therapy as first line therapy for chronic pain. When starting opioid
therapy for chronic pain, clinicians are advised to prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids and to prescribe the lowest effective dosage. Clinicians were directed to reassess patients
medication needs when considering doses of 50 morphine milligram equivalents (MME) or greater and should avoid increasing total daily doses to 90 MME or greater. The availability of the guidelines has resulted in confusion and cautiousness,
particularly among primary care physicians, and a reduced willingness to treat patients for chronic pain. A sharp reduction in prescriptions among Primary Care Physicians and an increase among Pain Specialists are evidence of the shift in
prescribing and in the dynamics of pain treatment.



In June 2017, the FDA requested that Endo Pharmaceuticals, Inc. remove Opana ER (oxymorphone), from the market
based on concerns that the benefits of the drug may no longer outweigh its risks. This is the first time the agency has taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse. The
FDAs decision was based on a review of all available post-marketing data, which demonstrated a significant shift in the route of abuse of Opana ER from nasal to injection following the products reformulation. It is anticipated that other
steps will be taken to further limit the use, duration dose or availability of certain opioids  particularly those with Schedule II designation.



In September 2017, the CDC removed the MME conversion factors for buprenorphine from its online oral MME data
file. And in 2018 it included a statement in the MME data file noting Buprenorphine doses are not expected to be associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids.



In December 2018 the Health and Human Services Pain Management Best Practices Inter-Agency Task Force issued a
Draft Report on Pain Management Best Practices: Updates, Gaps, Inconsistencies, and Recommendations. The report identifies that one of the barriers in pain management best practices is lack of coverage and reimbursement and understanding of
proper usage, limit access to buprenorphine treatment for chronic pain. The draft report then makes

recommendations that third-party payors should provide coverage and reimbursement for buprenorphine treatment approaches.



For 2019, The Centers for Medicare and Medicaid Services adopted a soft edit of 90 morphine milligram equivalents
per day for patients, aligning with the 2016 CDC Guideline recommendation.

Opioid Dependence

Opioid dependence is a medical diagnosis that is characterized by the inability of an individual to stop using opioids, either prescription
opioids such as morphine, hydrocodone and oxycodone, or illicit opioids such as heroin, even when it is in the best interest of the individual to do so. Opioid dependence is a complex medical condition that often requires long-term treatment and
care. The treatment of opioid dependence is important to reduce both the associated health and social consequences and to improve the well-being and social functioning of people affected. According to the 2016 National Survey on Drug Use and Health,
2.1 million people in the United States had an opioid use disorder.

Treatment Landscape for Opioid Dependence

Treatment with buprenorphine reduces the typical cravings and withdrawal symptoms associated with coming off opioid prescription painkillers
and heroin. This allows the individual suffering from an addiction to opioids along with counseling and support  to work toward recovery. On average, treatment lasts a couple months, reflecting relatively high dropout rates, but a
significant number of people remain on buprenorphine treatment chronically, with nearly one-quarter of patients still on therapy after nine months.

The total U.S. market for buprenorphine containing products for opioid dependence exceeded $3.5 billion in 2018, an increase of 13% over
2017 according to Symphony Health. The market has grown steadily as a result of the rapidly escalating problem of prescription opioid misuse and abuse, a recent resurgence of heroin use, the growing number of physicians treating opioid dependence,
and the inclusion of addiction treatment as an essential benefit in the Affordable Care Act.

The buprenorphine products currently
marketed for the treatment of opioid dependence include Suboxone®, a sublingual film formulation of buprenorphine and naloxone,
Zubsolv®,a sublingual tablet of buprenorphine and naloxone, and multiple generic formulations of both buprenorphine and
buprenorphine/naloxone tablets. Suboxone® film, the market leader with approximately 65% of total buprenorphine/naloxone prescriptions, achieved sales of over $2 billion in the U.S. in
2018 per Symphony Health data.

While limited information is available, a sublingual spray formulation of buprenorphine/naloxone is in
development from Insys and is currently in Phase I development studies.

Breakthrough Cancer Pain

According to the National Cancer Institute, there are approximately 14.5 million people in the United States diagnosed with or living with
cancer. Cancer patients often suffer from a variety of symptoms including pain as a result of their cancer or cancer treatment. Pain is a widely prevalent symptom in cancer patients, and an estimated 50% to 90% of those with cancer also suffer from
what is referred to as breakthrough cancer pain (or BTCP). BTCP episodes have a rapid onset that peaks in three to five minutes and can last several minutes to an hour, and usually occur several times per day.

Treatment Landscape for Breakthrough Cancer Pain

BTCP can be difficult to treat due to its severity, rapid onset and the often unpredictable nature. Physicians typically treat BTCP with a
variety of short-acting opioid medications, including morphine and fentanyl. The breakthrough cancer pain market has become increasingly crowded and more competitive in recent years.

A number of formulations of fentanyl are available employing a variety of drug delivery technologies, all which provide rapid onset and
relatively short duration of action to address the fast onset and short duration of BTCP. The principal competitors had traditionally been Actiq® (fentanyl citrate) oral transmucosal lozenge
and Fentora® (fentanyl buccal tablet). In recent years, newer product entries, particularly Subsys® (fentanyl sublingual spray) from
Insys, have gained significant market share. Additional

competitors include the sublingual tablet formulation of fentanyl (Abstral®) and a nasal spray formulation of fentanyl (Lazanda®). In addition, multiple generic formulations of Actiq® are currently available. All of the fentanyl based products are subject to the
Transmucosal Immediate Release Fentanyl (TIRF) REMS Access Program, which was designed to ensure informed risk-benefit decisions before initiating treatment with a transmucosal fentanyl product, and while patients are on treatment, to ensure
appropriate use.

Despite the increased number of fentanyl-based products approved for the treatment of BTCP, the market has contracted
significantly since peaking at almost 120,000 prescriptions in 2014, to less than 30,000 prescriptions in 2018, according to Symphony Health in January 2019.

The BEMA Drug Delivery Technology

Our BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application
to the buccal mucosa (the lining inside the cheek). BEMA films have the capability to deliver a rapid, reliable dose of drug across the buccal mucosa for time-critical conditions such as breakthrough cancer pain or in situations where
gastrointestinal absorption of an oral drug is not practical or reliable, or in facilitating the administration of drugs with poor oral bioavailability.

We believe that the BEMA technology permits control of two critical factors allowing for better dose-to-dose reproducibility: (i) the contact area for mucosal drug delivery, and (ii) the time the drug is in contact with that area, known as residence time. In contrast to competing transmucosal
delivery systems such as 1) lozenges, 2) buccal tablets and 3) matrix-based delivery systems placed under the tongue or sprayed in the oral cavity, BEMA products are designed to:



adhere to buccal mucosa in seconds and dissolve in minutes;



permit absorption without patients being required to move the product around in the mouth for absorption, thus
avoiding patient intervariability;



allow for unidirectional drug flow into the mucosa as a result of a backing layer on the side of the BEMA film
facing into the patients mouth



provide a reproducible delivery rate, not susceptible to varying or intermittent contact with oral membranes; and



dissolve completely, leaving no residual product or waste and avoiding patient removal, and the possibility for
diversion or disposal of partially used product.

We currently own the BEMA drug delivery technology.

Sales and Market Overview of our Products

The following table summarizes the status of our marketed products and our current product candidates:

Product/Formulation

Indication

Development Status

Commercial Status

BELBUCA

Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are
inadequate

Approval: U.S. in October 2015; Canada in June 2017

BDSI markets in U.S.

BUNAVAIL

Treatment of opioid dependence

Approval: U.S. in June 2014

BDSI markets in U.S.

ONSOLIS/BREAKYL /PAINKYL (U.S./E.U./Taiwan trade names, respectively)

Breakthrough cancer pain in opioid tolerant patients

Approval: U.S. in July 2009; Canada in May 2010; E.U. in October 2010 and Taiwan in July 2013

Partnership with Mylan in all regions except North America, Taiwan and South Korea; partnership with TTY in Taiwan; exploring options for U.S. commercialization

Buprenorphine ER Injection

Opioid dependence and chronic pain

IND submitted December 2016

Not yet approved for marketing

The pharmaceutical industry and the therapeutic areas in which we compete are highly competitive and subject
to rapid and substantial regulatory and technological changes. Developments by others may render our BEMA technology, our marketed products

and any proposed drug products and formulations under development noncompetitive or obsolete, or we may be unable to keep pace with technological developments or other market factors.
Technological competition in the industry from pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is intense and is expected to increase.

There have been a growing number of companies developing products utilizing various thin film drug delivery technologies. While numerous over-the-counter pharmaceutical products have been brought to market in thin film formulations, few containing prescription products have been introduced in the U.S. Among the
products to receive FDA approval are BELBUCA, BUNAVAIL, and ONSOLI (BDSI), Suboxone film (Indivior PLC) and Zuplenz (Midatech Pharma PLC). Companies in the development and manufacture of thin film technologies include LTS, Lohmann Therapie-Systeme
AG, ARx, LLC and Aquestive Therapeutics, Inc. (formerly known as MonoSol Rx LLC, or Aquestive). In addition, a number of companies are developing improved versions of existing products using oral dissolving, nasal spray, aerosol, sustained release
injection and other drug delivery technologies. We believe that potential competitors are seeking to develop and commercialize technologies for buccal, sublingual or mucosal delivery of various therapeutics or groups of therapeutics. While our
information concerning these competitors and their development strategy is limited, we believe our technology can be differentiated because the BEMA technology provides for a rapid and consistent delivery, high drug bioavailability and convenient
use based on how the BEMA technology adheres to the buccal membrane and dissolves. Our clinical trials across a number of BEMA products have demonstrated that the technology is an effective means of drug delivery that is well tolerated and offers
convenience to patients.

In 2016, we converted our contract sales force into one employed by us to provide greater flexibility to
accommodate future strategic options. Using our own sales force provides us with significantly more control over commercialization efforts and makes us capable of selling our own products in specialty pharmaceutical markets while leaving promotional
responsibilities for large primary care audiences and ex-U.S. markets with partners. In 2017 we expanded the sales force territories and further expanded in January and September 2018 to support the
commercialization efforts. BELBUCA and BUNAVAIL are currently supported by a field force of approximately 113 sales representatives, thirteen regional sales managers and two area directors.

BELBUCA(buprenorphine buccal film), CIII, for Chronic Pain

BELBUCA was approved by the FDA on October 26, 2015 for use in patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative options are inadequate. BELBUCA is differentiated from other opioids and has the potential to address some
of the most critical issues facing healthcare providers treating chronic pain with prescription opioids  abuse, misuse, addiction and the risk of overdose. As a Schedule III opioid, buprenorphine has less abuse and addiction potential compared
to Schedule II opioids such as oxycodone, hydrocodone and morphine. Compared to currently marketed products and products under development, we believe that BELBUCA is differentiated based on the following features:



Strong and durable efficacy in both opioid naïve and opioid experienced patients;



Schedule III designation by DEA, which indicates less abuse and addiction potential compared Schedule II opioids,
which include oxycodone, hydrocodone and morphine;



Published studies have shown that buprenorphines physiologic effects reach a plateau, and this ceiling
effect may result in a lower risk of overdose related respiratory depression;



Favorable tolerability with a low incidence of constipation and low discontinuation rate;



Flexible dosing options with 7 available strengths



Buccal administration to optimize buprenorphine delivery.



As prescribers are increasingly being guided to monitor total daily morphine milligram equivalents for their
patients taking opioids, the CDC has indicated that buprenorphine doses are not expected to be associated with overdose risk in the same dose-dependent manner as doses for full agonist opioids.

Because of the safety, tolerability and efficacy benefits associated with buprenorphine, we believe that BELBUCA is a clear first-line
long-acting opioid for patients with pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatments, such as non-opioids or immediate release opioids, are inadequate.

In January 2012, we announced the signing of
a worldwide licensing and development agreement for BELBUCA (with Endo, which we refer to herein as the Endo Agreement), under which we granted to Endo the exclusive, worldwide rights to develop and commercialize BELBUCA for the treatment of chronic
pain. On October 26, 2015, we and Endo announced the FDA approval of BELBUCA. BELBUCA became commercially available from Endo in February 2016. Endo reported favorable early healthcare provider feedback and positive patient experience with
regards to efficacy, tolerability and the buccal film formulation.

On December 8, 2016, we announced an agreement with Endo terminating Endos
licensing of rights for BELBUCA. This announcement followed a strategic decision made by Endo to discontinue commercial efforts of its branded pain business. Pursuant to the Endo Termination Agreement, we reacquired BELBUCA, which transition became
effective on January 6, 2017.

Our sales force is focused on current BELBUCA prescribers and clinicians we believe have the greatest opportunity to be adopters of BELBUCA,
such as high prescribers of long-acting opioids, BuTrans and/or HCPs who prescribe short acting opioids around-the-clock for patients with chronic pain. In parallel, we
are heavily focused on increasing market access for BELBUCA. As of January 2019, BELBUCA had formulary coverage for more than 88% of commercial lives. Approval rates within the commercial channel remained favorable throughout 2018 at about 80%. In
2018 BELBUCA attained preferred access for over 7.5 million Medicare lives within Humana. BELBUCA continues to have favorable approval rates within other Medicare plans, as we pursue improved access to BELBUCA for the senior population
suffering with chronic pain.

In 2018, we also made significant improvements in patient access for BELBUCA, resulting in over
100 million commercial lives having preferred access to BELBUCA. BELBUCA total prescriptions in 2018, according to Symphony Health, totaled over 160,000, an increase of 91% over 2017. BELBUCA share of total buprenorphine prescriptions (products
for the treatment of chronic pain only) for 2018 totaled 23% versus 12% for the prior year, ending 2018 with a 31% share in December. In addition to a steady increase in BELBUCA prescription volume through 2018, there was also an increase in the use
of higher doses of BELBUCA as healthcare providers continued to gain comfort titrating patients to higher optimal doses. In 2018, 36% of BELBUCA prescriptions were for doses of 450 mcg or greater, compared to 33% in 2017. Therefore, the weighted
average price per prescription continued to increase in 2018.

Canada

On July 12, 2017 we announced the signing of a licensing agreement under which we granted the exclusive rights to distribute, market and
sell BELBUCA in Canada to Purdue Pharma (Canada). Under terms of the agreement, we were to receive upfront and potential milestones of up to $4.5 million CAD as well as royalties on net sales from Purdue. In January 2018, BELBUCA became
commercially available in Canada. In June 2018, Health Canada requested pharmaceutical manufacturers discontinue actively marketing opioids. On January 8, 2019, Purdue terminated the license agreement with us, citing market conditions in
Canada. The termination was effective as of March 11, 2019. Given these developments, we are taking steps to discontinue the sale of BELBUCA in Canada.

Other Regions

For
commercialization of BELBUCA in other regions outside the U.S. and Canada, we are currently seeking partners with commercial reach and experience in pain management in their respective regions.

In June 2014, BUNAVAIL was approved by the FDA for the maintenance treatment of opioid dependence as part of a complete treatment plan to
include counseling and psychosocial support, and on November 3, 2014, we announced the availability of BUNAVAIL in the U.S. It was initially supported by a 60-person field sales force and a full marketing
effort targeting the nearly 5,000 physicians who are responsible for approximately ninety percent of prescriptions for buprenorphine products for the treatment of opioid dependence. The launch was also supported by a complete marketing effort aimed
at increasing product awareness including advertising and promotion, direct mail and email, a speakers program and a number of other initiatives to minimize patient access issues, including robust contracting with various payers.

In May 2017 we announced that the FDA had approved a Supplemental New Drug Application (known as an sNDA) for BUNAVAIL revising the BUNAVAIL
indication to include induction, or the initial process undertaken when a patient is transitioned from the abused opioid responsible for their addiction. BUNAVAIL contains the partial opioid agonist buprenorphine, which binds to the same receptors
as opiate drugs but has a higher affinity. Naloone, an opioid antagonist, is included as an abuse deterrent.

BUNAVAIL provides an
alternative treatment utilizing the advanced BEMA drug delivery technology. BUNAVAIL provides the highest bioavailability of any buprenorphine-containing product for opioid dependence, allowing for effective treatment with half the dose compared to
Suboxone® film. Additionally, BUNAVAIL offers convenient and discrete buccal administration and avoids the need for patients to avoid talking and swallowing during administration. BUNAVAIL has
demonstrated an excellent tolerability

profile with a 68% reduction at the end of 12 weeks in the incidence of constipation in a Phase 3 trial in patients converted from
Suboxone® sublingual tablets or film to BUNAVAIL.

As noted above, in January
2017 with the reacquisition of BELBUCA, we transitioned our primary commercial emphasis from BUNAVAIL to BELBUCA. Our BUNAVAIL efforts are now focused on current BUNAVAILprescribers and on
increasing prescriptions related to current, upcoming and future managed care contracts where BUNAVAIL is placed in a favorable formulary position. We believe that in this structure, and with the increases in our sales force size, we can maintain an
appropriate share of voice.

ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain

In July 2009, ONSOLIS was approved for the management of breakthrough pain in cancer patients 18 years of age and older who are already
receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. ONSOLIS is indicated for the treatment of breakthrough pain (i.e., pain that breaks through the effects of other medications being used to
control persistent pain) in opioid tolerant patients with cancer, or BTCP. ONSOLISprovides significant reduction in pain for patients suffering from BTCP in a convenient formulation with a range
of doses to allow patients to titrate to an adequate level of pain control.

North America

In September 2007, we secured an exclusive licensing and supply agreement with Mylan Pharmaceuticals, Inc, for the commercialization rights for
ONSOLIS, under which Mylan was responsible for the sales, marketing and distribution of ONSOLIS in the U.S., Canada and Mexico. ONSOLIS was commercially launched in the United States in October 2009. ONSOLIS was approved by the Canadian regulatory
authorities in May 2010 and was the first product approved in Canada for the management of breakthrough cancer pain. Mylan Valeant Pharma Canada Inc., a joint venture between Mylan and Valeant Canada Limited was responsible for promotion of ONSOLIS
in Canada. ONSOLIS was launched in Canada in the third quarter of 2011

On January 27, 2015, we announced that we had entered into the
Assignment Agreement with Mylan to return to us the marketing authorizations for ONSOLIS for the U.S. and the right to seek marketing authorizations for ONSOLIS in Canada and Mexico. On May 11, 2016, we announced the signing of a licensing
agreement under which we granted the exclusive rights to develop and commercialize ONSOLIS in the U.S. to Collegium. On December 8, 2017, we received a 90-day notice from Collegium regarding the return of
the U.S. rights to ONSOLIS from Collegium; which transition went into effect on March 8, 2018.

Although we have generated
licensing-related and other revenue to date from the commercial sales of ONSOLIS, BREAKYL and PAINKYL, such revenue has been limited to date due to multiple factors, including a highly restrictive Risk Evaluation and Mitigation Strategy, or REMS,
imposed by the FDA.

On December 29, 2011, the FDA approved a class-wide REMS program covering all transmucosal fentanyl
products under a single risk management program. The program, which is referred to as the Transmucosal Immediate Release Fentanyl, or TIRF, REMS Access Program, was designed to ensure informed risk-benefit decisions before initiating treatment with
a transmucosal fentanyl product, and while patients are on treatment, to ensure appropriate use. The TIRF REMS program was implemented in March 2012. The approved program covers all marketed transmucosal fentanyl products under a single program
which will enhance patient safety while limiting the potential administrative burden on prescribers and their patients. Having one common program also ended the disparity in prescribing requirements for ONSOLIS compared to similar products and
provided ONSOLIS with the opportunity for retail and inpatient facility access.

We are assessing options for U.S. commercialization of
ONSOLIS, including the use of our current sales force, or potentially out-licensing the product. Regulatory documentation to qualify an alternate manufacturer was submitted to FDA in June 2018. In October
2018, BDSI received notification of FDAs approval of Tapemark as the new ONSOLIS manufacturer.

Europe

We initially granted commercialization and distribution rights for ONSOLIS on a worldwide basis (except in South Korea and Taiwan) to Meda AB,
a leading international specialty pharmaceutical company based in Sweden that was subsequently acquired by Mylan N.V. (which we refer to herein as Mylan). Mylan secured access to additional markets through acquisition of European businesses from
Valeant Pharmaceuticals International. Since September 2006, we secured an exclusive licensing and supply agreement with Mylan for the commercialization rights for BEMA Fentanyl in the European Union, or E.U., which is being marketed in Europe under
the trade name BREAKYL. BREAKYL received marketing authorization from the European regulatory authorities in October 2010 and has been launched in over thirteen European countries including Germany, France and the U.K. . The sales royalties to be
received by us will be the same for all Mylan territories as agreed to for Europe. In Europe, multiple formulations of fentanyl have been approved and launched for the treatment of BTCP, including ONSOLIS/BREAKYL, as well as Abstral®, Effentora®, and Instanyl® (intranasal fentanyl spray).

In 2010, we licensed commercialization rights for ONSOLIS for South Korea and TTY Biopharm Co., Ltd., or TTY, for Taiwan where the product is
marketed as PAINKYL.

In May 2010, we announced a commercial partnership with Kunwha Pharmaceutical Co. Ltd. for the exclusive rights to
develop and commercialize ONSOLIS in the Republic of Korea known as the Kunwha License Agreement. Those rights were subsequently returned to us due to changes in the market dynamics and the Kunwha License Agreement was terminated on August 31,
2015.

In October 2010, a commercial partnership with TTY was announced, providing commercialization rights for Taiwan. This agreement
resulted in potential milestone payments of up to $1.3 million (including an upfront payment of $0.3 million) along with royalties based on sales. Milestones were achieved in November 2011 and July 2013 relating to the NDA submission and
regulatory approval, respectively, in Taiwan, where the product is marketed under the brand name PAINKYL. TTY launched PAINKYL in Taiwan in 2015.

Buprenorphine Extended Release Injection Product Candidate

In 2014, we entered into an exclusive agreement with Evonik Corporation (or Evonik) to develop and commercialize a proprietary, injectable
microparticle formulation of buprenorphine potentially capable of providing 30 days of continuous therapy following a single subcutaneous injection. Microsphere-based, long acting buprenorphine injection has the ability to change the treatment
paradigm in opioid dependence. Such a dosage form has the opportunity to improve therapy compliance through continuous delivery of drug for up to 30 days and addresses challenges regarding patient adherence to long-term buprenorphine treatment,
which is critical to successfully manage opioid dependence and the potential for misuse and diversion.

As part of the agreement, we had
the right to license the product(s) following the attainment of Phase 1 ready formulations. At that point, Evonik could receive downstream payments for milestones related to regulatory filings and subsequent NDA approvals as well as product
royalties. Evonik has the exclusive rights to develop the formulation and manufacture the product(s).

In 2015, we completed initial
development work and preclinical studies which have resulted in the identification of a formulation we believe is capable of providing 30 days of continuous buprenorphine treatment. During a pre-IND meeting
with the FDA in November 2015, the FDA requested an additional study to assess the fate of the polymers used in the formulation. In 2016, we completed this study as well as additional preclinical work and other activities to support a planned Phase
1 clinical study. We submitted an Investigational New Drug application (or IND) for this product candidate to the FDA in December 2016 and have completed steps necessary to initiate a Phase 1 clinical study. Subsequently, the agreement has
terminated and the options granted therein have expired. We continue to evaluate whether or not to advance this particular program.

In
terms of potential competition for Buprenorphine ER Injection, there are two products that have recently become commercially available and one that has received tentative approval from the FDA.

In May 2016, Probuphine®, a subcutaneous implantable rod containing buprenorphine
from Braeburn Pharmaceuticals, Inc., or Braeburn was approved. In December 2012, Titan Pharmaceuticals, or Titan, announced the signing of a license agreement with Braeburn. In May 2018 Braeburn returned the rights to Titan and Titan has
subsequently initiated the commercialization of Probuphine® through internal efforts.

In November 2017, Sublocade, a buprenorphine extended release injection for
subcutaneous use from Indivior was approved. Sublocade is the first once-monthly injectable buprenorphine formulation and was approved for the treatment of moderate to severe opioid use
disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product followed by dose adjustment for a minimum of seven days. Indivior announced commercial availability of Sublocade March 1, 2018.

In December 2018, Brixadi, an extended-release buprenorphine injection from Braeburn was granted tentative approval by the FDA. Brixadi can be dosed weekly or
monthly depending upon the dose administered.

Additional Overview Information

From our inception through December 31, 2018, we have recorded accumulated losses totaling approximately $351.3 million. Our
historical operating losses have resulted principally from our research and development activities, including clinical trial activities for our product candidates, sales, and general and administrative expenses. Ultimately, if we secure additional
approvals from the FDA and other regulatory bodies throughout the world for our product candidates or other products or product candidates that we may acquire or in-license in the future, our goal will be to
augment our current sources of revenue and, as applicable, deferred revenue (principally licensing fees), with sales of such products or royalties from such sales, on which we may pay royalties or other fees to our licensors and/or third-party
collaborators as applicable.

We intend to finance our commercialization and distribution efforts and our working capital
needs primarily through:



commercializing our approved products such as BELBUCA and BUNAVAIL;



partnering with other pharmaceutical companies , to assist in the distribution and commercialization of our
products, for which we could expect to receive an upfront payment, milestones and/or royalty payments; and



securing proceeds from public and private financings and other potential strategic transactions.

We have based our estimates of market size estimates, peak annual sales projections, development costs and similar
matters described below and elsewhere in this Report on our market research, third party reports and publicly available information which we consider reliable. However, readers are advised that the projected dates for filing and approval of our INDs
or NDAs with the FDA or other regulatory authorities, our estimates of development costs, our projected sales and similar metrics regarding BELBUCA, BUNAVAIL, ONSOLIS, Buprenorphine Extended Release Injection or any other product candidates
discussed below and elsewhere in this Report are merely estimates and subject to many factors, many of which may be beyond our control, which will likely cause us to revise such estimates. Readers are also advised that our projected sales figures do
not consider the royalties and other payments we will need to make to our licensors and strategic partners. Our estimates are based upon our managements reasonable judgments given the information available and their previous experiences,
although such estimates may not prove to be accurate.

Key Commercial Licensing Agreements

Endo Licensing Agreement for BELBUCA and its Termination

On January 6, 2012, we entered into a world-wide licensing and development agreement for BELBUCA with Endo, which was subsequently
terminated. Under terms of the agreement, Endo was responsible for the manufacturing, distribution, marketing and sales of BELBUCAon a worldwide basis. The agreement called for Endo to
commercialize BELBUCA outside the U.S. through its own efforts or through regional partnerships.

The FDAs approval of BELBUCA
triggered a milestone payment to us from Endo of $50 million, of which $20 million had been deferred for future revenue recognition as the payment was contingently refundable in the event a generic product was commercially launched during
the patent extension period. As mentioned below, the obligations of this milestone were extinguished upon the closing of the termination agreement. This $20 million was recognized as revenue in January 2017.

On December 8, 2016 we announced we had entered into a termination agreement with Endo (the Endo Termination Agreement)
terminating Endos licensing of rights for BELBUCA, which transaction closed on January 6, 2017. As a result of the agreement, the world-wide rights to BELBUCA were transferred back to us.

At the closing of the transactions by the Endo Termination Agreement we purchased from Endo the following assets (the Assets): (i)
BELBUCA product inventory and work-in-progress, (ii) material manufacturing contracts related to BELBUCA, (iii) BELBUCA-related domain names and trademarks
(including the BELBUCA trademark), (iv) BELBUCA-related manufacturing equipment, and (v) all pre-approval regulatory submissions, including any INDs and NDAs, regulatory approvals and post-approval
regulatory submissions concerning BELBUCA. The purchase price for the Assets (which we refer to as the Asset Purchase Price) was equal to the sum of: (i) the aggregate book value of the portion of the transferred product inventory forecasted to
be used or sold by the Company, (ii) the aggregate book value of work-in-progress inventory, and (iii) the assumption of any assumed liabilities. Upon Closing,
we accepted transfer of the Assets and assumed and agreed to discharge when due all applicable liabilities assumed by us, which consisted of post-closing obligations for liabilities and payments associated with the Assets, the assumed contracts
related to the Assets and applicable taxes (with the obligation for pre-closing and other certain liabilities resulting from the acts or omissions of Endo being retained by Endo).

In conjunction with the Endo Termination Agreement, we also entered into a distribution agreement (the Distribution Agreement)
with Par Pharmaceuticals, Inc. (or Par) for the distribution of an authorized generic BELBUCA product after the launch of a generic BELBUCA product by a third party. The Distribution Agreement covers distribution within the entire
United States, has an initial term of three years after the launch of a generic BELBUCA product by a third party, an initial automatic renewal period of two years, and additional automatic one-year renewal
periods thereafter, which will occur unless either party provides written notice of termination an agreed upon period of time prior to the expiration of the initial term or any renewal term. In exchange for distribution rights of the generic
product, Par will pay us an agreed upon base purchase price and a deferred purchase price equal to a percentage of profit (as such term is specifically agreed to in the Distribution Agreement) with respect to units of each dosage strength of generic
product. During the term of the Distribution Agreement, Par is precluded from manufacturing for sale in the United States, or distributing in the United States, any equivalent product, provided that nothing prohibits Par from continuing or
undertaking to develop any equivalent product or selling such equivalent product outside of the U.S. The Distribution Agreement contains customary termination provisions for bankruptcy, withdrawal of product from the market, and regulatory and
legislative changes, as

well as a termination right for insufficient profits or Pars acquisition by or of a party challenging our patents with respect to BELBUCA.

Mylan Licensing Agreements for ONSOLIS

North American Agreement. On September 5, 2007, we entered into a definitive License and Development Agreement with Mylan and our
subsidiary Arius pursuant to which we and Arius agreed to grant to Mylan an exclusive commercial license to market, sell, and, following regulatory approval, continue development of ONSOLIS in the United States, Mexico and Canada (which we refer to
as the Mylan North American License).

Pursuant to such license agreement, we are to receive the following future milestones:



sales milestones equaling an aggregate of $30 million will be payable at:



$10.0 million when and if annual sales meet or exceed $75.0 million;



$10.0 million when and if annual sales meet or exceed $125.0 million; and



$10.0 million when and if annual sales meet or exceed $175.0 million.

European Agreement. In 2006, we announced collaboration with Mylan to develop and commercialize BEMA Fentanyl (marketed as BREAKYL in Europe). Under terms of the agreement, we granted Mylan rights to the European development and commercialization of BREAKYL, in exchange for an upfront fee of $2.5 million and a
$2.5 million milestone payment (received in 2008) for completion of Phase 3 clinical trials. Mylan managed the regulatory submission in Europe that led to approval in October 2010. Mylan exclusively commercializes BREAKYL in Europe.

In 2009, we received a $3 million payment in exchange for amending the European agreement to provide Mylan the worldwide rights to
ONSOLIS, except for South Korea and Taiwan. The sales royalties to be received by us will be the same for all territories as agreed to for Europe. In addition, various terms of the European agreements have been modified to reflect the rights and
obligations of both us and Mylan in recognition of the expansion of the scope of the European agreements.

On January 27, 2015, we
entered into an assignment and revenue sharing agreement with Mylan (which we refer to as the ARS Agreement) to return to us the marketing authorization for ONSOLIS in the U.S. and the right to seek marketing authorizations for ONSOLIS in Canada and
Mexico. Under the ARS Agreement, financial terms were established that enable Mylan to share a significant portion of the proceeds of milestone and royalty payments received by us from any new North American partnership for ONSOLIS that may be
executed by us. Following the return of the U.S. marketing authorization from Mylan, we submitted a prior approval supplement for the new formulation to the FDA in March 2015, which was approved in August 2016.

Collegium License and Development Agreement for ONSOLIS and its Termination

On May 11, 2016, we entered into a definitive License and Development Agreement (which we refer to as the Collegium Agreement) with
Collegium under which we granted Collegium the exclusive rights to develop and commercialize ONSOLIS in the U.S. Under the terms of the Collegium Agreement, Collegium was to be responsible for the manufacturing, distribution, marketing and sales of
ONSOLIS in the U.S. We were obligated to use commercially reasonable efforts to continue the transfer of manufacturing to the anticipated manufacturer for ONSOLIS and to submit a corresponding Prior Approval Supplement (the Supplement)
to the FDA with respect to the current NDA for ONSOLIS. Following approval of the Supplement, the NDA and manufacturing responsibility for ONSOLIS (including the manufacturing relationship with our manufacturer, subject to our entering into an
appropriate agreement with such manufacturer that is acceptable and assignable to Collegium) was to be transferred to Collegium.

Pursuant
to such license agreement, we received:



$2.5 million upfront non-refundable payment, (received in June
2016); and



reimbursement to us for a pre-determined amount of the remaining expenses
associated with the ongoing transfer of the manufacturing of ONSOLIS;

The execution of the Collegium Agreement also
required the execution of a definitive termination agreement between us and Mylan embodying royalty-sharing terms, returning ONSOLIS-related assets and rights in the U.S., Canada, and Mexico to us, and including certain other provisions. In
addition, our royalty obligations to CDC IV, LLC (or CDC IV), an entity that originally provided funding for the development of ONSOLIS, and its assignees will remain in effect. CDC IV provided funding for the development of ONSOLIS in the past.

On December 8, 2017, Collegium provided us the required 90-day notice regarding termination
of the license and development agreement for ONSOLIS between us and Collegium. Collegiums decision to terminate the license involved their execution of a

license agreement to commercialize Nucynta® (tapentadol) Immediate Release and
Nucynta® ER (tapentadol). The license and development agreement for ONSOLIS between us and Collegium formally ended on March 8, 2018 and we received our assets back from Collegium.

Key Collaborative, Supply and Manufacturing Agreements

We are and have been a party to collaborative agreements with corporate partners, contractors, universities and government agencies. Our
collaboration arrangements are intended to provide us with access to greater resources and scientific expertise in addition to our in-house capabilities. We also have supply arrangements with several of the
key component producers of our delivery technology and we rely on third-party manufacturers and packagers to produce commercial product. Our collaborative, supply and manufacturing agreements include:



Mylan. For a description of our agreements with Mylan, please see Mylan Licensing Agreements for
ONSOLIS above.



Collegium. For a description of our agreements with Collegium, please see Collegium License and
Development Agreement for ONSOLIS above.



LTS Lohmann Therapie-Systeme AG. Effective December 15, 2006, we entered into a Process Development
Agreement with LTS Lohmann Therapie-Systeme AG (which we refer to herein as LTS). Under the agreement, LTS has granted us a license under European Patent No. 0 949 925, regarding BREAKYL in the E.U. Our BREAKYL agreement is renewable for
successive terms of two-year terms and shall continue until terminated under the following conditions: i) bankruptcy/insolvency, ii) intellectual property loss, iii) breach of contract iv) supply failure, and
v) mutual agreement. LTS manufactures BREAKYL for sale in the E.U. and PAINKYL for sale in the Republic of China (Taiwan). In accordance with the supply agreement executed by us with LTS in April 2012, LTS is the exclusive manufacturer of BEMA
Fentanyl for all countries with exception of the United States and Canada. The current term extends to December 31, 2019.



ARx. Effective July 30, 2014, we entered into an agreement with ARx, LLC. Pursuant to which ARx acts
as a supplier of BUNAVAIL laminate (bulk product) for the United States. Our supply agreement with ARx was then amended July 14, 2017 and now the agreement runs until December 31, 2023. The agreement can be further renewed for
additional terms by mutual agreement.

Effective January 6, 2017, we assumed Endos agreement with ARx to
supply BELBUCA laminate (bulk product). This agreement automatically renews for successive terms of one year each and currently covers minimum annual commitments for supply of bulk product through 2023.



Sharp. Effective March 6, 2014, we entered into an exclusive agreement with Sharp Corporation, or
Sharp, to convert the BUNAVAIL laminate (bulk product) into individual dosage units and package them to supply BUNAVAIL finished product. Our supply agreement with Sharp ran for an initial term from March 6, 2014 until December 31, 2016
and continues to be extended by mutual agreement for subsequent one-year terms. The current term extends to December 31, 2019.

Tapemark. Effective January 6, 2017, we assumed Endos agreement with The Tapemark Company, or
Tapemark, to convert the BELBUCA laminate (bulk product) into individual dosage units which were then transferred to Sharp for secondary packaging and supply of BELBUCA finished product. Tapemark continued to provide such services for BELBUCA
through 1st quarter of 2018 as we transitioned the converting and primary packaging operations for BELBUCA over to an alternate packaging site in 2018. Tapemark remains qualified to conduct
converting and primary packaging of BELBUCA and we continue to explore other opportunities to utilize Tapemarks contract manufacturing services going forward.

We initiated a program to qualify Tapemark as an alternate commercial manufacturing site for ONSOLIS. This program was necessary since previous
efforts to extend a supply agreement with the original ONSOLIS manufacturer Aveva Drug Delivery Systems, Inc. (subsequently acquired by Apotex) were unsuccessful and the agreement expired. In October 2018, we received notification of FDAs
approval of Tapemark as the new ONSOLIS manufacturer.

Relationship with CDC IV, LLC

On July 14, 2005, we entered into a Clinical Development and License Agreement (the CDLA), with the predecessor of CDC IV,
which provided funds to us for the development of ONSOLIS. Under the CDLA, as amended, CDC IV is entitled to receive a low-double digit royalty based on net sales of ONSOLIS. The CDLA includes minimum
royalties of $375,000 per quarter beginning in the second full year following commercial launch which came into effect in 2011. The royalty term and minimum payments end upon the latter of expiration of the patent or generic entry into any
particular country, or the CDLA is terminated.

We and CDC IV entered into a Royalty Purchase and Amendment Agreement, dated
September 5, 2007 (the RPAA) pursuant to which we granted CDC IV a 1% royalty on sales of the next BEMA product, which was BUNAVAIL, including an active pharmaceutical ingredient other than fentanyl, to receive FDA
approval. In connection with the 1% royalty grant: (i) CDC IV shall have the option to exchange its royalty rights to BUNAVAIL in favor of royalty rights to a substitute BEMA product, (which CDC subsequently exchanged for BELBUCA) (ii) we
shall have the right, no earlier than six (6) months prior to the initial commercial launch of BUNAVAIL or BELBUCA, to propose in writing and negotiate the key terms pursuant to which it would repurchase the royalty from CDC IV, (iii) CDC
IVs right to the royalty shall immediately terminate at any time if annual net sales of BUNAVAIL or BELBUCA equal less than $7.5 million in any calendar year following the third (3rd) anniversary of initial launch of the product and
CDC IV receives $18,750 in three (3) consecutive quarters as payment for CDC IVs 1% royalty during such calendar year and (iv) CDC IV shall have certain information rights with respect to BUNAVAIL or BELBUCA.

In April 2016, CDC IV exercised its right pursuant to the RPAA to exchange its royalty rights to the next BEMA product which was BUNAVAIL, in
favor of royalty rights to the Substitute BEMA product which was BELBUCA (the CDC IV Option).

On November 21, 2016 we entered into
an Amended and Restated CDLA with CDC IV and Athyrium LLC that did not materially change the rights of the parties under the CDLA, but merely clarified and memorialized in a single agreement the rights and obligations of our company, CDC IV and
Athyrium under the CDLA and its various amendments as described above.

However, patent positions of biotechnology and pharmaceutical organizations are uncertain and involve complex legal and technical issues.
There is considerable uncertainty regarding the breadth of claims in patent cases which results in varied degrees of protection. While we believe that our intellectual property position is sound, it may be that our pending patent applications will
not be granted or that our awarded claims may be too narrow to protect the products against competitors. It is also possible that our intellectual property positions will be challenged or that patents issued to others prior to our patent issuance
may preclude us from commercializing our products. It is also possible that other parties could have or could obtain patent rights which may cover or block our products or otherwise dominate our patent position.

BEMA Technology

The drug delivery technology space is congested, although we do not believe that our BEMA products conflict with, are dominated by, or infringe
any external patents and we do not believe that we require licenses under external patents for our BEMA based products in the United States. It is possible, however, that a court of law in the United States or elsewhere might determine otherwise. If
a court were to determine that we were infringing other patents and that those patents were valid, we might be required to seek one or more licenses to commercialize our products or technologies and we may be unable to obtain such licenses from the
patent holders. If we were unable to obtain a license, or if the terms of the license were onerous, there may be a material adverse effect upon our business plan to commercialize these products.

On March 1, 2011, we were granted a patent extending the exclusivity of the BEMA drug delivery technology in Canada to 2027. The Canadian
Patent No. 2,658,585 provides additional patent protection for ONSOLIS and BELBUCA. In April 2012, the USPTO granted US Patent No. 8,147,866, which will extend the exclusivity of the BEMA drug delivery technology for BELBUCA and BUNAVAIL
in the United States from 2020 to 2027. In April 2014, the USPTO granted US Patent No. 8,703,177 (issued from US Patent Application No. 13/590,094), which will extend the exclusivity of the BEMA drug delivery technology for BUNAVAIL in the
United States to at least 2032. In February 2018, we were granted US Patent No. 9,901,539, which will extend the exclusivity of the BEMA technology for BELBUCA in the United States to December 21, 2032.

We own various patents and patent applications relating to the BEMA technology. US Patent No. 6,159,498 (expiration date October 2016),
US Patent No. 7,579,019 (expiration date January 22, 2020), US Patent No. 8,147,866 (expiration date July 23, 2027), US Patent 8,703,177 (expiration date August 20, 2032), US Patent 9,522,188 (expiration date April 24,
2035), US Patent 9,597,288 (expiration date July 23, 2027), US Patent 9,655,843 (expiration date July 23, 2027), US Patent 9,901,539 (expiration date December 21, 2032, Canadian Patent No. 2,658,585 (expiration date July 2027),
EP2054031 (expiration date July 2027) and EP 0 973 497 (expiration date October 2017) are of particular value to our business and technology platform relating to the BEMA delivery technology. On February 16, 2010, we filed a complaint with the
United States Federal District Court for the District of Columbia, requesting the USPTO be required to further extend the patent term for US 7,579,019 from 835 days to 1,191 days. In March 2011, we

prevailed in this case, and the patent expiration date of US Patent No. 7,579,019 is now extended from January 31, 2019 to January 22, 2020.

On January 22, 2014, Aquestive filed a Petition for Inter Partes Review, or IPR, on US Patent No. 7,579,019 with the USPTO. In the
Petition, Aquestive is requesting an inter partes review because it is asserting that the claims of US Patent No. 7,579,019 are alleged to be unpatentable over certain prior art references. The USPTO instituted the IPR on the US Patent
No. 7,579,019 (which we refer to as the 019 Patent). The USPTO found all claims patentable and Aquestive filed a Request for Rehearing. On December 19, 2016, the PTAB issued a final decision denying Aquestives request for
rehearing. Aquestive did not appeal this final decision.

With respect to trademarks, BDSI®, BEMA®, BELBUCA® and BUNAVAIL® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS® and BREAKYL are also trademarks owned by BioDelivery Sciences International, Inc. PAINKYL is a trademark owned by TTY Biopharm.

Government Regulation

The
nonclinical and clinical development, manufacturing and marketing of any drug product is subject to significant regulation by governmental authorities in the United States and other countries. Complying with these regulations involves considerable
time, expense and uncertainty.

In the United States, drugs are subject to rigorous federal regulation and, to a lesser extent, state
regulation. The Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder, and other federal and state statutes and regulations govern, among other things, the testing, manufacture, safety, efficacy, labeling,
storage, record keeping, approval, advertising and promotion of our drugs. Drug development and approval within this regulatory framework is difficult to predict, requires several years and involves the expenditure of substantial resources.
Moreover, ongoing legislation by Congress and rulemaking by the FDA presents an ever-changing landscape where we could be required to undertake additional activities before any governmental approval to market our products is granted.

The steps required before a pharmaceutical product may be marketed in the United States include:

1.

small scale manufacturing of the product;

2.

laboratory and nonclinical tests for safety of the product;

3.

submission of an IND to the FDA for the product (the IND must become effective before human clinical trials can
commence);

4.

larger scale manufacturing of the product;

5.

clinical trials to characterize the efficacy and safety of the product in the intended patient population;

6.

submission of an NDA to the FDA; and

7.

approval of the NDA by the FDA.

In addition to obtaining FDA approval for each product, each product-manufacturing establishment must be registered with, and approved by, the
FDA. Manufacturing establishments are generally subject to biennial inspections by the FDA and must comply with the FDAs Good Manufacturing Practices and with other federal and local regulations.

Nonclinical testing includes laboratory evaluations of the active drug substance and formulation, as well as tissue culture and animal studies
to assess the safety and potential efficacy of the investigational product. Nonclinical tests must be conducted by laboratories that comply with FDA Good Laboratory Practices regulations. Nonclinical testing is inherently risky, and the results can
be unpredictable or difficult to interpret. The results of nonclinical testing are submitted to the FDA as part of an IND and are reviewed by the FDA prior to the commencement of clinical trials. Unless the FDA places a clinical hold on an IND,
clinical studies may begin thirty (30) days after the IND is submitted.

We have relied and intend to continue to rely on third party
contractors to perform nonclinical trials.

Clinical Research

Clinical research involves administration of the investigational product to healthy volunteers and/or to patients under the supervision of a
qualified investigator. Clinical trials must be conducted in accordance with Good Clinical Practices following protocols acceptable to FDA that detail the objectives of the study, the parameters to be used to monitor safety and the efficacy and the
planned evaluation of results. Each protocol must be submitted to the FDA prior to its conduct. Further, each clinical study must be conducted under the auspices of an independent institutional review board that protects the rights and welfare of
the study subjects. The drug product used in clinical trials must be manufactured according to Good Manufacturing Practices.

Clinical
research is typically conducted in three sequential phases, but the phases may overlap and not all phases may be necessary when developing investigational products that will utilize the FDAs 505(b)(2) approval process. Phase 1 studies are
typically performed in normal healthy volunteers to assess the safety (adverse side effects), absorption, metabolism, bio-distribution, excretion, and food and drug interactions of the investigational drug
product. Additional studies may be performed to assess abuse potential as well as limited measures of pharmacologic effect. Phase 2 is the proof of principle stage and involves studies in a limited number of patients in order to:



assess the potential efficacy of the product for specific, targeted indications;



identify the range of doses and dose regimens likely to be effective for the indication; and



identify possible adverse events and safety risks.

When there is evidence that the product may be effective and has an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are
undertaken to establish the clinical efficacy and safety profile of the product within a larger population at geographically dispersed clinical study sites. Phase 3 frequently involves randomized controlled trials and, whenever possible, studies are
conducted in a manner so that neither the patient nor the investigator knows what treatment is being administered. We, or the FDA, may suspend clinical trials at any time if it is believed that the individuals participating in such trials are being
exposed to unacceptable health risks.

New Drug Application and FDA Approval Process

The results of the pharmaceutical and manufacturing development work, nonclinical studies and clinical studies are submitted to the FDA in the
form of an NDA for approval to market and sell the product. The testing and approval process is likely to require substantial time and effort. In addition to the results of nonclinical and clinical testing, the NDA applicant must submit detailed
information about chemistry, manufacturing and controls that will describe how the product is made, packaged, labeled, and tested through the manufacturing process. The manufacturing process continues to develop throughout the period of clinical
trials such that, at the time of the NDA, it has been demonstrated that there is control of the process and the product can be made consistently at commercial scale.

The NDA review process involves FDA investigation into the details of the manufacturing process, as well as the design and analysis of each of
the nonclinical and clinical studies. This review includes inspection of the manufacturing facility, the data recording process for the clinical studies, the record keeping at a sample of clinical trial sites and a thorough review of the results for
each nonclinical and clinical study. Through this review, the FDA reaches a decision about the risk-benefit profile of a product candidate. If the benefit outweighs the risk, the FDA begins negotiation with the company on the content of an
acceptable package insert and an associated REMS plan if required.

The NDA review process is affected by many factors, including the
severity of the disease, the availability of alternative treatments, and the risks and benefits demonstrated in clinical trials. Consequently, there is a risk that approval may not be granted on a timely basis, if at all. The FDA may deny approval
of an NDA if applicable regulatory criteria are not satisfied. Moreover, if regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which it may be marketed, require additional testing or
information, or require post-marketing testing (Phase 4) and surveillance to monitor the safety of a companys product if it does not believe the NDA contains adequate evidence of its safety. Finally, product approvals may be withdrawn if
compliance with regulatory standards is not maintained or health problems are identified that would alter the risk-benefit

analysis for the product. Post-approval studies may be conducted to explore the use of the product for new indications or populations such as pediatrics.

Among the conditions for NDA approval is the requirement that any prospective manufacturers quality control and manufacturing procedures
conform to Good Manufacturing Practices and the specifications approved in the NDA. In complying with standards set forth in these regulations, manufacturers must continue to expend time, money and effort in the area of quality control and quality
assurance to ensure full technical compliance. Manufacturing establishments, both foreign and domestic, also are subject to inspections by or under the authority of the FDA and by other federal, state or local agencies. Additionally, in the event of
non-compliance, the FDA may issue warning letters and/or seek criminal and civil penalties, enjoin manufacture, seize product or revoke approval.

Risk Evaluation and Mitigation Strategy

In March 2008, new legislation designated as the Food and Drug Administration Amendments Act of 2007 (the FDAAA) took effect. This legislation
strengthened the FDAs authority over drug safety and directs the FDA to develop systems aimed at managing the risk-benefit ratio of a drug, with a particular focus on post-approval safety. FDAAA authorized the FDA to require and enforce a Risk
Evaluation and Mitigation Strategy, or REMS, if the FDA determines that it is necessary to ensure that the benefits of a drug outweigh the potential risks. The legislation also provides the FDA with authority to require a REMS at any point in a drug
products lifecycle based on new safety information.

A REMS is defined by the FDA as a strategy to manage a known or potential
serious risk associated with a drug or biological product. The FDAs assessment of whether to require a REMS as a condition for approval considers factors such as the size of the population likely to use the drug, the seriousness of the disease
or condition that is to be treated by the drug, the expected benefit, and the seriousness of any known or potential adverse events that may be related to the drug. A REMS may be conveyed through the use of a number of tools including a Medication
Guide for distribution when the drug is dispensed, a communication plan to physicians to convey potential risks, and elements to ensure safe use. These elements may include provisions that healthcare providers who prescribe the drug and pharmacists
who dispense the drug have particular training, experience or special certifications; that the drug be dispensed only in certain healthcare settings; that the drug be dispensed to patients with evidence of
safe-use conditions; and/or that patients must be enrolled in a registry. Under the FDAAA, the FDA has also been granted enforcement authority over violations of the REMS provisions. The FDA may impose civil
monetary penalties, the drug or biological product can be deemed misbranded, and/or the FDA may obtain injunctive relief against further distribution of the product.

On December 29, 2011, the FDA approved a class-wide REMS program covering all transmucosal fentanyl products under a single
risk management program. ONSOLIS is subject to this REMS, which includes a number of Elements to Assure Safe Use (ETASU).

Additionally,
FDA has implemented a class-wide REMS covering all opioid analgesic drug products. The class-wide REMS includes a REMS-compliant educational program offered by an accredited provider of continuing medical education, patient counseling materials and
a medication guide. BELBUCA is subject to this REMS.

A REMS is also in place for buprenorphine for the treatment of opioid dependence.
BUNAVAIL is included in this REMS, which includes a medication guide and healthcare professional and patient education.

The cost and
implementation of all of these shared system REMS is shared among multiple companies that are required to participate by way of having an approved product that is subject to the particular REMS.

International Approval

Whether or not FDA approval has been obtained, approval of a product by regulatory authorities in foreign countries must be obtained prior to
the commencement of commercial sales of the drug in such countries. The requirements governing the conduct of clinical trials and drug approvals vary widely from country to country, and the time required for approval may be longer or shorter than
that required for FDA approval. Although there are some procedures for unified filings for certain European countries, in general, each country currently has its own procedures and requirements.

BELBUCA is approved in Canada, and ONSOLIS (under different trade names and with a slightly different formulation) is approved in Europe and in
Taiwan.

Other Regulation

In addition to regulations enforced by the FDA, we are also subject to United States regulation under the Controlled Substances Act, the
Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state, local or similar foreign regulations. Our
research

and development may involve the controlled use of hazardous materials, chemicals and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such
materials comply with the standards prescribed by state and federal regulations, the risk of accidental contamination or injury from these materials cannot be completely eliminated. In the event of any accident, we could be held liable for any
damages that result and any such liability could exceed our resources.

Research and Development

Most of our research and development relating to our BEMA and other technologies has been conducted through third parties in collaboration with
us.

Research and development expenses have historically consisted of product development expenses incurred in identifying, developing and
testing product candidates. Product development expenses consist primarily of labor, benefits and related employee expenses for personnel directly involved in product development activities; fees paid to professional service providers for monitoring
and analyzing clinical trials; regulatory costs; costs of contract research and manufacturing of inventory used in testing and clinical trials. For the years ended December 31, 2018, 2017 and 2016, we spent approximately $4.9 million,
$13.0 million and $18.9 million, respectively, on research and development, and such expenses represented approximately 8%, 18% and 28%, respectively, of our total operating expenses for such fiscal years.

Employees

As of March 14, 2019, we
have 164 full-time employees. 127 handle our outside sales and training, thirteen are involved in our medical affairs, clinical development program and operations, seventeen handle our administration, accounting, and supply chain management and
seven handle our marketing and managed markets. Advanced degrees and certifications of our staff include one Ph.D, one M.D, three PharmDs, two CPAs, eighteen MBAs, seven MSs, five MAs, one JD, one MPA, one MEDU and one RN. None of our employees are
covered by collective bargaining agreements. From time to time, we also employ independent contractors on a consulting basis or to support our administrative functions. We consider relations with all our employees to be good. Each of our employees
has entered into confidentiality, intellectual property assignment and non-competition agreements with us.

Available Information

Our Annual Reports
on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to reports filed pursuant to Sections
13(a) and 15(d) of the Securities Exchange Act of 1934, as amended (which we refer to herein as the Exchange Act), are filed with the SEC. Such reports and other information that we file with the SEC are available free of charge on our website at http://ir.bdsi.com/financials/sec-filings when such reports are available on the SEC website. The SEC maintains an Internet site that contains reports, proxy and information statements and other information
regarding issuers that file electronically with the SEC at http://www.sec.gov. The contents of these websites are not incorporated into this filing. Further, the foregoing references to the URLs for these websites are intended to be inactive textual
references only.

Investing in our common stock involves a high degree of risk. Before purchasing our common stock, you should carefully consider the
following risk factors as well as all other information contained in this Report, including our consolidated financial statements and the related notes. The risks and uncertainties described below are not the only ones facing us. Additional risks
and uncertainties that we are unaware of, or that we currently deem immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition or results of operations could be materially and
adversely affected. In that case, the trading price of our common stock could decline, and you may lose some or all of your investment.

Risks Relating to Our Business

We have incurred significant losses since inception and as such, you cannot rely upon our historical operating performance to make an
investment decision regarding our company.

From our inception in January 1997 and through December 31, 2018, we have recorded
significant losses. Our accumulated deficit at December 31, 2018 was approximately $351.3 million. As of December 31, 2018, we had working capital of approximately $44.5 million, and until our product revenue grows more
substantially, we will continue to use our working capital to maintain our operations. Our ability to generate revenue and achieve profitability depends upon our ability, alone or with others, to effectively market and sell our products, secure and
maintain payer access and manufacture our products to meet demand. We may be unable to achieve any or all of these goals consistently.

Although we have generated licensing-related and other revenue to date, we have only recently begun to generate revenue from the commercial
sales of our approved products  BELBUCA, BUNAVAIL and ONSOLIS. In the case of BELBUCA, our approval has generated milestone revenue from our prior commercial partner Endo. However, in January 2017, we obtained the commercialization rights back
to BELBUCA and are utilizing our internal sales force to sell our product. In the case of BUNAVAIL, sales have been challenging since we commenced the commercial launch of the product in November 2014 and are subject to the risks of launching a new
product. There is a risk that we will be unable to generate sustained and predictable revenues from product sales. In the case of ONSOLIS, sales have been adversely affected by: (i) the lack of a uniform REMS program at the time of the launch
of ONSOLIS, and (ii) certain post-FDA manufacturing issues associated with ONSOLIS which have led to the temporary suspension of manufacturing and marketing of ONSOLIS in the US and Canada.

We have limited experience as a company in self-commercializing pharmaceutical products, which heightens the risks related to our
self-commercialization of BELBUCA and BUNAVAIL.

Prior to our decision to commercialize BUNAVAIL, we had relied on third parties to
manage sales and marketing efforts for us, including Mylan for ONSOLIS and Endo for BELBUCA until January 2017. We therefore have limited experience as a company in commercializing a product, and our sales, marketing and distribution
capabilities are fairly new. As such, we may not achieve success in marketing and promoting BELBUCA and BUNAVAIL, or any other products we develop or acquire in the future or products we may commercialize through the exercise of co-promotion rights. Specifically, to optimize the commercial potential of BELBUCA and BUNAVAIL, we must execute upon our commercialization plan effectively and efficiently. In addition, we must continually assess
and modify our commercialization plan to adapt to the promotional response. Further, we must continue to focus and refine our marketing campaign to ensure a clear and understandable physician-patient dialogue around BELBUCA and BUNAVAIL as an
appropriate therapies. In addition, we must provide our sales force with the highest quality training, support, guidance and oversight for them to effectively promote BELBUCA and BUNAVAIL. If we fail to perform these commercial functions in the
highest quality manner, BELBUCA and BUNAVAIL will not achieve its maximum commercial potential or any level of success at all. The deterioration or loss of our sales force would materially and adversely impact our ability to generate sales
revenue, which would hurt our results of operations. Finally, we are competing and expect to compete with other companies that currently have extensive and well-funded marketing and sales operations, and our marketing and sales efforts may be
unable to compete against these other companies, which would also hurt our results of operations.

If our competitors are successful
in obtaining approval for Abbreviated New Drug Applications for products that have the same active ingredients as BELBUCA or BUNAVAIL, sales of BELBUCA or BUNAVAIL may be adversely affected.

Our competitors may submit for approval certain Abbreviated New Drug Applications, or ANDAs, which provide for the marketing of a drug product
that has the same active ingredients in the same strengths and dosage form as a drug product already listed with the FDA, and which has been shown to be bioequivalent to such FDA-listed drug. Drugs approved in
this way are commonly referred to as generic versions of a listed drug and can often be substituted by pharmacists under prescriptions written for an original listed drug. Any applicant filing an ANDA is required to certify to the FDA that the new
product subject to the ANDA will

not infringe an already approved products listed patents or that such patents are invalid (otherwise known as a Paragraph IV Certification).

In February 2016, we announced that a generic competitor, Teva Pharmaceutical Industries Ltd., or Teva, had filed a Paragraph IV Certification
challenging certain of our BUNAVAIL-related patents and we received notices regarding Paragraph IV certifications from Teva in November and December 2016, seeking to find invalid two Orange Book listed patents relating specifically to BELBUCA.
The filing of this certification required us to initiate costly litigation against Teva. In addition, a number of our competitor companies have filed Paragraph IV Certifications challenging the patent for Suboxone® film, the market leader in the field in which we are seeking to generate sales of BUNAVAIL. To the extent that any company is successful in challenging the validity of certain patents covering
BUNAVAIL or Suboxone® film under a Paragraph IV Certification, it could result in FDA approval of a drug that is lower in price to BUNAVAIL or Suboxone® film. Such a new drug could make it more difficult for BUNAVAIL to gain any significant market share in an increasingly generic marketplace, which would have a material adverse effect on our
results of operations, cash flow, reputation and stock price.

In October 2017, we announced that we had entered into a settlement
agreement with Teva that resolved our BUNAVAIL patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the Settlement Agreement, which is subject to review by the U.S. Federal Trade Commission
and the U.S. Department of Justice, we entered into a non-exclusive license agreement with Teva that permits Teva to first begin selling its generic version of BUNAVAIL in the U.S. on July 23, 2028
or earlier under certain circumstances. Other terms of the agreement are confidential.

In February 2018, we announced that we had
entered into a Settlement Agreement with Teva that resolves our previously reported BELBUCA, patent litigation against Teva pending in the United States District Court for the District of Delaware. As part of the settlement agreement, which is
subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice, we entered into a non-exclusive license agreement with Teva that permits Teva to first begin selling its generic
version of BELBUCA in the U.S. on January 23, 2027 or earlier under certain circumstances. Other terms of the agreement are confidential.

As such, we have been and may continue to be subject to ANDA-related litigation, which is costly and distracting and has the potential to
impair the long-term value of our products.

We may have difficulty raising any needed additional capital.

Our business currently generates a limited amount of revenue from product sales and milestone revenues, and such current sources of revenue may
not be sufficient to meet our present and short-term capital requirements. Therefore, given that we plan to continue to spend on commercialization activities (including those relating to BELBUCA and BUNAVAIL) as well as potentially on other
strategic initiatives, there is a risk that we may require additional capital to fund these activities. If adequate funds are unavailable, we may be required to delay, reduce the scope of or eliminate one or more of our commercialization programs or
marketing efforts, any of which may materially harm our business, financial condition and results of operations.

Our long-term
capital requirements are subject to numerous risks.

Our long-term capital requirements are expected to depend on many factors,
including, among others:



time and costs involved in obtaining regulatory (including FDA) clearance and addressing regulatory and other
issues that may arise post-approval (such as we have experienced with ONSOLIS and, to a lesser extent, with BELBUCA and BUNAVAIL);

We may consume available resources more rapidly than currently anticipated, resulting in the
need for additional funding sooner than anticipated. We may seek to raise any necessary additional funds through equity or debt financings, collaborative arrangements with corporate partners or other sources, which may have a material effect on our
current or future business prospects.

Our additional financing requirements could result in dilution to existing stockholders.

The additional financings which we have undertaken and which we may in the future require, have and may be obtained through one or
more transactions that have diluted or could dilute (either economically or in percentage terms) the ownership interests of our stockholders. Further, we may not be able to secure such additional financing on terms acceptable to us, if at all. We
have the authority to issue additional shares of common stock and preferred stock, as well as additional classes or series of ownership interests or debt obligations which may be convertible into any one or more classes or series of ownership
interests. We are authorized to issue 125 million shares of common stock and 5 million shares of preferred stock. Such securities may be issued without the approval or other consent of our stockholders.

Our term loan agreement with CRG Servicing LLC (or CRG) and other lenders party thereto contains restrictions that limit our flexibility
in operating our business. We may be required to make a prepayment or repay the outstanding indebtedness earlier than we expect under our Credit Agreement if a prepayment event or an event of default occurs, including a material adverse change with
respect to us, which could have a materially adverse effect on our business.

Our agreement with CRG contains various covenants
that limit our ability to engage in specified types of transactions. These covenants limit our ability to, among other things:



incur additional indebtedness;



enter into a merger, consolidation or certain changing of control events without complying with the terms of the
loan agreement;



change the nature of our business;



change our organizational structure or type;



amend, modify or waive any of our material agreements or organizational documents;



grant certain types of liens on our assets;



make certain investments;



pay cash dividends;



enter into material transactions with affiliates; and

The restrictive covenants of the term loan agreement could cause us to be unable to pursue business opportunities that we or our stockholders
may consider beneficial. A breach of any of these covenants could result in an event of default under the term loan agreement. An event of default will also occur if, among other things, a material adverse change in our business, operations or
condition occurs, or a material impairment of the prospect of our repayment of any portion of the amounts we owe under the term loan agreement occurs. In the case of a continuing event of default under the agreement, CRG could elect to declare all
amounts outstanding to be immediately due and payable and terminate all commitments to extend further credit, proceed against the collateral in which we granted CRG a security interest under the term loan agreement and related agreements, or
otherwise exercise the rights of a secured creditor. Amounts outstanding under the term loan agreement are secured by all of our existing and future assets (excluding certain intellectual property).

We may not have enough available cash or be able to raise additional funds on satisfactory terms, if at all, through equity or debt financings
to make any required prepayment or repay such indebtedness at the time any such prepayment event or event of default occurs. In such an event, we may be required to delay, limit, reduce or terminate our product development or commercialization
efforts or grant to others rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our business, financial condition and results of operations could be materially adversely affected as a
result.

Until ONSOLIS returns to the market in North America, we will not receive additional revenues from ONSOLIS.

ONSOLIS was originally licensed to and launched in the U.S. by Mylan. In January 2015, we entered into an assignment and revenue sharing
agreement with Mylan under which Mylan transferred the marketing authorizations for ONSOLIS for the U.S. back to us. On May 11, 2016, we and Collegium executed a definitive license and development Agreement under which we granted the
exclusive rights to develop and commercialize ONSOLIS in the U.S. to Collegium.

On December 8, 2017, we received the
required 90-day notice from Collegium regarding termination of the License Agreement and the effective date of termination is March 8, 2018. We are assessing our commercial options for
ONSOLIS. Until such time that we commercialize or license ONSOLIS in the U.S., we will not receive additional revenues from this product.

Social issues around the abuse of opioids, including law enforcement and other legal concerns over diversion of opioids and regulatory
efforts to combat abuse, misuse and addiction, could impact the potential market for BELBUCA, BUNAVAIL and any product candidates we may develop that contain opioids.

Opioid abuse in the United States is a significant healthcare issue, and our two currently marketed products (BELBUCA and BUNAVAIL) contain
opioids as their active ingredients. Media stories regarding prescription drug abuse and the diversion of opioids and other controlled substances are commonplace. Law enforcement and regulatory agencies have and will likely continue to apply
policies and guidelines that seek to limit the availability or use of opioids. In addition, federal, state and local governments have and may enact legislation or executive orders with similar goals. State and local governments have also taken legal
action against opioid manufacturers to recoup alleged damages arising out of the opioid crisis. Such efforts have challenged and could inhibit our ability to commercialize BELBUCA and BUNAVAIL and any product candidates we may develop that contain
opioids.

Aggressive enforcement and unfavorable publicity regarding, for example, the use or misuse of oxycodone or other opioid drugs;
the limitations of abuse-resistant formulations; the ability of drug abusers to discover previously unknown ways to abuse opioid drugs; public inquiries and investigations into prescription drug abuse; litigation; or regulatory activity regarding
sales, marketing, distribution or storage of opioid drugs could have a material adverse effect on our business. Additionally, there may be continued reluctance of some regulators and third-party payers to pay a premium for abuse-deterrent
formulations of opioids or opioids such as BELBUCA with less abuse and addiction potential compared to Schedule II opioids. These factors could reduce the potential size of the market for BELBUCA, and possibly BUNAVAIL and our product
candidates and decrease the revenues we are able to generate from their sale.

Efforts by the FDA and other regulatory bodies to combat
abuse of opioids may negatively impact the market for BELBUCA and BUNAVAIL. For example, in February 2016, the FDA released an action plan to address the opioid abuse epidemic and reassess the FDAs approach to opioid medications. The plan
identifies FDAs focus on implementing policies to reverse the opioid abuse epidemic, while maintaining access to effective treatments. The actions set forth in the FDAs plan include strengthening post marketing study requirements to
evaluate the benefit of long-term opioid use, changing the REMS requirements to provide additional funding for physician education courses, releasing a draft guidance setting forth approval standards for generic-abuse deterrent opioid formulations,
and seeking input from the FDAs Scientific Board to broaden the understanding of the public risks of opioid abuse. The FDAs Scientific Advisory Board met to address these issues on March 1, 2016. The FDAs plan is part of a
broader initiative led by the HHS to address opioid-related overdose, death and dependence. The HHS initiatives focus is on improving physicians use of opioids through education and resources to address opioid over-prescribing,
increasing use and development of improved delivery systems for naloxone, which can reverse overdose from both prescription opioids and heroin, to reduce overdose-related deaths, and expanding the use of Medication-Assisted Treatment, which couples
counseling and behavioral therapies with medication to address substance abuse. Also, as part of this initiative, the CDC has launched a state grant program to offer state health departments resources to assist with abuse prevention efforts,
including efforts to track opioid prescribing through state-run electronic databases. In March 2016, as part of the HHS initiative, the CDC released a new Guideline for Prescribing Opioids for Chronic Pain.
The guideline is intended to assist primary care providers treating adults for chronic pain in outpatient settings. The guideline provides recommendations to improve communications between doctors and patients about the risks and benefits of
opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy. The guideline does not specifically address the use of buprenorphine for chronic pain or make
treatment recommendations about the use of abuse-deterrent opioids.

In addition, at least 41 U.S. states and many cities and counties
have filed civil suits or instituted other proceedings against opioid manufacturers and wholesalers of opioid drugs seeking damages under various claims for contributing to the opioid crisis. Such litigations could further damage the market for
opioid products like BELBUCA and BUNAVAIL. To the extent our company is named in such lawsuits (such as the lawsuit in Arkansas described under Legal Proceedings, of which the plaintiffs filed a notice to voluntarily dismiss us from the
case in July 2018), we could be required to participate in the settlement of such litigations or the payment of damages, which could divert our managements attention from our business, deplete our financial resources, and damage our
reputation.

Government agencies may establish and promulgate usage guidelines that could limit the use of our products and drug
candidate.

National and state level government agencies, professional and medical societies, and other groups may establish usage
guidelines that apply to our products and drug candidate. These guidelines could address such matters as usage and dose, among other factors. Application of such guidelines could limit the clinical use or commercial appeal of our products or drug
candidate.

Acceptance of our technologies, product candidates or products in the marketplace is
uncertain and failure to achieve market acceptance will prevent or delay our ability to generate material revenues.

Our future
financial performance will depend, to a large extent, upon the introduction and physician and patient acceptance of our technologies, product candidates and products. Even if approved for marketing by the necessary regulatory authorities, our
technologies, product candidates and products may not achieve market acceptance.

The degree of market acceptance for our products and
product candidates will depend upon a number of factors, including:



regulatory clearance of marketing claims for the uses that we are developing;



demonstration of the advantages, safety and efficacy of our products and technologies;



pricing and reimbursement policies of government and third-party payers such as insurance companies, health
maintenance organizations and other health plan administrators;

regulatory programs such as the class-wide REMS for ONSOLIS, BELBUCA and BUNAVAIL or market (including
competitive) forces that may make it more difficult for us to penetrate a particular market segment; and



ability to timely and effectively manufacture and market our products.

Physicians, various other health care providers, patients, payers or the medical community in general may be unwilling to accept, utilize or
recommend any of our approved products or product candidates. If we are unable to obtain regulatory approval or are unable (either on our own or through third parties) to manufacture, commercialize and market our proposed formulations or products
when planned, we may not achieve any market acceptance or generate revenue.

All these risks are particularly true for BELBUCA and
BUNAVAIL, which are our two products that we are commercializing ourselves.

If we are unable to convince physicians as to the
benefits of our products or product candidates, we may incur delays or additional expense in our attempt to establish market acceptance.

Use of our products and, if approved, our product candidates will require physicians to be informed regarding the intended benefits of our
products and product candidates. The time and cost of such an educational process may be substantial. Inability to carry out this physician education process may adversely affect market acceptance of our proposed formulations or products. We may be
unable to timely educate physicians regarding our intended pharmaceutical formulations or products in sufficient numbers to achieve our marketing plans or to achieve product acceptance. Any delay in physician education may materially delay or reduce
demand for our formulations or products. In addition, we may expend significant funds toward physician education before any acceptance or demand for our products or product candidates are created, if at all. Nonetheless, even with our best efforts,
certain physicians may never prescribe our product.

We have been and expect to be significantly dependent on our collaborative
agreements for the manufacturing of our products, which expose us to the risk of reliance on the performance of third parties.

In
conducting our operations, we currently rely, and expect to continue to rely, on numerous collaborative agreements with third parties such as manufacturers, commercial partners, governmental agencies and not-for-profit organizations for both strategic and financial resources. Key among these agreements are our manufacturing agreements with LTS relating to BREAKYL and Sharp relating to BELBUCA and BUNAVAIL.

The termination of these relationships, or failure to perform by us or our partners (who are subject to regulatory, competitive and other
risks) under their applicable agreements or arrangements with us, or our failure to secure additional agreements for our product candidates, would substantially disrupt or delay our development activities. Any such loss would likely increase our
expenses and materially harm our business, financial condition and results of operation.

We depend upon key personnel who may
terminate their employment with us at any time.

Our ability to achieve our corporate objectives will depend to a significant
degree upon the continued services of key management, particularly our senior executive officers. Our management and other employees may voluntarily terminate their employment with us at any time. The loss of the services of these or other key
personnel, or the inability to attract and retain additional qualified personnel, could result in delays to loss of sales and diversion of management resources. In addition, we depend on our ability to attract and retain other highly skilled
personnel. Competition for qualified personnel is intense, and the process of hiring and integrating such qualified personnel is often lengthy. We may be unable to recruit such personnel on a timely basis, if at all, which would negatively impact
our commercialization programs. Additionally, we do not currently maintain key person life insurance on

the lives of our executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.

We may be unable to manage our growth effectively.

After focusing our efforts for many years on clinical development of products, our business strategy now involves growth and expansion as we
continue our evolution into a fully integrated specialty pharmaceutical company. For example, as we in-license or acquire additional product candidates, we will likely have to expand existing operations to
increase our contract manufacturing capabilities, hire and train new personnel to handle the marketing and sales of our products and assist patients in obtaining reimbursement for the use of our products. We may also need to grow to support our
commercial activities for BELBUCA and BUNAVAIL or other approved products. This growth may place significant strain on our management and financial and operational resources. Successful growth is also dependent upon our ability to implement
appropriate financial and management controls, systems and procedures. Our ability to effectively manage growth depends on our success in attracting and retaining highly qualified personnel, for which the competition may be intense. If we fail to
manage these challenges effectively, our business could be harmed.

We are exposed to product liability, non-clinical and clinical liability risks which could place a substantial financial burden upon us, should lawsuits be filed against us.

Our business exposes us to potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing
of pharmaceutical formulations and products. We expect that such claims could be asserted against us at some point. In addition, the use in our clinical trials of pharmaceutical formulations and products and the subsequent sale of these formulations
or products by us or our potential collaborators may cause us to bear a portion of or all product liability risks. A successful liability claim or series of claims brought against us could have a material adverse effect on our business, financial
condition and results of operations.

We currently have a general liability/product liability policy which includes coverage for our
clinical trials and our commercially marketed products. Annual aggregate limits include $2 million for general liability, with $1 million for each occurrence; product liability is $10 million for aggregate and $10 million per
occurrence with excess liability in the amount of an additional $5 million; umbrella liability is $5 million aggregate and $5 million per occurrence. It is possible that this coverage will be insufficient to protect us from
future claims. Under our agreements, our partners are required to carry comprehensive general product liability and tort liability insurance, each in amounts not less than $2 million per incident and $2 million annual aggregate and to name
us as an additional insured thereon. However, we or our commercial partners may be unable to obtain or maintain adequate product liability insurance on acceptable terms, if at all, and there is a risk that our insurance will not provide adequate
coverage against our potential liabilities. Furthermore, our current and potential partners with whom we have collaborative agreements, or our future licensees may not be willing to indemnify us against these types of liabilities and may not
themselves be sufficiently insured or have sufficient assets to satisfy any product liability claims. Claims or losses in excess of any product liability insurance coverage that may be obtained by us or our partners could have a material adverse
effect on our business, financial condition and results of operations.

Moreover, product liability insurance is costly, and due to the
nature of the pharmaceutical products underlying BELBUCA, BUNAVAIL, ONSOLIS and our product candidates, we or our partners may not be able to obtain such insurance, or, if obtained, we or our partners may not be able to maintain such insurance on
economically feasible terms. If a product or product candidate related action is brought against us, or liability is found against us prior to our obtaining product liability insurance for any product or product candidate, or should we have
liability found against us for any other matter in excess of any insurance coverage we may carry, we could face significant difficulty continuing operations.

We are presently a party to lawsuits by third parties who claim that our products, methods of manufacture or methods of use infringe on
their intellectual property rights, and we may be exposed to these types of claims in the future.

We are presently, and may
continue to be, exposed to litigation by third parties based on claims that our technologies, processes, formulations, methods, or products infringe the intellectual property rights of others or that we have misappropriated the trade secrets of
others. This risk is exacerbated by the fact that the validity and breadth of claims covered in pharmaceutical patents is, in most instances, uncertain and highly complex. Any litigation or claims against us, whether or not valid, would result in
substantial costs, could place a significant strain on our financial and human resources and could harm our reputation. Such a situation may force us to do one or more of the following:

delay the launch of, or cease selling, making, importing, incorporating or using one or more or all of our
technologies and/or formulations or products that incorporate the challenged intellectual property, which would adversely affect our revenue;

obtain a license from the holder of the infringed intellectual property right, which license may be costly or may
not be available on reasonable terms, if at all; or



redesign our formulations or products, which would be costly and time-consuming.

With respect to our BEMA delivery technology, the thin film drug delivery technology space is highly competitive. There is a risk that a court
of law in the United States or elsewhere could determine that one or more of our BEMA based products conflicts with or covered by external patents. This risk presently exists in our litigation with Aquestive which was filed by Aquestive in
November 2010, wherein Aquestive claims that our and our partners trade secret manufacturing process for ONSOLIS is infringing upon Aquestive patented manufacturing process, as well as a similar litigation with Reckitt Benckiser, Inc., RB
Pharmaceuticals Limited, and Aquestive relating to our BUNAVAIL product which was filed in October 2013. If the courts in these cases were to rule against us and our partner in that case, we could be forced to license technology from Aquestive or
otherwise incur liability for damages, which could have a material adverse effect on our ability for us or our partners to market and sell BUNAVAIL or ONSOLIS.

We have been granted non-exclusive license rights to European Patent No. 949 925, which is
controlled by LTS to market BELBUCA and ONSOLIS within the countries of the European Union. We are required to pay a low single digit royalty on sales of products that are covered by this patent in the European Union. We have not conducted freedom
to operate searches and analyses for our other proposed products. Moreover, the possibility exists that a patent could issue that would cover one or more of our products, requiring us to defend a patent infringement suit or necessitating a patent
validity challenge that would be costly, time consuming and possibly unsuccessful.

Our lawsuits with Aquestive and RB Pharmaceuticals
have caused us to incur significant legal costs to defend ourselves, and we would be subject to similar costs if we are a party to similar lawsuits in the future Furthermore, if a court were to determine that we infringe any other patents and that
such patents are valid, we might be required to seek one or more licenses to commercialize our BEMA products. We may be unable to obtain such licenses from the patent holders, which could materially and adversely impact our business.

If we are unable to adequately protect or enforce our rights to intellectual property or secure rights to third-party patents, we may
lose valuable rights, experience reduced market share, assuming there is any market share, or incur costly litigation to, enforce, maintain or protect such rights.

Our ability to license, enforce and maintain patents, maintain trade secret protection and operate without infringing the proprietary rights of
others will be important to our commercializing any formulations or products under development. The current and future development of our drug delivery technologies is contingent upon whether we are able to maintain licenses and access patented
technologies. Without these licenses, the use of technologies would be limited and the sales of our products could be prohibited. Therefore, any disruption in access to the technologies could substantially delay the development and sale of our
products.

The patent positions of biotechnology and pharmaceutical companies, including ours, which involve licensing agreements, are
frequently uncertain and involve complex legal and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued. Consequently, our patents, patent applications and licensed
rights may not provide protection against competitive technologies or may be held invalid if challenged or could be circumvented. Our competitors may also independently develop drug delivery technologies or products similar to ours or design around
or otherwise circumvent patents issued to, or licensed by, us. In addition, the laws of some foreign countries may not protect our proprietary rights to the same extent as U.S. law.

We also rely upon trade secrets, technical know-how and continuing technological innovation to develop
and maintain our competitive position. We require our employees, consultants, advisors and collaborators to execute appropriate confidentiality and
assignment-of-inventions agreements with us. These agreements provide that materials and confidential information developed or made known to the individual during the
course of the individuals relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances and assign the ownership of relevant inventions created during the course of employment to us. These
agreements may be breached, and in some instances, we may not have an appropriate remedy available for breach of the agreements. Furthermore, our competitors may independently develop substantially equivalent proprietary information and techniques,
reverse engineer, or otherwise gain access to our proprietary technology. We may be unable to meaningfully protect our rights in trade secrets, technical know-how and other
non-patented technology.

In addition, we may have to resort to costly and time consuming
litigation to protect or enforce our rights under certain intellectual property, or to determine their scope, validity or enforceability. Enforcing or defending our rights could be expensive, could cause significant diversion of our resources and
may not prove successful. Any failure to enforce or protect our rights could cause us to lose the ability to exclude others from using our technologies to develop or sell competing products.

We are dependent on third party suppliers for key components of our delivery
technologies, products and product candidates.

Key components of our drug delivery technologies, products and product candidates
may be provided by sole or limited numbers of suppliers, and supply shortages or loss of these suppliers could result in interruptions in supply or increased costs. Certain components used in our development activities, such as the active
pharmaceutical component of our products, are currently purchased from a single or a limited number of outside sources. The reliance on a sole or limited number of suppliers could result in:



delays associated with development and non-clinical and clinical trials
due to an inability to timely obtain a single or limited source component;



inability to timely obtain an adequate supply of required components; and



reduced control over pricing, quality and timely delivery.

Our relationships with our manufacturers and suppliers are particularly important to us and any loss of or material diminution of their
capabilities due to factors such as regulatory issues, accidents, acts of God or any other factor would have a material adverse effect on our company. Any loss of or interruption in the supply of components from our suppliers or other third-party
suppliers would require us to seek alternative sources of supply or require us to manufacture these components internally, which we are currently not able to do.

If the supply of any components is lost or interrupted, product or components from alternative suppliers may not be available in sufficient
quality or in volumes within required time frames, if at all, to meet our or our partners needs. This could delay our ability to complete clinical trials, obtain approval for commercialization or commence marketing or cause us to lose sales,
force us into breach of other agreements, incur additional costs, delay new product introductions or harm our reputation. Furthermore, product or components from a new supplier may not be identical to those provided by the original supplier. Such
differences could have material effects on our overall business plan and timing, could fall outside of regulatory requirements, affect product formulations or the safety and effectiveness of our products that are being developed.

We have limited manufacturing experience and therefore depend on third parties to formulate and manufacture our products. We may not be
able to secure or maintain the manufacture of sufficient quantities or at an acceptable cost necessary to successfully commercialize or continue to sell our products.

Our managements expertise has primarily been in commercial operations. Our managements experience in the manufacturing of
pharmaceutical products is more limited and we have limited equipment and no facilities of our own from which these activities could be performed. Therefore, we are fully dependent on third parties for our formulation development, manufacturing and
the packaging of our products. This is particularly true with respect to ARx and Sharp, the primary manufacturers of our approved and commercialized product, BELBUCA and BUNAVAIL. We also rely on LTS, the manufacturer for BREAKYL in the E.U. This
reliance exposes us to the risk of not being able to directly oversee the production and quality of the manufacturing process and provide ample commercial supplies to formulate sufficient product to conduct clinical trials and maintain adequate
supplies to meet market demand for our products.

Furthermore, these third-party contractors, whether foreign or domestic, may experience
regulatory compliance difficulty, mechanical shut downs, employee strikes, or any other unforeseeable acts that may delay or limit production, which could leave our commercial partners with inadequate supplies of product to sell, especially when
regulatory requirements or customer demand necessitate the need for additional product supplies. Our inability to adequately establish, supervise and conduct (either ourselves or through third parties) all aspects of the formulation and
manufacturing processes, and the inability of third party manufacturers like ARx, Sharp and LTS to consistently supply quality product when required would have a material adverse effect on our ability to commercialize and sell our products. We have
faced risks associated with reliance on key third party manufacturers in the past and may be faced with such risks in the future. Any future manufacturing interruptions or related supply issues could have an adverse effect on our company, including
loss of sales and royalty revenue and claims by or against us or our partners for breach of contract.

There are risks associated
with our reliance on third parties for managed care, distribution infrastructure and channels.

We expect that we may from time to
time choose to enter into agreements with commercial partners to engage in sales, marketing and distribution efforts around our products and product candidates. We may be unable to establish or maintain third-party relationships on a commercially
reasonable basis, if at all. In addition, these third parties may have similar or more established relationships with our competitors.

If we fail to develop sales, managed care, marketing and distribution channels, we would experience delays in generating sales and incur
increased costs, which would harm our financial results.

The class-wide Risk Evaluation and Mitigation Strategy (REMS) for all
transmucosal fentanyl products, and similar programs for other narcotic products, may slow sales and marketing efforts for products that contain narcotics, which could impact our royalty and sales revenue from such products.

Our approved product ONSOLIS is formulated with the potent narcotic fentanyl. On December 29, 2011, FDA approved a REMS program covering
all transmucosal fentanyl products. The program, which is referred to as the Transmucosal Immediate Release Fentanyl (TIRF) REMS Access Program, was designed to ensure informed risk-benefit decisions before initiating treatment with a transmucosal
fentanyl product, and while patients are on treatment, to ensure appropriate use. The approved program covers all approved transmucosal fentanyl products under a single program and was implemented in March 2012. Additionally, the FDA has implemented
a class-wide REMS covering the extended release and long acting opioid class. The class-wide REMS program consists of a REMS-compliant educational program offered by an accredited provider of continuing medical education, patient counseling
materials and a medication guide. BELBUCA falls within the existing class-wide REMS program. The cost and implementation of the extended release and long-acting opioid REMS is shared among multiple companies in the category.

There also continues to be a REMS in place for buprenorphine for the treatment of opioid dependence referred to as the BTOD
(Buprenorphine-containing Transmucosal products for Opioid Dependence) REMS. BUNAVAIL falls within the existing REMS, which is far less cumbersome and includes a medication guide and healthcare professional and patient education. Given the existence
of a REMS in both the extended release and long-acting opioid and opioid dependence markets, we anticipate our products will fit within the existing REMS and will avoid the issues initially encountered with ONSOLIS, where a REMS program was yet to
be developed.

Our business and operations could suffer in the event of system failures.

Despite the implementation of security measures, our internal computer systems and those of our current and any future partners, contractors,
and consultants are vulnerable to damage from cyber-attacks, computer viruses, unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures. System failures, accidents, or security breaches could cause
interruptions in our operations, and could result in a material disruption of our commercialization activities, development programs and our business operations, in addition to possibly requiring substantial expenditures of resources to remedy. The
loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the commercialization of any potential product candidate could be
delayed.

Actions of activist shareholders could be disruptive and potentially costly and the possibility that activist shareholders
may seek changes that conflict with our strategic direction could cause uncertainty about the strategic direction of our business.

Activist investors may attempt to effect changes in our strategic direction and how our company is governed or may seek to acquire control over
our company. Some investors (commonly known as activist investors) seek to increase short-term stockholder value by advocating corporate actions such as financial restructuring, increased borrowing, special dividends, stock repurchases,
or even sales of assets or the entire company. Activist campaigns can also seek to change the composition of our board of directors, and campaigns that contest or conflict with our strategic direction could have an adverse effect on our results of
operations and financial condition as responding to proxy contests and other actions by activist shareholders can disrupt our operations, be costly and time-consuming, and divert the attention of our board of directors and senior management from the
pursuit of our business strategies. In addition, perceived uncertainties as to our future direction that can arise from potential changes to the composition of our board of directors sought by activists may lead to the perception of a change in the
direction of the business, instability or lack of continuity which may be exploited by our competitors, may cause concern to our current or potential customers, may result in the loss of potential business opportunities and may make it more
difficult to attract and retain qualified personnel and business partners. These types of actions could divert our managements attention from our business or cause significant fluctuations in our stock price based on temporary or speculative
market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business, all of which could have a material adverse effect on our company.

We depend in large part on our BEMA drug delivery technology, and the loss of access to this technology would terminate or delay the
further development of our products, injure our reputation or force us to pay higher fees.

We depend, in large part, on our BEMA
drug delivery technology. The loss of this key technology would seriously impair our business and future viability, and could result in delays in developing, introducing or maintaining our products and formulations until equivalent technology, if
available, is identified, licensed and integrated. In addition, any defects in the BEMA technology or other technologies we gain access to in the future could prevent the implementation or impair the functionality of our products or formulations,
delay new product or formulation introductions or injure our reputation. If we are required to acquire or enter into license agreements with third parties for replacement technologies, we could be subject to higher fees, milestone or royalty
payments, assuming we could access such technologies at all.

Our failure to obtain government approvals, including required FDA
approvals, or to comply with ongoing governmental regulations relating to our technologies and proposed products and formulations could delay or limit introduction of our proposed formulations and products and result in failure to achieve revenues
or maintain our ongoing business.

Our development activities and the manufacture and marketing of our products and product
candidates are subject to extensive regulation for safety, efficacy and quality by numerous government authorities in the United States and abroad. Before receiving FDA or foreign regulatory clearance to market our proposed formulations and
products, we will have to demonstrate that our formulations and products are safe and effective in the patient population and for the diseases that are to be treated. Clinical trials, manufacturing and marketing of drugs are subject to the rigorous
testing and approval process of the FDA and equivalent foreign regulatory authorities. The Federal Food, Drug and Cosmetic Act and other federal, state and foreign statutes and regulations govern and influence the testing, manufacture, labeling,
advertising, distribution and promotion of drugs and medical devices. As a result, regulatory approvals can take a number of years or longer to accomplish and require the expenditure of substantial financial, managerial and other resources.

Our failure to complete or meet key milestones relating to the development of our technologies and proposed products and formulations
would significantly impair the viability of our company.

In order to be commercially viable, we must develop, obtain regulatory
approval for, manufacture, introduce, market and distribute formulations or products incorporating our technologies. For each drug that we formulate with our drug delivery technologies, we must meet a number of critical developmental milestones,
including:



demonstration of the benefit from delivery of each specific drug through our drug delivery technologies;



demonstration, through non-clinical and clinical trials, that our drug
delivery technologies are safe and effective; and



establishment of a viable Good Manufacturing Process capable of potential
scale-up.

The estimated required capital and time-frames necessary to achieve
these developmental milestones is subject to inherent risks, many of which may be beyond our control. As such, we may not be able to achieve these or similar milestones for any of our proposed product candidates or other product candidates in the
future. Our failure to meet these or other critical milestones would adversely affect the viability of our company.

If users of our
products and product candidates are unable to obtain adequate reimbursement from third-party payers, or if new restrictive legislation is adopted, market acceptance of our proposed formulations or products may be limited and we may not achieve
material revenues.

The continuing efforts of government and insurance companies, health maintenance organizations and other payers
of healthcare costs to contain or reduce costs of health care may affect our future revenues and profitability, and the future revenues and profitability of our potential customers, suppliers and collaborative partners and the availability of
capital. For example, in certain foreign markets, pricing or profitability of prescription pharmaceuticals is subject to government control. In the United States, given recent federal and state government initiatives directed at lowering the total
cost of health care, the U.S. Congress and state legislatures will likely continue to focus on health care reform, the cost of prescription pharmaceuticals and on the reform of the Medicare and Medicaid systems. While we cannot predict whether any
such legislative or regulatory proposals will be adopted, the announcement or adoption of such proposals and related laws, rules and regulations could materially harm our business, financial conditions, results of operations or stock price.
Moreover, the passage of the Patient Protection and Affordable Care Act in 2010, and efforts to amend or repeal such law, has created significant uncertainty relating to the scope of government regulation of healthcare and related legal and
regulatory requirements, which could have an adverse impact on sales of our products.

The ability of our company to commercialize BELBUCA and BUNAVAIL, or any partners with which
we have a licensing arrangement to sell ONSOLIS will depend in part on the extent to which appropriate reimbursement levels for the cost of our proposed formulations and products and related treatments are obtained by governmental authorities,
private health insurers and other organizations, such as HMOs. Consumers and third-party payers are increasingly challenging the prices charged for drugs and medical services. Also, the trend toward managed health care in the United States, which
could control or significantly influence the purchase of health care services and drugs, as well as legislative proposals to reform health care or reduce government insurance programs, may all result in lower prices for or rejection of our drugs.

In connection with our or our partners clinical development
activities, as well as the manufacture of materials and products, we and our partners are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent
discharge, handling and disposal of certain materials, biological specimens and wastes. We and our partners may be required to incur significant costs to comply with environmental and health and safety regulations in the future. Our clinical
development, as well as the activities of our manufacturing and commercial partners, both now and in the future, may involve the controlled use of hazardous materials, including but not limited to certain hazardous chemicals and narcotics. We cannot
completely eliminate the risk of accidental contamination or injury from these materials. In the event of such an occurrence, we could be held liable for any damages that result and any such liability could exceed our resources.

Government and other efforts to reform the healthcare industry could have adverse effects on our company, including the inability of
users of our current and future approved products to obtain adequate reimbursement from third-party payers, which could lead to diminished market acceptance of, and revenues from, such products.

Our ability to commercialize BELBUCA, BUNAVAIL and to sell ONSOLIS (once it is reformulated and placed back on the market in the U.S. and
Canada), alone or with collaborators, will depend in part on the extent to which coverage and reimbursement for the product will be available from:



government and health administration authorities;



private health maintenance organizations and health insurers; and



other healthcare payers.

Significant uncertainty exists as to the reimbursement status of newly approved healthcare products. The regulations that govern marketing
approvals, pricing and reimbursement for new drug products vary widely from country to country. In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability
Reconciliation Act of 2010, or the ACA, is significantly changing the way healthcare is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this law or any amendment to it will
continue to have in general or specifically on any product that we commercialize, the ACA or any such amendment may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of new products. In
addition, although the United States Supreme Court has upheld the constitutionality of most of the ACA, several states have not implemented certain sections of the ACA, including 19 that have rejected the expansion of Medicaid eligibility for low
income citizens, and some members of the U.S. Congress are still working to repeal the ACA. More recently, President Trump and the Republican majorities in both houses of the U.S. Congress have been seeking to repeal or replace all or portions of
the ACA but to date they have been unable to agree on any such legislation.

The Tax Cuts and Jobs Act of 2017 includes a provision
repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that
is commonly referred to as the individual mandate. Additionally, on January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain fees mandated by
the ACA, including the so-called Cadillac tax on certain high cost employer- sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and
the medical device excise tax on non-exempt medical devices. Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the ACA, effective January 1, 2019, to increase from 50% to
70% the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans,
commonly referred to as the donut hole. Congress may still consider other legislation to repeal and replace elements of the ACA. We expect that the ACA, as currently enacted or as it may be amended or repealed in the future, and other
healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to successfully commercialize our products. We cannot predict the likelihood, nature or extent of
government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new
requirements or policies, or if we or our collaborators are not able to

maintain regulatory compliance, our products may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our
business.

In addition, we are subject to the Federal Drug Supply Chain Security Act of 2013, or the DSCSA. The U.S. government
has enacted DSCSA which requires development of an electronic product tracking and tracing of each prescription drug at the salable unit level through the distribution system, which will be effective incrementally over a 10-year period. Compliance with DSCSA and future U.S. federal or state electronic requirements may increase our operational expenses and impose significant administrative burdens.

We may also be subject to healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material
adverse effect on our results of operations and financial conditions.

We may also be subject to several healthcare regulations and
enforcement by the federal government and the states and foreign governments in which we conduct our business. The laws that may affect our ability to operate include:



the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health
Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information;



the federal healthcare programs Anti-Kickback Law, which prohibits, among other things, persons from
knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which
payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;



federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting,
or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;



federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false
statements relating to healthcare matters; and



state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may
apply to items or services reimbursed by any third-party payor, including commercial insurers.

If our operations are
found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our
operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to operate our business and our financial results.

Our business is subject to increasingly complex corporate governance, public disclosure, and accounting requirements and regulations
that could adversely affect our business and financial results and condition.

We are subject to changing rules and regulations of
various federal and state governmental authorities as well as the stock exchange on which our common stock is listed. These entities, including the Public Company Accounting Oversight Board, the Securities and Exchange Commission, or the SEC and the
Nasdaq Capital Market, have issued a significant number of new and increasingly complex requirements and regulations over the course of the last several years and continue to develop additional requirements and regulations in response to laws
enacted by Congress, including the Sarbanes-Oxley Act of 2002 and, most recently, the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act.

There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that expressly authorized or
required the SEC to adopt additional rules in these areas, such as an advisory shareholder vote to approve of our executives compensation (or Say on Pay), proxy access, and an advisory shareholder vote on how often we should include a Say on
Pay proposal in our proxy materials for future annual shareholder meetings or any special shareholder meeting for which we must include executive compensation information in the proxy statement for that meeting. Our efforts to comply with these
requirements are likely to result in an increase in expenses which is difficult to quantify at this time.

In addition, we are subject to
often complex accounting rules and interpretations promulgated by the Financial Accounting Standards Board (including its Emerging Issues Task Force). We have faced challenges of compliance with accounting rules in the

past and may face such challenges in the future, and adjustments to or restatements of our financial statements or accounting policies based on such challenges could have a material adverse
effect on our public stock price and our reputation.

Our stock price is subject to market factors and market volatility, both
generally and with respect to our industry and our company specifically. As such, there is a risk that your investment in our common stock could fluctuate in value.

The overall market for securities in recent years has experienced extreme price and volume fluctuations that have particularly affected the
market prices of many smaller companies. In particular, the market prices of securities of biotechnology and pharmaceutical companies have been extremely volatile and have experienced fluctuations that often have been unrelated or disproportionate
to operating performance of these companies. These broad market fluctuations (as well as market reactions to particular developments with our company) have and could continue to result in extreme fluctuations in the price of our common stock, which
could cause a decline in the value of your common stock. These fluctuations, as well as general economic and market conditions, may have a material or adverse effect on the market price of our common stock.

Our Series A Non-Voting Convertible Preferred Stock ranks senior to our common stock in the
event of a bankruptcy, liquidation or winding up of our assets.

As of the date of this Report, we currently have 2,709,300 issued
and 2,093,155 outstanding shares of Series A Non-Voting Convertible Preferred Stock (Series A), which we issued in connection with our $40 million financing which closed on December 2012. In
the event of our bankruptcy, liquidation or winding up, our assets will be available to pay obligations on our Series A in preference to the holders of our common stock.

Our Series B Non-Voting Convertible Preferred Stock ranks senior to our common stock in the
event of a bankruptcy, liquidation or winding up of our assets.

As of the date of this Report, we currently have 5,000 issued and
3,100 outstanding shares of Series B Non-Voting Convertible Preferred Stock (Series B), which is convertible into 17,222,223 shares of our Company Common Stock. We issued the Series B in connection
with our $50 million registered direct offering which closed on May 22, 2018. In the event of our bankruptcy, liquidation or winding up, our assets will be available to pay obligations on our Series B
Non-Voting Convertible Preferred Stock, which ranks on par with Series A, in preference to the holders of our common stock.

Additional authorized shares of our common stock and preferred stock available for issuance may adversely affect the market for our
common stock.

As of March 14, 2019, there are 70,968,435 shares of common stock issued and 70,952,944 shares of
common stock outstanding. Additionally, there were 2,709,300 shares issued and 2,093,155 shares outstanding of Series A and 5,000 shares issued and 3,100 shares outstanding of Series B. On August 2, 2018, our stockholders approved an amendment
to our certificate of incorporation to increase the number of authorized shares of common stock, par value $.001, of our common stock from 75,000,000 to 125,000,000 shares. This increase in our authorized shares of common stock provides us with the
flexibility to issue more shares in the future, which might cause dilution to our stockholders. In addition, the total number of shares of our common stock issued and outstanding does not include shares reserved in anticipation of the exercise of
outstanding options or warrants. To the extent such options (including options under our stock incentive plan) or warrants are exercised, the holders of our common stock may experience further dilution.

Moreover, in the event that any future financing should be in the form of, be convertible into or exchangeable for, equity securities, and
upon the exercise of options and warrants, investors would experience additional dilution. Finally, in addition to the above referenced shares of common stock which may be issued without stockholder approval, we have 5 million shares of
authorized preferred stock, of which 2,709,300 shares have been designated as Series A and 5,000 have been designated as Series B. The remaining 2,285,700 shares of preferred stock remain undesignated shares of preferred stock, the terms of which
may be fixed by our board of directors. We have issued preferred stock in the past, and our board of directors has the authority, without stockholder approval, to create and issue one or more additional series of such preferred stock and to
determine the voting, dividend and other rights of holders of such preferred stock. The issuance of any of such series of preferred stock may have an adverse effect on the holders of common stock.

Additionally, on November 9, 2018, we filed a shelf registration statement (as amended on January 18, 2019) which registered up to
$75 million of our securities for potential future issuance and such registration statement became effective on February 7, 2019. To the extent we issue such shares of stock under this registration statement, the current holders of our
common stock may experience further dilution.

Shares eligible for future sale may adversely affect the market for our common stock.

We have a material number of shares of common stock underlying securities of our company, the future sale of which could depress
the price of our publicly-traded stock. As of March 14, 2019: (i) 5,629,608 shares of common stock are issuable upon exercise

of outstanding stock options at a weighted average exercise price of $3.34 per share, (ii) 2,302,018 restricted stock units eligible to be converted shares of our common stock
(iii) 2,093,155 shares of Series A eligible to be converted into shares of our common stock (iv) 3,100 Series B eligible to be converted into shares of our common stock and (v) 2,136,020 common stock shares underlying outstanding warrants at an
average exercise price of $2.60 per share.

In addition, from time to time, certain of our stockholders may be eligible to sell all or
some of their shares of common stock by means of ordinary brokerage transactions in the open market pursuant to Rule 144, promulgated under the Securities Act of 1933, as amended, which we refer to herein as the Securities Act, subject to certain
limitations. In general, pursuant to Rule 144, after satisfying a six month holding period: (i) affiliated stockholder (or stockholders whose shares are aggregated) may, under certain circumstances, sell within any three month period a number
of securities which does not exceed the greater of 1% of the then outstanding shares of common stock or the average weekly trading volume of the class during the four calendar weeks prior to such sale and
(ii) non-affiliated stockholders may sell without such limitations, provided we are current in our public reporting obligations. Rule 144 also permits the sale of securities by non-affiliates that have satisfied a one year holding period without any limitation or restriction. Any substantial sale of our common stock pursuant to Rule 144 or pursuant to any resale report may have a material
adverse effect on the market price of our securities.

Furthermore, sales of our common stock by our directors, officers, or employees may
occur as a result of sales effected pursuant to predetermined trading plans adopted under the safe-harbor afforded by SEC Rule 10b5-1.

Our certificate of incorporation and bylaws contain provisions that may discourage, delay or prevent a change in our management team
that stockholders may consider favorable.

Our certificate of incorporation, as amended, our amended and restated bylaws (which
were adopted in 2010 and as amended and restated in 2017 and 2018) and Delaware law contain provisions that may have the effect of preserving our current management, such as:



authorizing the issuance of blank check preferred stock without any need for action by stockholders;



limiting the ability of stockholders to call special meetings of stockholders;



permitting stockholder action by written consent;



establishing advance notice requirements for nominations for election to the board of directors or for proposing
matters that can be acted on by stockholders at stockholder meetings;



requiring a super-majority vote of our stockholders to remove directors of our company; and



providing that our stockholders may only remove our directors for cause (as defined in our bylaws).

These provisions affect your rights as a stockholder since they permit our board of directors to make it more difficult
for common stockholders to replace members of the board or undertake other significant corporate actions. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any
attempt to replace our current management team.

The financial and operational projections that we may make from time to time are
subject to inherent risks.

The projections that our management may provide from time to time (including, but not limited to, those
relating to potential peak sales amounts, production and supply dates, and other financial or operational matters) reflect numerous assumptions made by management, including assumptions with respect to our specific as well as general business,
economic, market and financial conditions and other matters, all of which are difficult to predict and many of which are beyond our control. Accordingly, there is a risk that the assumptions made in preparing the projections, or the projections
themselves, will prove inaccurate. There will be differences between actual and projected results, and actual results may be materially different from those contained in the projections. The inclusion of the projections in (or incorporated by
reference in) this Report should not be regarded as an indication that we or our management or representatives considered or consider the projections to be a reliable prediction of future events, and the projections should not be relied upon as
such.

We do not intend to pay dividends on our common stock.

We have never declared or paid any cash dividend on our capital stock. We currently intend to retain any future earnings and do not expect to
pay any dividends for the foreseeable future. Therefore, you should not invest in our common stock in the expectation that you will receive dividends.

Our corporate headquarters is located in Raleigh, North Carolina. We moved into our current headquarters in February 2015. The lease for this
office, which commenced November 14, 2014 for 89 months, is approximately 12,000 square foot space and has remaining base rent of $1.3 million payable through July 2022. Rent is payable in monthly installments and is subject to yearly
price increases and increases for our share of common area maintenance costs. The landlord for this space is HRLP Raleigh, L.P. We believe this space is adequate as our principal executive office location.

Item 3.

Legal Proceedings.

Readers are advised that the following disclosure regarding our ongoing litigations with MonoSol RX, dba Aquestive Therapeutics and Reckitt
Benckiser is intended to provide some background and an update on the matter as required by the rules of the SEC. Additional details regarding the past procedural history of the matter can be found in our previously filed periodic filings with the
SEC.

On October 29, 2013, Reckitt Benckiser, Inc., RB Pharmaceuticals Limited, and Aquestive (collectively, the RB Plaintiffs) filed an action
against us relating to our BUNAVAIL product in the United States District Court for the Eastern District of North Carolina (EDNC) for alleged patent infringement. BUNAVAIL is a drug approved for the maintenance treatment of opioid
dependence. The RB Plaintiffs claim that the formulation for BUNAVAIL, which has never been disclosed publicly, infringes its US Patent No. 8,475,832 (the 832 Patent). On May 21, 2014, the Court granted our motion to dismiss.

On January 22, 2014, Aquestive initiated an inter partes review (IPR) on U.S. Patent No. 7,579,019, the 019
Patent. The PTAB upheld all claims of our 019 Patent in 2015 and this decision was not appealed by Aquestive.

On September 20,
2014, we proactively filed a declaratory judgment action in the United States District Court for the EDNC requesting the Court to make a determination that our BUNAVAIL product does not infringe the 832 Patent, US Patent No. 7,897,080
(the 080 Patent) and US Patent No. 8,652,378 (the 378 Patent). We invalidated the 080 Patent in its entirety in an inter partes reexamination proceeding. We invalidated all relevant
claims of the 832 Patent in an IPR proceeding. And, in an IPR proceeding for the 378 Patent, in its decision not to institute the IPR proceeding the PTAB construed the claims of the 378 Patent narrowly. Shortly thereafter, by joint
motion of the parties, the 378 Patent was subsequently removed from the action.

On June 6, 2016, in an unrelated case in which
Indivior and Aquestive asserted the 832 Patent against other parties, the Delaware District Court entered an order invalidating other claims in the 832 Patent. Indivior and Aquestive cross-appealed all adverse findings in that decision
to the Court of Appeals for the Federal Circuit in Case No. 17-2587. Our declaratory judgment action remains stayed pending the outcome of that cross-appeal by Indivior and Aquestive.

On September 22, 2014, the RB Plaintiffs filed an action against us (and our commercial partner) relating to our BUNAVAIL product in the
United States District Court for the District of New Jersey for alleged patent infringement. The RB Plaintiffs claim that BUNAVAIL, whose formulation and manufacturing processes have never been disclosed publicly, infringes its patent U.S. Patent
No. 8,765,167 (the 167 Patent. As with prior actions by the RB Plaintiffs, we believe this is another anticompetitive attempt by the RB Plaintiffs to distract our efforts from commercializing BUNAVAIL. We strongly refute as without merit
the RB Plaintiffs assertion of patent infringement. On our motion, this case was transferred to the Eastern District of North Carolina. A Joint Motion to Stay the case was granted and the case is now stayed until a final resolution of the
167 IPRs discussed directly below. We will continue to vigorously defend this case.

On October 28, 2014, we filed multiple IPR
petitions on certain claims of the 167 Patent. The USPTO instituted three of the four IPR petitions. The PTAB upheld the claims and denied collateral estoppel applied to the PTAB decisions in March 2016. We appealed to Court of Appeals for the
Federal Circuit. The USPTO intervened with respect to whether collateral estoppel applied to the PTAB. On June 19, 2018, we filed a motion to remand the case for further consideration by the PTAB in view of intervening authority. On
July 31, 2018, the Federal Circuit vacated the decisions, and remanded the 167 Patent IPRs for further consideration on the merits.

Litigation related to BELBUCA

On
January 13, 2017, Aquestive filed a complaint in the United States District Court for the District of New Jersey alleging BELBUCA infringes the 167 Patent. In lieu of answering the complaint, we filed motions to dismiss the complaint and,
in the

alternative, to transfer the case to the EDNC. On July 25, 2017, the New Jersey Court administratively terminated the case pending the parties submission of a joint stipulation of transfer
because the District of New Jersey was an inappropriate venue. This case was later transferred to the Delaware District Court. On October 31, 2017 we filed motions to dismiss the complaint and, in the alternative, to transfer the case to the
EDNC. On October 16, 2018, denying the motion to dismiss as moot, the Delaware District Court granted our motion to transfer the case to the EDNC. The case is now pending in the EDNC. We strongly refute as without merit Aquestives
assertion of patent infringement and will vigorously defend the lawsuit.

Teva Pharmaceuticals USA (formerly Actavis)

On February 8, 2016, we received a notice relating to a Paragraph IV certification from Teva Pharmaceuticals USA, or Teva, (formerly
Actavis) seeking to find invalid three Orange Book listed patents relating specifically to BUNAVAIL. The Paragraph IV certification related to an ANDA filed by Teva with the FDA for a generic formulation of BUNAVAIL. The patents subject to
Tevas certification were the 019 Patent, U.S. Patent No. 8,147,866 (the 866 Patent) and 8,703,177 (the 177 Patent).

On March 18, 2016, we asserted three different patents against Teva, the 019 Patent, the 866 Patent, and the 177
Patent. Teva did not raise non-infringement positions about the 019 and the 866 Patents in its Paragraph IV certification. Teva did raise a
non-infringement position on the 177 Patent but we asserted in our complaint that Teva infringed the 177 Patent either literally or under the doctrine of equivalents.

On December 20, 2016 the USPTO issued U.S. Patent No. 9,522,188 (the 188 Patent), and this patent was properly
listed in the Orange Book as covering the BUNAVAIL product. On February 23, 2017 Teva sent a Paragraph IV certification adding the 9,522,188 to its ANDA. An amended Complaint was filed, adding the 188 Patent to the litigation.

On January 31, 2017, we received a notice relating to a Paragraph IV certification from Teva relating to Tevas ANDA on additional
strengths of BUNAVAIL and on March 16, 2017, we brought suit against Teva and its parent company on these additional strengths. On June 20, 2017, the Court entered orders staying both BUNAVAIL suits at the request of the parties.

On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the 843 Patent) relating to the BEMA technology, and this
patent was properly listed in the Orange Book as covering the BUNAVAIL product.

Finally, on October 12, 2017, we announced that we
had entered into a settlement agreement with Teva that resolved our BUNAVAIL patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the Settlement Agreement, which is subject to review by the U.S.
Federal Trade Commission and the U.S. Department of Justice, we have entered into a non-exclusive license agreement with Teva that permits Teva to first begin selling its generic version of BUNAVAIL in
the U.S. on July 23, 2028 or earlier under certain circumstances. Other terms of the agreement are confidential.

We received notices
regarding Paragraph IV certifications from Teva on November 8, 2016, November 10, 2016, and December 22, 2016, seeking to find invalid two Orange Book listed patents relating specifically to BELBUCA. The Paragraph IV certifications
relate to three ANDAs filed by Teva with the FDA for a generic formulation of BELBUCA. The patents subject to Tevas certification were the 019 Patent and the 866 Patent. We filed complaints in Delaware against Teva on
December 22, 2016 and February 3, 2017 in which we asserted against Teva the 019 Patent and the 866 Patent. Teva did not contest infringement of the claims of the 019 Patent and did not contest infringement of the
claims of the 866 Patent.

The 019 Patent had already been the subject of an unrelated IPR before the USPTO under which we
prevailed, and all claims of the 019 Patent survived. Aquestives request for rehearing of the final IPR decision regarding the 019 Patent was denied by the USPTO on December 19, 2016. Aquestive did not file a timely appeal at
the Federal Circuit.

On May 23, 2017, the USPTO issued U.S. Patent 9,655,843 (the 843 Patent) relating to the BEMA
technology, and this patent was properly listed in the Orange Book as covering the BELBUCA product.

On August 28, 2017, the Court
entered orders staying both BELBUCA suits at the request of the parties.

In February 2018, we announced that we had entered into a
settlement agreement with Teva that resolved our BELBUCA patent litigation against Teva pending in the U.S. District Court for the District of Delaware. As part of the settlement agreement, which is subject to review by the U.S. Federal Trade
Commission and the U.S. Department of Justice, we have granted Teva a non-exclusive license (for which we will receive no current or future payments) that permits Teva to first begin selling the generic
version of our BELBUCA product in the U.S. on January 23, 2027 or earlier under certain circumstances (including, for example, upon (i) the delisting of the
patents-in-suit from the U.S. FDA Orange Book, (ii) the granting of a license by us to a third party to launch another

generic form of BELBUCA at a date prior to January 23, 2027, or (iii) the occurrence of certain conditions regarding BELBUCA market share). Other terms of the Agreement are
confidential.

Alvogen

On
September 7, 2018, we filed a complaint for patent infringement in Delaware against Alvogen Pb Research & Development LLC, Alvogen Malta Operations Ltd., Alvogen Pine Brook LLC, Alvogen, Incorporated, and Alvogen Group, Incorporated
(collectively, Alvogen), asserting that Alvogen infringes our Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and U.S. Patent No. 9,901,539, expiring in
December of 2032. This complaint follows receipt by us on July 30, 2018 of a Paragraph IV Patent Certification from Alvogen stating that Alvogen had filed an ANDA with the FDA for a generic version of BELBUCA Buccal Film (75 mcg, 150
mcg, 300 mcg, 450 mcg, 600 mcg, 750 mcg and 900 mcg). Because we initiated a patent infringement suit to defend the patents identified in the Paragraph IV notice within 45 days after receipt of the Paragraph IV Certification, the FDA is
prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Alvogens notice letter also does not provide any information on the timing or approval status
of its ANDA.

In its Paragraph IV Certification, Alvogen does not contest infringement of at least several independent claims of each of
the 866, 843, and 539 patents. Rather, Alvogen advances only invalidly arguments for these independent claims. We believe that we will be able to prevail on our claims of infringement of these patents, particularly as
Alvogen does not contest infringement of certain claims of each patent. Additionally, as we have done in the past, we intend to vigorously defend our intellectual property against assertions of invalidity. Each of the three patents carry a
presumption of validity, which can only be overcome by clear and convincing evidence.

2018 Arkansas Opioid Litigation

On March 15, 2018, the State of Arkansas, and certain counties and cities in that State, filed an action in the Circuit Court of Arkansas,
Crittenden County against multiple manufacturers, distributors, retailers, and prescribers of opioid analgesics, including our company. We were served with the complaint on April 27, 2018. The complaint specifically alleged that we licensed our
branded fentanyl buccal soluble film ONSOLIS to Collegium, and Collegium is also named as a defendant in the lawsuit. ONSOLIS is not presently sold in the United States and the license agreement with Collegium was terminated prior to Collegium
launching ONSOLIS in the United States. Therefore, on June 28, 2018, we moved to dismiss the case against us and most recently, on July 6, 2018, the plaintiffs filed a notice to voluntarily dismiss us from the Arkansas case,
without prejudice.

Chemo Research, S.L

On March 1, 2019, we filed a complaint for patent infringement in Delaware against Chemo Research, S.L., Insud Pharma S.L., IntelGenx
Corp., and IntelGenx Technologies Corp. (collectively, Defendants), asserting that the Defendants infringe our Orange Book listed patents for BELBUCA, including U.S. Patent Nos. 8,147,866 and 9,655,843, both expiring in July of 2027, and
U.S. Patent No. 9,901,539 expiring December of 2032. This complaint follows a receipt by us on January 31, 2019, of a Notice Letter from Chemo Research S.L. stating that it has filed with the FDA an ANDA containing a Paragraph IV Patent
Certification, for a generic version of BELBUA Buccal Film in strengths 75 mcg, 150 mcg, 300 mcg, 450 mcg, and 900 mcg. Because we initiated a patent infringement suit to defend the patents identified in the Notice Letter within 45 days after
receipt, the FDA is prevented from approving the ANDA until the earlier of 30 months or a decision in the case that each of the patents is not infringed or invalid. Chemo Research S.L.s Notice Letter also does not provide any information on
the timing or approval status of its ANDA.

We believe that we will be able to prevail in this lawsuit. As we have done in the past, we
intend to vigorously defend our intellectual property against assertions of invalidity.

Our common stock is listed for quotation on the NASDAQ Capital Market under the symbol BDSI.

As of March 14, 2019, we had approximately 118 holders of record of our common stock. No cash dividends have been paid on the common stock to date.
We currently intend to retain earnings for further business development and do not expect to pay cash dividends in the foreseeable future.

Performance Graph

The following graph shows a comparison of the five-year total cumulative returns of an investment of $100 in cash on December 31, 2013 in
(i) our common stock (ii) the Nasdaq Composite Index (iii) the Nasdaq Biotechnology Index and (iv) the NYSE Pharmaceutical Index. All values assume reinvestment of the full amount of all dividends (to date, we have not declared
any dividends).

This stock performance graph shall not be deemed filed with the SEC or subject to Section 18 of the
Securities Exchange Act, nor shall it be deemed incorporated by reference in any of our filings under the Securities Act of 1933, as amended (the Securities Act). Comparison of cumulative total return on investment since
December 31, 2013:

The statements of operations data and statements of cash flows data for the years ended December 31, 2018, 2017 and 2016 and the balance
sheet data as of December 31, 2018 and 2017 have been derived from our audited consolidated financial statements included elsewhere in this annual report. The statements of operations data and statements of cash flows data for the years ended
December 31, 2015 and 2014 and the balance sheet data as of December 31, 2016, 2015 and 2014 have been derived from our audited consolidated financial statements not included in this annual report. The following selected financial data
should be read in conjunction with our Managements Discussion and Analysis of Financial Condition and Results of Operations and consolidated financial statements and related notes beginning on page
F-1 and other financial information included in this Report.

2018

2017

2016

2015

2014

Statements of Operations Data:

Total revenue (1)

$

55,640

$

61,985

$

15,546

$

48,231

$

38,944

Operating loss

(23,648

)

(29,420

)

(63,935

)

(35,179

)

(38,740

)

Net (loss) income (2) (3)

(46,367

)

5,285

(67,138

)

(37,672

)

(54,218

)

Diluted net (loss) income per share

(0.73

)

0.09

(1.25

)

(0.72

)

(1.12

)

Balance Sheet Data:

Cash, short-term and long-term investments

$

43,822

$

21,195

$

32,019

$

83,560

$

70,472

Total assets (4)

108,533

88,101

51,720

102,772

88,840

Long-term liabilities

57,252

53,075

50,097

42,993

4,402

Accumulated deficit

(351,288

)

(305,056

)

(310,341

)

(243,203

)

(205,531

)

Total stockholders equity (deficit)

29,742

8,877

(17,665

)

31,696

54,396

Statements of Cash Flows Data:

Net cash flows from operating activities

$

(24,113

)

$

(32,451

)

$

(53,982

)

$

(3,732

)

$

(28,833

)

(1)

Total revenue in 2017 includes $20 million in contract revenue from Endo related to a patent extension
that was previously recorded as deferred revenue because all or a portion of such $20 million was contingently refundable to Endo if a third party generic product was introduced in the U.S. during the patent extension period from 2020 to 2027.
However, due to us and Endo entering into a termination agreement which terminated the BELBUCA license to Endo effective January 6, 2017, the deferred $20 million was recognized as revenue in January 2017.

(2)

Net loss in 2018 includes the deemed dividend related to the beneficial conversion feature in Series B
Preferred Stock of $12.5 million.

(3)

Net loss in 2017 includes the bargain purchase gain of the BELBUCA acquisition from Endo totaling
$27.3 million, recorded as income in January 2017.

(4)

Total assets for the year ended December 31, 2017 includes the value of the BELBUCA license and
distribution rights intangible asset, net, totaling $40.5 million.

Managements Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in
conjunction with our consolidated financial statements and related notes appearing elsewhere in this Report. This discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. The actual results may
differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited to, those which are not within our control.

Our Strategy

Our strategy is evolving
with the establishment of our commercial footprint in the management of chronic pain; we seek to build a well-balanced, diversified, high-growth specialty pharmaceutical company. Through our industry-leading commercialization infrastructure, BDSI is
executing the commercialization of our existing products. As part of our corporate growth strategy, we have licensed, and will continue to explore opportunities to acquire or license additional products that meet the needs of patients living with
debilitating chronic conditions and treated primarily by therapeutic specialists. As we gain access to these drugs and technologies, we will employ our commercialization experience to bring them to the marketplace. With a strong commitment to
patient access and a focused business-development approach for transformative acquisitions or licensing opportunities, we will leverage our experience and apply it to developing new partnerships that enable us to commercialize novel products that
can change the lives of people suffering from debilitating chronic conditions.

Our historical clinical and regulatory development
strategy has focused primarily on our ability to use the U.S. Food and Drug Administration, or the FDAs, 505(b)(2) approval process to obtain more timely and efficient approval of new formulations of previously approved, active therapeutics
incorporated into our drug-delivery technology. Because the 505(b)(2) approval process is designed to address new formulations of previously approved drugs, we believe it has the potential to be more cost efficient and expeditious, with less
regulatory approval risk than other FDA-approval approaches.

Our Company

We are a publicly listed company. Our common stock is listed on The Nasdaq Capital Market under the symbol BDSI. We were
incorporated in the state of Indiana in 1997 and reincorporated as a Delaware-based corporation in 2002.

2018 and Beyond Highlights



On February 6, 2018, we announced that we had entered into a Settlement Agreement with Teva that resolves
our previously reported BELBUCA patent litigation against Teva pending in the United States District Court for the District of Delaware.



On May 7, 2018, we announced the appointment of Herm Cukier as our new Chief Executive Officer and member of
our board of directors, effective as of May 8, 2018.



On May 22, 2018, we announced the closing of the $50 million registered direct offering of newly
designated Series B Stock. The offering closed on May 21, 2018, yielding net proceeds of $8048.0 million to BDSI. As part of the financing closing, Broadfin Managing Partner Kevin Kotler joined our board, along with Todd
Davis and Peter Greenleaf. Furthermore, Peter Greenleaf has been named Chairman of our Board of Directors. In addition, and effective as of the closing, Thomas W. DAlonzo, Barry I. Feinberg, Samuel P. Sears, Jr. and Timothy
C. Tyson have each resigned and retired from the Board.



On July 20, 2018, we extended an offer to Dr. Thomas Smith, as our Chief Medical Officer and member of
our Executive Leadership Team effective July 30, 2018.



On August 2, 2018, in connection with our 2018 Annual Meeting of Stockholders, our stockholders approved,
among other matters, (i) amending our Certificate of Incorporation to increase the number of authorized shares of Common Stock from 75,000,000 to 125,000,000; and (ii) to ratify the issuance and sale of our Series B Preferred Stock, par
value $.001 per share, and to approve the issuance of Common Stock issuable upon the conversion of the Series B Preferred Stock as required by and in accordance with NASDAQ Marketplace Rule 5635(d).



On October 29, 2018, we announced the appointment of James Vollins as General Counsel and member of our
Executive Leadership Team effective November 5, 2018. Mr. Vollins serves as our Chief Compliance Officer and Corporate Secretary. We also announced the enhanced title of Scott Plesha to President and Chief Commercial Officer of the
Company.

On November 9, 2018, we filed a shelf registration statement (as amended on January 18, 2019) which
registered up to $150 million of our securities for potential future issuance and such registration statement was became effective on February 7, 2019.



On January 15, 2019, we announced the appointment of Terry Coelho as Chief Financial Officer.
Ms. Coelho will also serve as our principal financial officer and principal accounting officer. Ms. Coelho replaced Ernest De Paolantonio in these positions effective as of January 15, 2019. Mr. De Paolantonio will remain at our
Company past such date in order to allow for an orderly transition.



On February 4, 2019  we announced that a leading national managed care organization has moved BELBUCA
into preferred status across all its commercial formularies from its previous position of not-covered effective February 1, 2019. In addition, patients will no longer require a prior authorization to
receive their BELBUCA script. This significant improvement in access for more than 7 million covered lives brings the total of Americans with preferred access for BELBUCA to more than 115 million.

Our Products and Related Trends

Our product portfolio currently consists of four products. As of the date of this report, three products are approved by the FDA; the fourth
product, while we are not actively studying it at this time, we are evaluating further development opportunities. The three approved products utilize our patented BEMA thin film drug delivery technology.



BELBUCA is indicated for the management of chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. This product was originally licensed on a worldwide basis to Endo. On
October 26, 2015, we announced with Endo that the FDA approved BELBUCA. BELBUCA was launched by Endo in February 2016. On December 7, 2016, we entered into an agreement with Endo terminating Endos licensing of rights for BELBUCA.
This followed a strategic decision made by Endo to discontinue commercial efforts in the branded pain business. On January 6, 2017, we announced the closing of the transaction to reacquire the license to BELBUCA from Endo. As a result, the
worldwide rights to BELBUCA were transferred back to us. Behind a revised commercialization plan, we are leveraging our existing sales force to capitalize on commercial synergies with BUNAVAIL. This effort is a focused commercial approach targeting
identified healthcare providers which we believe create the potential to incrementally grow BELBUCA sales without the requirement for significant resources. We also will explore other options for longer-term growth for BELBUCA. Since the initial
launch in February 2017, we further expanded our sales force beginning in January 2018 and again in September to support the commercialization efforts. BELBUCA and BUNAVAIL are currently supported by a field force of approximately 113 sales
representatives, thirteen regional sales managers and two area directors. As previously disclosed, the launch has been more challenging because of the increased scrutiny over the prescribing of opioids that is driven by the Centers for Disease
Control and Prevention guidelines issued in March 2016. The difference that BELBUCA as Schedule III offers over Schedule II opioids, such as oxycodone, hydrocodone, morphine, etc., include higher safety index, lower addiction, diversion and abuse
risks accompanied by a dose-ceiling effect on respiratory depression, but not on analgesia. The approval of BELBUCA carries a standard post-approval requirement by the FDA to conduct a study to determine the effect of BELBUCA on QT prolongation
(i.e. an abnormal lengthening of the heartbeat). Also required is a study assessing the safety and efficacy of BELBUCA in pediatric patients and participation in a consortium with other holders of NDAs for long-acting opioids to assess and better
understand the risk of abuse, misuse, addiction and overdose with opioids. Both studies are pending. Prescription sales of BELBUCA have significantly increased since promotion began.



BUNAVAIL was approved by the FDA in June 2014 and is indicated for the treatment of opioid dependence.
BUNAVAILuses our BEMA technology combined with buprenorphine in tandem with naloxone, an opioid antagonist. We are commercializing BUNAVAIL ourselves and launched the product during the fourth
quarter of 2014. We have been actively engaged in efforts to optimize our commercialization of BUNAVAIL with particular emphasis in 2016 on better aligning costs with revenue and reducing spending. We will seek to continue to manage our BUNAVAIL
business by focusing sales efforts on those healthcare providers who have been prescribers of BUNAVAIL. And we will continue to use published data demonstrating diversion (i.e., the illicit use of a legally prescribed controlled
substance) associated with the market leaders product and highlight the other attributes of BUNAVAIL as we seek to win additional managed care contracts. We also believe there will be an opportunity to introduce more patients to BUNAVAIL with
the lifting of the long-standing limit on the number of buprenorphine-treated patients per practitioner from 100 to 275 (as outlined in the final ruling under the Drug Addiction Treatment Act of 2000, or DATA 2000, and effective on October 27,
2016), and a more recent legislation allowing nurse practitioners and physician assistants to prescribe buprenorphine for opioid dependence. We will continue to closely monitor commercial efforts and seek to increase revenue and profitability, as
well as evaluate all options available to preserve the long-term prospects for and maximize the value of BUNAVAIL. Separately, as with all other buprenorphine-containing products for opioid dependence, the approval of BUNAVAIL

carries a standard post-approval requirement by the FDA to conduct a study to determine the effect of BUNAVAIL on QT prolongation.



ONSOLIS is approved in the U.S., the EU (where it is marketed as BREAKYL) and Taiwan (where it is marketed
as PAINKYL), for the management of breakthrough pain in opioid tolerant adult patients with cancer. ONSOLIS utilizes our BEMA thin film drug delivery technology in combination with fentanyl. The commercial rights to ONSOLIS were originally licensed
to Mylan, a subsidiary of Mylan N.V., in 2006 and 2007 for all territories worldwide except for Taiwan (where it is licensed to TTY) and South Korea. The marketing authorization for ONSOLIS was returned to us in early 2015 as part of an assignment
and revenue sharing agreement with Mylan for the United States, Canada and Mexico. Such agreement also facilitated the approval of a new formulation of ONSOLIS in the U.S. We are currently assessing our commercial options for ONSOLIS. On
January 27, 2015, we announced that we had entered into an assignment and revenue sharing agreement with Mylan to return to us the marketing authorizations for ONSOLIS for the U.S. and the right to seek marketing authorizations for ONSOLIS in
Canada and Mexico. On May 11, 2016, we announced the signing of a licensing agreement under which we granted the exclusive rights to commercialize ONSOLIS in the U.S. to Collegium. Under terms of the agreement, Collegium was responsible for the
manufacturing, distribution, marketing and sales of ONSOLIS in the U.S. Mylan continues to commercialize ONSOLIS under the brand name BREAKYL in the E.U. However, on December 8, 2017, Collegium provided us the required 90-day notice regarding termination of the license and development agreement for ONSOLIS between us and Collegium. The license and development agreement for ONSOLIS between us and Collegium formally ended on
March 8, 2018. Previous efforts to extend our supply agreement with our original ONSOLIS manufacturer Aveva, who was subsequently acquired by Apotex, were unsuccessful and the agreement expired. However, an alternate supplier was identified and
data to support qualification of the new manufacturer was submitted to the FDA in June 2018. On October 22, 2018, we received notification of FDAs approval of the regulatory submission and the new ONSOLIS manufacturer. We are
currently assessing options to commercialize ONSOLIS including partnership or introducing ONSOLIS utilizing the companys existing pain sales force.



Buprenorphine Extended Release Injection is an injectable, extended-release, microparticle formulation of
buprenorphine for the treatment of opioid dependence and chronic pain, the rights to which were secured when we entered into a definitive development and exclusive license option agreement from Evonik in October 2014. In 2015, we completed initial
development work and preclinical studies which have resulted in the identification of a formulation we believe can provide 30 days of continuous buprenorphine treatment. We submitted an IND for this product candidate to the FDA in December 2016.
Subsequently, the agreement has terminated and the options granted therein have expired. We continue to evaluate whether or not to further advance this particular program.

We expect to continue our development of pharmaceutical products and related drug delivery technologies, some of which will be funded by our
commercialization agreements. We will continue to seek additional license agreements, which may include upfront payments. We anticipate that funding for the next several years will come primarily from earnings from sales of BELBUCA and BUNAVAIL,
milestone payments and royalties from Mylan and TTY, potential sales of securities and collaborative development agreements, including those with pharmaceutical companies.

We have, since our founding, received revenue in the form of: (i) product sales from our BELBUCA and BUNAVAIL products,
(ii) contract revenue from Endo related to an upfront, non-refundable payment for a license of our BELBUCA product in 2012, (iii) payment from Endo for certain patent-related milestones
(iv) royalty revenue from Mylan for sales of BREAKYL and ONSOLIS, (vi) upfront non-refundable license and milestone payments from Mylan in 2007, 2008, 2009 and 2012 (vi) contract revenue from
Endo related to two full database locks in 2014, (vii) contract revenue from Endo upon FDA acceptance of the filed NDA of our BELBUCA product in 2015 and subsequent regulatory approval, (viii) and sponsored research revenue from both Endo
and Mylan. Only the BELBUCA and BUNAVAIL product sales and BREAKYL royalty revenues have the potential to be repeating or predictable.

Readers are cautioned that period-to-period comparisons of our
operating results should not be relied upon as predictive of future performance. Our prospects must be considered in light of the risks, expenses and difficulties normally encountered by companies that are involved in the commercialization of their
products and related technologies, particularly companies in new and rapidly changing markets such as pharmaceuticals, drug delivery and biotechnology. We must maintain our relationships with our key commercial partners and address regulatory, legal
and/or commercial issues and risks that relate to our business from time to time, many of which could impact, perhaps negatively, our planned operations. We may not be able to appropriately address these risks and difficulties.

Critical Accounting Policies and Estimates

Estimates

The preparation of consolidated financial statements requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial

statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. We review all significant estimates affecting the consolidated
financial statements on a recurring basis and records the effect of any necessary adjustments prior to their issuance. Significant estimates of our include: revenue recognition, sales allowances such as returns of product sold, government program
rebates, customer coupon redemptions, wholesaler/pharmacy discounts, product service fees, rebates and chargebacks, sales bonuses, stock-based compensation, determination of fair values of assets and liabilities relating to business combinations,
and deferred income taxes.

Impairment Testing

In accordance with Generally Accepted Accounting Principles, or GAAP, goodwill impairment testing is performed at the reporting unit level
annually, or more frequently if indicated by events or conditions. We performed an evaluation and determined that there is only one reporting unit. In performing a goodwill impairment test, GAAP allows for either a qualitative or a quantitative
assessment to be performed. If a qualitative evaluation determines that no impairment exists, then no further analysis is performed. If a qualitative evaluation is unable to determine whether impairment has occurred, a quantitative evaluation is
performed. The quantitative impairment test first identifies potential impairments by comparing the fair value of the reporting unit with its carrying value. If the carrying value exceeds the fair value, an impairment charge is recorded based on
that difference. The determination of goodwill impairment is highly subjective. It considers many factors both internal and external and is subject to significant changes from period to period. No goodwill impairment charges have resulted from this
analysis for 2018, 2017 or 2016.

An impairment of a long-lived asset other than goodwill is recognized under GAAP if the carrying value
of the asset (or the group of assets of which it is a part) exceeds (i) the future estimated undiscounted cash flow from the use of the asset (or group of assets) and (ii) the fair value of the asset (or asset group). In making this
impairment assessment, we predominately use an undiscounted cash flow model derived from internal forecasts. Factors that could change the result of our impairment test include, but are not limited to, different assumptions used to forecast future
net sales, expenses, capital expenditures, and working capital requirements used in our cash flow models. If our management determines that the value of intangible assets have become impaired using this approach, we will record an accounting charge
for the impairment. No impairment charges have been recorded for other amortizing intangibles in 2018, 2017 or 2016.

The Assigned Value of Acquired
Tangible and Intangible Assets and Assumed and Contingent Liabilities Associated with Business Combinations

We account for
acquisitions of businesses using the acquisition method of accounting where the cost is allocated to the underlying net tangible and intangible assets acquired, based on their respective estimated fair values. If the estimated fair values of the net
assets acquired is more than the purchase price, the excess is immediately recorded in earnings as a bargain purchase gain. Alternatively, if the purchase price is greater than the estimated fair values of the net assets acquired, the excess is
recorded as goodwill. Determining the fair value of certain acquired assets and liabilities is subjective in nature and often involves the use of significant estimates and assumptions, including, but not limited to, the selection of appropriate
valuation methodology, projected revenue, expenses and cash flows, weighted average cost of capital, discount rates and estimates of terminal values. Business acquisitions are included in our consolidated financial statements as of the date of the
acquisition.

Inventory Valuation

We
provide inventory write-downs determined primarily by the accumulated cost to manufacture our inventory, which is impacted by component costs and manufacturing yields. The write-down is measured as the difference between the cost of the inventory
and net realizable value and charged to cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in
that newly established cost basis.

We provide a reserve for excess and obsolete inventories identified by a lot-by-lot analysis of our finished goods inventory which considers the expiration dates and future demand forecasts. The write-down is measured as the difference between the
cost of the inventory on-hand and the expected demand of the inventory. At the point of the loss recognition, a charge to cost of sales is recorded and a reserve is established for that inventory. The
inventory reserve is relieved upon the future sale or disposal of that inventory.

Stock-Based Compensation and other Stock-Based Valuation Issues

We account for stock-based awards to employees and non-employees using fair value-based method
to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. Fair values of equity securities issued are determined by management based predominantly on the trading price of our common
stock. The values of these awards are based

upon their grant-date fair value. That cost is recognized over the period during which the employee is required to provide service in exchange for the award.

We use the Black-Scholes option pricing model to determine the fair value of stock option and warrant grants. In applying the Black-Scholes
option pricing model, assumptions are as follows:

2018

2017

2016

Expected price volatility

60.34%-68.77%

68.76%-78.79%

62.65%-80.78%

Risk-free interest rate

2.05%-3.00%

1.77%-2.05%

0.56%-1.70%

Weighted average expected life in years

6 years

6 years

6 years

Dividend yield







Revenue Recognition

Revenue from Contracts with Customers

Effective January 1, 2018, we adopted Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with
Customers, using the modified retrospective approach. We utilized a comprehensive approach to assess the impact of the guidance on our contract portfolio. We reviewed our current accounting policies and practices to identify potential
differences resulting from the application of the new requirements to our revenue contracts, including evaluation of performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price,
allocating the transaction price to each separate performance obligation and accounting treatment of costs to obtain and fulfill contracts. In addition, we will update certain disclosures, as applicable, included in our financial statements to meet
the requirements of the new guidance beginning in January 1, 2018. Under the new guidance, we are required to evaluate the impact of estimating variable consideration related to our product sales and licensing contracts. We will use the
expected value method to estimate the total revenue of the contract, constrained by the probability that there would not be a significant revenue reversal in a future period. We will continue to evaluate the expected value of revenue over the term
of the contract and adjust revenue recognition as appropriate. Based on this evaluation, the adoption will not have a material impact on our financial position, results of operations, cash flows, accounting policies, business processes, internal
controls or disclosures.

Product sales

Under the new accounting guidance, we recognize revenue on product sales when control of the promised goods is transferred to our customers in
an amount that reflects the consideration expected to be received in exchange for transferring those goods. We account for a contract when we have approval and commitment from both parties, the rights of the parties are identified, payment terms are
identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the customer has obtained control of the goods, we consider any future performance obligations. Generally, there is no
post-shipment obligations on product sold.

Performance obligations

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in Topic
606. A contracts transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The majority of our product sales contracts have a single performance
obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, therefore, not distinct. Our performance obligations are satisfied at a point in time. The multiple performance
obligations are not allocated based off of the obligations but based off of standard selling price.

In our analyses, we use prescription data purchased from a third-party data provider to develop estimates of historical inventory channel
sell-through. We utilize an internal analysis to compare historical net product shipments to estimated historical prescriptions written. Based on that analysis, management develops an estimate of the quantity of product in the channel which may be
subject to various rebate, chargeback and product return exposures. To estimate months of ending inventory in our distribution channel, we divide estimated ending inventory in the distribution channel by our recent prescription data, not considering
any future anticipated demand growth beyond the succeeding quarter. Monthly for each product line, we prepare an internal estimate of ending inventory units in the distribution channel by adding estimated inventory in the channel at the beginning of
the period, plus net product shipments for the period, less estimated prescriptions written for the period. This is done for each product line by applying a rate of historical activity for rebates, chargebacks and product returns, adjusted for
relevant quantitative and qualitative factors discussed above, to the potential exposed product estimated to be in the distribution channel. In addition, we receive daily information from the wholesalers regarding their sales and actual on hand
inventory levels of our products. This enables us to execute accurate provisioning procedures.

Product returns-Consistent with
industry practice, we offer contractual return rights that allow our customers to return our products within an 18-month period that begins six months prior to and ends twelve months after expiration of the
products.

Rebates- The liability for government program rebates is calculated based on historical and current rebate redemption
and utilization rates contractually submitted by each programs administrator.

Price adjustments and chargebacks-Our estimate
of price adjustments and chargebacks are based on its estimated mix of sales to various third-party payers, which are entitled either contractually or statutorily to discounts from our listed prices of our products. If the sales mix to third-party
payers is different from our estimates, we may be required to pay higher or lower total price adjustments and/or chargebacks than it had estimated, and such differences may be significant.

From time to time, we offer certain promotional product-related incentives to our customers. These programs include certain product incentives
to pharmacy customers and other sales stocking allowances. We have voucher programs for BELBUCA and BUNAVAIL whereby we offer a point-of-sale subsidy to retail
consumers. We estimate our liabilities for these voucher programs based on the actual redemption rates as reported to us by a third-party claims processing organization. We account for the costs of these special promotional programs as price
adjustments, which are a reduction of gross revenue.

Prompt payment discounts-We typically offers our wholesale customers a prompt
payment discount of 2% as an incentive to remit payments within the first 30 to 37 days after the invoice date depending on the customer and the products purchased.

Gross To Net Accruals

A significant
majority of our gross to net adjustments to gross product revenues are the result of accruals for our voucher program and rebates related to Medicare Part D, the Part D Coverage Gap, Medicaid, and commercial contracts with most of
those programs having an accrual to payment cycle of anywhere from one to three months. In addition to this relatively short accrual to payment cycle, we receive daily information from the wholesalers regarding their sales of our products and actual
on hand inventory levels of its products. This enables us to execute accurate provisioning procedures. Consistent with the pharmaceutical industry, the accrual to payment cycle for returns is longer and can take several years depending on the
expiration of the related products.

Prior to January 2017, we were recording sales when prescriptions were filled. However, beginning in
January 1, 2017, we began recording revenue based on a sell-in method, as we now have achieved the ability to record sales ex-factory.

License and development agreements

We
periodically enter into license and development agreements to develop and commercialize our products. The arrangements typically are multi-deliverable arrangements that are funded through upfront payments, milestone payments and other forms of
payment. Depending on the nature of the contract these revenues are classified as research and development reimbursements or contract revenue.

Product royalty revenue amounts are based on a percentage of net sales revenue of the ONSOLIS product under our license agreement with Mylan.
Product royalty revenues are computed on a quarterly basis when revenues are fixed or determinable, collectability is reasonably assured, and all other revenue recognition criteria are met. Mylan has the right to reject products that do not comply
with product, packaging, or regulatory specifications. Defective product must be identified by Mylan within 10 days after inspection at Mylans distribution site. We bill Mylan immediately upon receipt by Mylan of product (FOB manufacturer). On
a quarterly basis, a reconciliation is prepared that reflects the difference between actual net sales by Mylan multiplied by the royalty percentage, and the actual royalty payments made during the quarter (which is based on a transfer
price at the time we invoice Mylan). The parties true-up the differences within 45 days of each quarter-end.

Cost of Sales

Cost of sales includes
direct costs attributable to the production of BELBUCA, BUNAVAIL, BREAKYLand PAINKYL. Cost of sales also includes royalty expenses owed to third parties.

For BELBUCA and BUNAVAIL, cost of sales includes raw materials, production costs at our contract manufacturing sites, quality testing directly
related to the product, lower of cost of market and depreciation on equipment that we have purchased to produce BELBUCA and BUNAVAIL. It also includes any batches not meeting specifications and raw material yield loss. Beginning
January 1, 2017, cost of sales for BELBUCA and BUNAVAIL were recognized when sold to the wholesaler from our distribution center. There was no deferred cost of sales for the years ended December 31, 2017 nor 2018. Yield losses and batches
not meeting specifications are expensed as incurred.

For BREAKYL and PAINKYL, we do not take ownership of the subject product as we do
not have inventory. Accordingly, raw material product is transferred to Mylan, in the case of BREAKYL and TTY in the case of PAINKYL, immediately in accordance with the terms of our contractual arrangements with Mylan and TTY. LTS manufactures both
products for us. Mylans and TTYs royalty payments to us include an amount related to cost of sales. Ownership and title to the product, including insurance risk, belong to LTS from raw material through completion and inventory
of the subject product, and then to Mylan and TTY upon shipment of such subject product. This is in accordance with our contracts with LTS and Mylan and TTY, which identify the subject product as FOB manufacturer.

Income taxes

On December 22, 2017,
the United States enacted major tax reform legislation, Public Law No. 115-97, commonly referred to as the Tax Cuts and Jobs Act, or the 2017 Tax Act. The 2017 Tax Act, among other changes, lowers the
general corporate income tax rate to 21% for tax years beginning after December 31, 2017, transitions U.S. international taxation from a worldwide tax system to a territorial system, and provides for a
one-time transition tax on the mandatory deemed repatriation of cumulative foreign earnings as of December 31, 2017, which is not applicable to us. We have calculated our impact of the 2017 Tax Act in our
income tax provision during the year ended December 31, 2018, in accordance with our understanding of the 2017 Tax Act and guidance available as of the date of this filing.

We recorded federal income tax benefit during 2018 due to the impact of the 2018 Tax Cuts and Jobs Act. For years beginning after
December 31, 2017, the Act repeals corporate AMT. The credit becomes refundable in an amount equal to 50% of the excess of the credit for the tax year over the amount of the credit allowable for the year against regular tax liability. We
recorded state income tax expense of $0.05 million due to state audit findings related to prior periods. We have recognized valuation allowances for all deferred tax assets for years ending 2018 and 2017.

We are required to reduce any deferred tax asset by a valuation allowance if, based on an assessment of positive and negative evidence,
including estimates of future taxable income necessary to realize future deductible amounts, it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. The valuation
allowance should be sufficient to reduce the deferred tax asset to the amount, which is more likely than not to be realized. As a result, we recorded a valuation allowance with respect to all of our deferred tax assets.

One or more of our legal entities file income tax returns in the U.S. federal jurisdiction and various U.S. state jurisdictions. Our income
tax returns are subject to audit by the tax authorities in those jurisdictions. Significant disputes may arise with authorities involving issues of the timing and amount of deductions, the use of tax credits and allocations of income and expenses
among various tax jurisdictions because of differing interpretations of tax laws, regulations and the interpretation of the relevant facts. We are no longer subject to U.S. federal or state tax examinations for years ended on or before
December 31, 2014.

For the Year Ended December 31, 2018 Compared to the Year Ended December 31, 2017

Product Sales. We recognized $51.4 million and $34.9 million in product sales during the years ended 2018 and 2017,
respectively, from our products BELBUCA and BUNAVAIL. The increase in 2018 over 2017 is a result of managed care wins and the expansion of our salesforce in 2018.

Product Royalty Revenues. We recognized $3.4 million and $5.1 million in product royalty revenue during the years ended 2018
and 2017, respectively. The decrease in product royalty revenues in 2018 can be attributed to timing of BREAKYL sales from Mylan and PAINKYL sales from TTY.

Research and Development Reimbursements. We recognized $0.0 million and $0.8 million of reimbursable revenue during the years
ended 2018 and 2017, respectively, which relates to our former license agreement with Collegium and composed of reimbursement to us for a pre-determined amount of the remaining expenses associated with the
transfer of the manufacturing of ONSOLIS.

Contract Revenues. We recognized $0.8 million and $21.2 million in contract
revenue during the years ended 2018 and 2017, respectively. We recognized $1.0 million in contract revenue during the year ended December 31, 2018 related to our license agreement with Purdue, which was for the Canadian commercial
launch and related milestones. Due to the termination of the Purdue contract in March 2019, the aforementioned contract revenue was offset by the reversal of $0.2 million in milestone revenue. Contract revenue in 2017 includes $20 million
from Endo related to a patent extension that was previously recorded as deferred revenue because all or a portion of such $20 million was contingently refundable to Endo if a third party generic product was introduced in the U.S. during the
patent extension period from 2020 to 2027. However, due to the termination agreement with Endo signed on December 7, 2016 which terminated the BELBUCA license to Endo effective January 6, 2017, the deferred $20 million was recognized
as revenue in January 2017. The remaining $1.2 million in contract revenues during 2017 was related to our license agreement with Purdue Canada.

Cost of Sales. We incurred $15.8 million and $19.5 million in cost of sales during the years ended 2018 and 2017,
respectively. In 2018, we had minimum $1.5 million contractual royalty due to CDC related to our ONSOLIS and BREAKYL product. Also, in 2018, we incurred $11.5 million in cost of sales for BELBUCA and BUNAVAIL plus $0.9 million
related depreciation of manufacturing equipment and $0.3 million in immediate expensing of certain production that did not meet specifications during product validation and batch size scale up and yield losses. Also included in 2018 was
$0.7 million in cost of sales for BREAKYL, $0.5 million in cost of sales for PAINKYL and $0.4 million cost of sales related to BELBUCA royalty. In 2017, we had minimum $1.5 million contractual royalty due to CDC related to our
ONSOLIS and BREAKYL product. Also, in 2017, we incurred $15.8 million in cost of sales for BELBUCA and BUNAVAIL royalties paid, lower of cost or net realized value, plus $0.6 million related depreciation of manufacturing equipment and
$0.2 million in immediate expensing of certain production that did not meet specifications during product validation and batch size scale up and yield losses. Also included in 2017 was $1.0 million in cost of sales for BREAKYL,
$0.3 million in cost of sales for PAINKYL and $0.1 million cost of sales related to ONSOLIS.

Selling, General and
Administrative Expenses. During the years ended December 31, 2018 and 2017, selling, general and administrative expenses totaled $58.6 million and $58.9 million, respectively. Selling, general and administrative costs include
BELBUCA and BUNAVAIL sales, marketing, and commercial expenses. These costs also include legal expenses for patent defense, professional fees, wages and stock-based compensation expense.

Interest Expense, Net. During the year ended December 31, 2018, we had net interest expense of $10.2 million, consisting of
$6.1 million of scheduled interest payments and $3.0 million of related amortization of discount and loan costs and $1.1 million of warrant interest expense all related to the February 2017 CRG Term Loan Agreement. During the year
ended December 31, 2017, we had net interest expense of $8.6 million, consisting of $4.4 million of scheduled interest payments and $1.1 million of related amortization of discount and loan costs and $0.6 million of warrant
interest expense all related to the February 2017 CRG Term Loan Agreement. In addition, we had remaining $0.9 million of scheduled interest payments and $1.4 million of related amortization of discount, loan costs and loan pay off and
$0.2 million of warrant interest expense all related to the July 2013 secured loan facility from MidCap, which was paid off with the CRG term loan.

Bargain Purchase Gain. During the year ended December 31, 2017, we recorded the value of the bargain purchase gain of the BELBUCA
acquisition from Endo totaling $27.3 million to income. There was no such amount recorded during the year ended December 31, 2018 nor 2016.

Income Tax Expense and Tax Net Operating Loss Carryforwards. We have a federal net operating loss carry forward, or NOLs, of
approximately $279 million as of December 31, 2018. Under Section 382 and 383 of the Internal Revenue Code, if an ownership

change occurs with respect to a loss corporation, as defined, there are annual limitations on the amount of the NOLs and other deductions, which are available to us. The portion of
the NOLs incurred prior to May 16, 2006 is subject to this limitation. As such, the use of these NOLs to offset taxable income is limited to approximately $1.5 million per year. Our State NOLs are approximately $264 million as of
December 31, 2018. These loss carryforwards expire between 2024 and 2037 for federal NOLs and 2030 for state NOL generated prior to December 31, 2017. The federal NOLs generated in 2018 of $3.28 million will have an indefinite
carryforward life due to tax reform. Management has evaluated all other tax positions that could have a significant effect on the financial statements and determined that we have no uncertain income tax positions at December 31, 2018.

Expenditures for Research and Development Programs (2018 vs. 2017)

Our research and development expenditures for our approved products and product candidates are as follows in thousands:

Year EndedDecember 31,

CumulativethroughDecember 31,

2018

2017

2018

BELBUCA

$

3,869

$

8,497

$

126,566

BUNAVAIL

418

2,185

41,303

ONSOLIS

615

1,254

3,669

Buprenorphine ER Injection

(14

)

885

9,771

Clonidine Topical Gel*

15

219

27,534

*

Clonidine Topical Gel product candidate was discontinued in December 2016. Minimal expenses in 2017 consist of
the winding down of the product candidate which includes allocated wages and compensation.

Results of Operations

For the Year Ended December 31, 2017 Compared to the Year Ended December 31, 2016

Product Sales. We recognized $34.9 million and $8.3 million in product sales during the years ended 2017 and 2016,
respectively, from our products BELBUCA and BUNAVAIL. The increase in 2017 over 2016 is a result of the reacquisition of BELBUCA in January 2017.

Product Royalty Revenues. We recognized $5.1 million and $3.6 million in product royalty revenue during the years ended 2017
and 2016, respectively. The increase in product royalty revenues in 2017 can be attributed to timing of BREAKYL sales from Mylan and PAINKYL sales from TTY.

Research and Development Reimbursements. We recognized $0.8 million and $1.1 million of reimbursable revenue during the years
ended 2017 and 2016, respectively, which relates to our license agreement with Collegium and composed of reimbursement to us for a pre-determined amount of the remaining expenses associated with the ongoing
transfer of the manufacturing of ONSOLIS.

Contract Revenues. We recognized $21.2 million and $2.5 million in contract
revenue during the years ended 2017 and 2016, respectively. Contract revenue in 2017 includes $20 million from Endo related to a patent extension that was previously recorded as deferred revenue because all or a portion of such
$20 million was contingently refundable to Endo if a third party generic product was introduced in the U.S. during the patent extension period from 2020 to 2027. However, due to us and Endo entering into a termination agreement on
December 7, 2016 which terminated the BELBUCA license to Endo effective January 6, 2017, the deferred $20 million was recognized as revenue in January 2017. The remaining $1.2 million in contract revenues during 2017 was related
to our license agreement with Purdue Canada. We recognized $2.5 million in contract revenue during 2016 related to our license agreement with Collegium for ONSOLIS.

Cost of Sales. We incurred $19.5 million and $11.3 million in cost of sales during the years ended 2017 and 2016,
respectively. In 2017, we had minimum $1.5 million contractual royalty due to CDC related to our ONSOLIS and BREAKYL product. Also, in 2017, we incurred $15.8 million in cost of sales for BELBUCA and BUNAVAIL royalties paid, lower of
cost or net realized value, plus $0.6 million related depreciation of manufacturing equipment and $0.2 million in immediate expensing of certain production that did not meet specifications during product validation and batch size scale up
and yield losses. Also included in 2017 was $1.0 million in cost of sales for BREAKYL, $0.3 million in cost of sales for PAINKYL and $0.1 million cost of sales related to ONSOLIS. In 2016, we had $1.9 million contractual royalty
due to Mylan related to our ONSOLIS licensing arrangement with Collegium and a standard, minimum $1.5 million contractual royalty due to CDC related to our ONSOLIS and BREAKYL product. Also, in 2016, we incurred $6.3 million in cost
of sales for BUNAVAIL plus $0.6 million related depreciation of manufacturing equipment and $0.2 million in immediate expensing of certain production that did not meet specifications during product validation and batch size scale up. Also
included in 2016 was $0.7 million in cost of sales for BREAKYL and $0.1 million cost of sales related to BELBUCA.

Selling, General and Administrative Expenses. During the years ended
December 31, 2017 and 2016, selling, general and administrative expenses totaled $58.9 million and $49.3 million, respectively. Selling, general and administrative costs include BELBUCA and BUNAVAIL sales, marketing, and commercial
expenses. These costs also include legal expenses for patent defense, professional fees, wages and stock-based compensation expense. The increase in selling, general and administrative expenses in 2017 can be attributed to the increased
marketing related to our 2017 reacquisition of BELBUCA and expansion of our sales force as a result.

Interest Expense, Net. During
the year ended December 31, 2017, we had net interest expense of $8.6 million, consisting of $4.4 million of scheduled interest payments and $1.0 million of related amortization of discount and loan costs and $0.6 million of
warrant interest expense all related to the February 2017 CRG Term Loan Agreement. In addition, we had remaining $0.9 million of scheduled interest payments and $1.4 million of related amortization of discount, loan costs and loan pay off
and $0.2 million of warrant interest expense all related to the July 2013 secured loan facility from MidCap, which was paid off with the CRG term loan. During the year ended December 31, 2016 we had net interest expense
of $3.3 million, consisting of $2.9 million of scheduled interest payments and $0.4 million of related amortization of discount and loan costs associated with the July 2015 secured loan facility from MidCap.

Bargain Purchase Gain. During the year ended December 31, 2017, we recorded the value of the bargain purchase gain of the BELBUCA
acquisition from Endo totaling $27.3 million to income. There was no such amount recorded during the year ended December 31, 2016.

Income Tax Expense and Tax Net Operating Loss Carryforwards. We had federal and state NOLs of approximately $263 million and
$292 million, respectively at December 31, 2017 as compared to federal and state NOLs of $225 million and $258 million, respectively as of December 31, 2016. These loss carryforwards expire principally beginning in 2020
through 2035 for federal and 2030 for state purposes, respectively. In accordance with GAAP, it is required that a deferred tax asset be reduced by a valuation allowance if, based on an assessment of positive and negative evidence, including
estimates of future taxable income necessary to realize future deductible amounts, it is more likely than not (a likelihood of more than 50 percent) that some portion or all of the deferred tax assets will not be realized. The valuation allowance
should be sufficient to reduce the deferred tax asset to the amount which is more likely than not to be realized. As a result, we recorded a valuation allowance with respect to all of our deferred tax assets. Under Section 382 and 383 of the
Internal Revenue Code, if an ownership change occurs with respect to a loss corporation (as defined in the Internal Revenue Code), there are annual limitations on the amount of the net operating loss and other deductions which are
available to us.

Expenditures for Research and Development Programs (2017 vs. 2016)

Our research and development expenditures for our approved products and product candidates are as follows in thousands:

Year EndedDecember 31,

CumulativethroughDecember 31,

2017

2016

2017

BELBUCA

$

8,497

$

31

$

122,697

BUNAVAIL

2,185

5,161

40,885

ONSOLIS

1,254

1,487

3,054

Buprenorphine ER Injection

885

5,674

9,785

Clonidine Topical Gel*

219

6,525

27,519

*

Clonidine Topical Gel product candidate was discontinued in December 2016. Minimal expenses in 2017 consist of
the winding down of the product candidate which includes allocated wages and compensation.

Revenues

The following table summarizes net product sales for the years ended December 31 in thousands:

In 2018 we transitioned from a research and development-oriented organization into one that is more commercially focused. As such, we expanded
our medical affairs capabilities and honed our efforts toward maximizing our products in the market, particularly with our lead asset, BELBUCA. Specifically, our resources and energies were focused on:

Developing a robust medical affairs plan for BELBUCA and defining future clinical studies, publications, congress
activities, and educational initiatives to deliver on the strategic imperatives in order to inform all stakeholders on the attributes of BELBUCA in order that it can become an option for patients suffering with chronic pain



Continuing to progress post-marketing requirements, or PMRs and plans for BELBUCA and BUNAVAIL; and



Providing Pharmacovigilance, or PV and drug safety support for BELBUCA, BUNAVAIL, and ONSOLIS.

Our estimates of development costs, medical affairs initiatives, and our projected sales associated with each of our
product candidates discussed below and elsewhere in this Report are merely estimates and subject to multiple factors, many of which are, or may be beyond our control, including those detailed in the Risk Factors section of this Report. These factors
and risks could cause delays, cost overruns or otherwise cause us to not achieve these estimates. Readers are also advised that our projected sales figures do not consider the royalties and other payments we will need to make to our licensors and
strategic partners. Our estimates are based upon our market research and managements reasonable judgments, but readers are advised that such estimates may prove to be inaccurate.

The following is a summary of our current and past major product and product candidate initiatives at December 31, 2018:

BELBUCA (buprenorphine buccal film). Following the transfer of BELBUCA to us in January 2017, we led clinical and Medical Affairs
support behind BELBUCA. We have assumed responsibility for the conduct of post approval commitments specified by FDA in the approval of BELBUCA, which include a thorough QT, or TQT study and a pediatric study. In September 2013, the FDA announced
that it will require all companies holding NDAs for extended-release/long-acting, or ER/LA opioid analgesic drug products to conduct four post-marketing studies regarding risks associated with their long-term use and one clinical trial to estimate
risk of hyperalgesia. The FDA replaced the original requirements with new post-marketing requirements in February 2016. The Opioid PMR Consortium was formed with representatives from each of the member companies providing an opportunity for one
set of studies to be completed to satisfy the FDA requirements and distributing the associated costs across all member companies. Each member company pays an equal share of the program costs and new members are required to pay equal share of the
costs to date upon program entry and of future costs going forward. We joined the Opioid PMR Consortium in October 2017 and our initial share of the program cost was paid in late 2017. To date, six of eleven studies have been completed and the
program is expected to continue into 2020.

BUNAVAIL. Activities in 2017 included work to support a label expansion of BUNAVAIL for
the induction (conversion to buprenorphine) of opioid dependent subjects, performance of FDA post-marketing study requirements and improvements in commercial manufacturing. In May 2017, we announced that the FDA expanded the BUNAVAIL label to
include induction of opioid dependent patients.

ONSOLIS. We had been collaborating with our U.S. partner Collegium on the ongoing
transfer of manufacturing (including the production of registration batches) toward the submission of a Prior Approval Supplement to the FDA. In December 2017, we announced the termination of our U.S. ONSOLIS agreement with Collegium. In 2018 we
continued to explore U.S. commercialization options, including the use of our current sales force, or potentially out-licensing the product, and obtained FDA approval of an alternate manufacturing site.

Buprenorphine Extended Release Injection. In 2014, we entered into an agreement with Evonik to develop and commercialize a long-acting
buprenorphine injection capable of providing 30 days of continuous buprenorphine blood concentrations following a single monthly injection. In 2015, we completed initial development work and preclinical studies which have resulted in the
identification of a formulation we believe can provide 30 days of continuous buprenorphine treatment. During a pre-IND meeting with FDA in November 2015, the FDA requested an additional study to assess the
fate of the polymers used in the formulation. We completed this study and submitted an IND for this product candidate to FDA in December 2016. Subsequently, the agreement has terminated and the options granted therein have expired. We continue to
evaluate whether or not to further advance this program.

Liquidity and Capital Resources

Since inception, we have financed our operations principally from the sale of equity securities, proceeds from borrowings, convertible notes,
and notes payable, funded research arrangements, revenue generated as a result of our worldwide license and

development agreements , the commercialization of our BELBUCA and BUNAVAIL products. We intend to finance our commercialization and working capital needs from existing cash, earnings from the
commercialization of BELBUCA and BUNAVAIL, royalty revenue, new sources of debt and equity financing, existing and new licensing and commercial partnership agreements and, potentially, through the exercise of outstanding common stock options and
warrants to purchase common stock.

On May 11, 2016, we and Collegium executed a definitive License and Development Agreement under
which we granted to Collegium the exclusive rights to develop and commercialize ONSOLIS in the U.S, resulting in a milestone of $2.5 million paid to us in June 2016.

During 2016, we received cumulative payments totaling $1.3 million which related to royalties based on product purchased in Europe by
Mylan of BREAKYL.

During 2016, we received cumulative payments totaling $0.9 which related to royalties based on product purchased in
Taiwan by TTY of PAINKYL.

On December 8, 2016, we announced that we had entered into an agreement Endo terminating Endos
licensing of rights for BELBUCA. The closing of the Termination Agreement, and the formal termination of the BELBUCA license to Endo and closing of the transactions occurred on January 6, 2017.

On July 12, 2017, we, along with Purdue Pharma (Canada) announced that we had signed an exclusive agreement for the licensing,
distribution, marketing and sale of BELBUCA in Canada. In return for the licensing and distribution rights to BELBUCA in Canada, we were eligible to receive upfront and potential milestones of up to CAD 4.5 million as well as royalties on net
sales, including approximately CAD 1.5 million (0.5 million CAD and 1.0 million CAD received August 2017 and October 2017, respectfully).

During 2017, we received cumulative payments totaling $2.2 million which related to royalties based on product purchased in Europe by
Mylan of BREAKYL.

During 2017, we received cumulative payments totaling $1.2 million which related to royalties based on product
purchased in Taiwan by TTY of PAINKYL.

On May 22, 2018, we announced the closing of the $50 million registered direct
offering of newly designated Series B Stock. The offering closed on May 21, 2018, yielding net proceeds of $47.9 million to us.

During 2018, we received cumulative payments totaling $1.8 million which related to royalties based on product purchased in Europe by
Mylan of BREAKYL.

During 2018, we received cumulative payments totaling $1.5 million which related to royalties based on product
purchased in Taiwan by TTY of PAINKYL.

During 2018, we received cumulative payments totaling $1.0 million which related to
milestones and royalties based on product purchased in Canada by Purdue of BELBUCA.

CRG Term Loan Agreement

On February 21, 2017, we entered into a term loan agreement, or the Term Loan Agreement with CRG, as administrative agent and collateral
agent, and the lenders named in the Term Loan Agreement (the Lenders). We utilized approximately $29.4 million of the initial loan proceeds under the Term Loan Agreement to repay all the amounts owed by us under the 2015 MidCap
Credit Agreement.

Pursuant to the Term Loan Agreement, we borrowed $45.0 million from the Lenders as of the Closing Date and were
eligible to borrow up to an additional $15.0 million contingent upon achievement of certain conditions. On December 26, 2017, we were eligible and elected to receive the Second Draw for gross proceeds of $15.0 million.

After the payoff of the MidCap Credit Agreement, we utilized the initial proceeds under the Term Loan Agreement (after deducting loan
origination costs and broker and other fees) of approximately $13.7 million, plus any additional amounts borrowed in the future, for general corporate purposes and working capital. The original Term Loan Agreement had a six-year term with three years of interest-only payments, (from 2017-2019). On May 16, 2018, we entered into an amendment to our Term Loan Agreement with CRG. Pursuant to the amendment: (i) the
interest only period of the Loan Agreement was extended by one year, and certain milestones previously required for the extended interest only period have been removed; (ii) the PIK period (under which a portion

of the interest accrued under the Loan Agreement can be deferred to maturity) will also be extended for a year, (to 2020); (iii) amortization of the loan principal can be deferred until
maturity (making the payment of the loan a balloon payment) if we achieve and maintain a market capitalization of $200 million prior to the conclusion of the interest only period (provided that if we achieve, and thereafter falls
below a $200 million market capitalization, amortization of the loan principal will resume); and (iv) certain our revenue targets, the failure of which would create an event of default under the loan, have been recalculated. Interest on
the amounts borrowed under the Term Loan Agreement accrues at an annual fixed rate of 12.50%, 3.5% of which may be deferred during the interest-only period by adding such amount to the aggregate principal loan amount. On each borrowing date
(including the Closing Date), we are required to pay CRG a financing fee based on the loan drawn on that date. We are also required to pay the Lenders a final payment fee equivalent to 9% of the original loan amount upon repayment of the loans in
full, in addition to prepayment amounts described below.

At December 31, 2018, we had cash of approximately $43.8 million. We
used $24.1 million of cash in operations during the year ended December 31, 2018 and had stockholders equity of $29.7 million, versus stockholders equity of $8.9 million at December 31, 2017. We believe that we
have sufficient current cash, along with expected proceeds from sales to manage the business as currently planned.

Additional capital may
be required to support the continued commercialization of our BELBUCA and BUNAVAIL products, the anticipated commercial relaunch of ONSOLIS, the potential continued development of Buprenorphine Extended Release Injection or other products which may
be acquired or licensed by us, and for general working capital requirements. Based on product development timelines and agreements with our development partners, the ability to scale up or reduce personnel and associated costs are factors considered
throughout the product development life cycle. Available resources may be consumed more rapidly than currently anticipated, potentially resulting in the need for additional funding. Additional funding, capital or loans (including, without
limitation, milestone or other payments from commercialization agreements) may be unavailable on favorable terms, if at all.

Also,
product development timelines and agreements with our development partners, the ability to scale up or reduce personnel and associated costs are factors considered throughout the product development life cycle. Available resources may be consumed
more rapidly than currently anticipated, resulting in the need for additional funding.

Accordingly, we anticipate that we will be
required to raise additional capital, which may be available to us through a variety of sources, including:



public equity markets;



private equity financings;



commercialization agreements and collaborative arrangements;



sale of product royalty;



grants and new license revenues;



bank loans;



equipment financing;



public or private debt; and



exercise of existing warrants and options.

Readers are cautioned that additional funding, capital or loans (including, without limitation, milestone or other payments from
commercialization agreements) may be unavailable on favorable terms, if at all. If adequate funds are not available, we may be required to significantly reduce or refocus our operations or to obtain funds through arrangements that may require us to
relinquish rights to certain technologies and drug formulations or potential markets, either of which could have a material adverse effect on us, our financial condition and our results of operations in 2019 and beyond. To the extent that additional
capital is raised through the sale of equity or convertible debt securities, the issuance of such securities would result in ownership dilution to existing stockholders.

Contractual Obligations and Commercial Commitments

Our non-cancellable contractual obligations as of December 31, 2018 are as follows (in thousands):

Minimum royalty expenses represent a contractual floor that we are obligated to pay CDC and NB Athyrium LLC
regardless of actual sales. The minimum payment is $0.4 million per quarter or $1.5 million per year until patent expiry on July 23, 2027.

**

Purchase obligations represent an agreement for the supply of active pharmaceutical ingredient for use in
production.

Off Balance Sheet Arrangements

We are not a party to any off balance sheet arrangements.

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk.

Interest rate risk

Our
cash includes all highly liquid investments with an original maturity of three months or less. Because of the short-term maturities of our cash, we do not believe that an increase in market rates would have a significant impact on the realized value
of our investments. We place our cash on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation covers $0.25 million for substantially all depository accounts. As of December 31, 2018, we had
approximately $43.6 million, which exceeded these insured limits.

Foreign currency exchange risk

We currently have limited, but may in the future have increased, clinical and commercial manufacturing agreements which are denominated in
Euros, CAD or other foreign currencies. As a result, our financial results could be affected by factors such as a change in the foreign currency exchange rate between the U.S. dollar and the Euro, CAD or other applicable currencies, or by weak
economic conditions in Europe, Canada or elsewhere in the world. We are not currently engaged in any foreign currency hedging activities.

Market
indexed security risk

We have issued warrants to various holders underlying shares of our common stock. These warrant investments
were measured at their fair value at date of issuance and recorded as warrant expense in the accompanying consolidated statement of operations. We use the Black-Scholes model for valuation of the warrants.

Item 8.

Financial Statements and Supplementary Data.

Our Consolidated Financial Statements and Notes thereto and the report of Cherry Bekaert LLP, our independent registered public accounting
firm, are set forth on pages F-1 through F-35 of this Report.

Item 9.

Changes In and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

Item 9A.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we
carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e)
under the Exchange Act. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, at December 31, 2018, such disclosure controls and procedures were effective.

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in
our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time

periods specified by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports
filed or submitted under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate, to allow timely decisions regarding
required disclosure.

Limitations on the Effectiveness of Controls

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure
control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected. Our Chief Executive Officer and Chief
Financial Officer have concluded, based on their evaluation as of the end of the period covered by this Report that our disclosure controls and procedures were sufficiently effective to provide reasonable assurance that the objectives of our
disclosure control system were met.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the year ended December 31, 2018 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Managements Report on
Internal Control Over Financial Reporting

As required by the SEC rules and regulations for the implementation of Section 404
of the Sarbanes-Oxley Act, our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of our consolidated financial statements for external reporting purposes in accordance with GAAP. Our internal control over financial reporting includes those policies and procedures that:

(1)

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of our company,

(2)

provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated
financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors, and

(3)

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or
disposition of our assets that could have a material effect on the consolidated financial statements.

Because of its
inherent limitations, internal control over financial reporting may not prevent or detect errors or misstatements in our consolidated financial statements. Also, projections of any evaluation of effectiveness to future periods are subject to the
risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of our internal control over financial reporting at
December 31, 2018. In making these assessments, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (COSO). Based on our assessments and those criteria, management
determined that we maintained effective internal control over financial reporting at December 31, 2018.

Our directors and executive officers and their ages as of March 14, 2019 are as follows:

Name

Age

Position(s) Held

Peter S. Greenleaf

48

Chairman of the Board and Director

Mark A. Sirgo, Pharm.D.

65

Vice Chairman and Director

Herm Cukier

52

Chief Executive Officer and Director

Scott M. Plesha

54

President and Chief Commercial Officer

Mary Theresa Coelho

57

Chief Financial Officer and Treasurer

Thomas B. Smith, M.D.

58

Chief Medical Officer

James Vollins

50

General Counsel, Chief Compliance Officer and Corporate Secretary

Frank E. ODonnell, Jr., M.D.

69

Director

William M. Watson

68

Director

Todd C. Davis

58

Director

Kevin Kotler

47

Director

There are no family relationships between any of our directors or executive officers.

Peter S. Greenleaf, age 48, has been our Chairman of the Board and Director since May 2018. He has served as the Chief Executive
Officer of Cerecor, Inc., since March 2018 and previously served as Chief Executive Officer of Sucampo Pharmaceuticals, Inc. from March 2014 to February 2018, when Sucampo was sold to Mallinckrodt PLC. Prior to that, Mr. Greenleaf served as
Chief Executive Officer of Histogenics Corporation from June 2013 to March 2014, as President of MedImmune, Inc., and MedImmune Ventures from 2010 to June 2013, and Senior Vice President, Commercial Operations of MedImmune from 2006 to 2010.
Mr. Greenleaf also held senior commercial roles at Centocor Biotech, Inc. (now Janssen Biotechnology, Johnson & Johnson), from 1998 to 2006, and at Boehringer Mannheim G.m.b.H. (now Roche Holdings) from 1996 to 1998. Mr. Greenleaf
is a member of the board of directors of Cerecor since May 2017, EyeGate Pharmaceuticals since August 2018 and Antares Pharma since December 2018. Mr. Greenleaf chairs the Maryland Venture Fund Authority and serves a member of the board of
directors of the Biotechnology Industry Organization. He previously served on the boards of PhARMA, the Tech Council of Maryland and the University of Maryland Baltimore Foundation, Inc. Mr. Greenleaf earned an MBA degree from St. Josephs
University and a BS degree from Western Connecticut State University.

Mark A. Sirgo, Pharm.D., age 65, has been our Director since
August 2005 and Vice Chairman since October 2016. He was formerly our President since January 2005 and Chief Executive Officer since August 2005. He joined our company in August 2004 as Senior Vice President of Commercialization and Corporate
Development upon our acquisition of Arius Pharmaceuticals, of which he was a co-founder and Chief Executive Officer. He has also served as our Executive Vice President, Corporate and Commercial Development and
our Chief Operating Officer. Dr. Sirgo has over 35 years of experience in the pharmaceutical industry, including 16 years in clinical drug development, 7 years in marketing, sales, and business development, and 12 years in executive management
positions. Prior to his involvement with Arius Pharmaceuticals, from 2003 to 2004, he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome, and GlaxoSmithKline,
including Vice President of International OTC Development and Vice President of New Product Marketing. Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome, among other accomplishments.
From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc., a leading contract service provider to the pharmaceutical industry. Dr. Sirgo served on the Board of
Directors and as Chairman of the Compensation Committee of Salix Pharmaceuticals, Inc. (NASDAQ:SLXP), a specialty pharmaceutical company specializing in gastrointestinal products, from 2008 until its sale in 2015. Dr. Sirgo was added to the
Board of Directors of Biomerica, Inc. (NASDAQ: BMRA), a diagnostics and therapeutic company, in July 2016 and as Chairman of the Board of RDD Pharma, a private gastrointestinal development company, in April 2018. In January 2019, Dr. Sirgo was
appointed Chief Executive Officer of ArunA Bio, a private CNS and neurodegenerative disorder development company. Dr. Sirgo received his BS in Pharmacy from The Ohio State University and his Doctorate from Philadelphia College of Pharmacy and
Science.

Herm Cukier, age 52, has been our Chief Executive Officer and a member of our Board of Directors since May 2018. From
December 2013 to April 2018, he served in various capacities at Allergan plc, ultimately as Senior Vice President, Head of Commercial Strategy and Innovation. He also served as the Senior Vice President of Allergans Eye Care division and as
Senior Vice President of Allergans Womans Healthcare division. From 2010 to 2013, he served as Vice President of Bayer HealthCare, and from

2009 to 2010, he served as President, Chief Executive Officer and board member at Reverion Pharmaceuticals, Inc., a start-up company associated with Weill
Cornell Medical College. From 2005 to 2008, he served as Chief Marketing Officer and member of the Executive Committee at Organon Biosciences, which was acquired by Schering-Plough. He began his career in 1992 at Pfizer and later served as Executive
Director of Global Marketing at Bristol-Myers Squibb. Mr. Cukier received an MBA from the Columbia Business School and a BSE in Bioengineering from the University of Pennsylvania.

Scott M. Plesha, age 54, joined the company in August 2015 as our Senior Vice President, Sales, with more than 26 years of sales
experience and over 18 years of sales management experience within the pharmaceutical and medical industries. Mr. Plesha assumed the additional responsibility of leading our Marketing department in December 2015. In January 2018,
Mr. Plesha was appointed to the role of President of the Company. Mr. Plesha leads our Specialty Sales Force, Marketing, and Training departments. Prior to joining the company, Mr. Plesha was Senior Vice President, GI Sales
Force & Training at Salix Pharmaceuticals, where since 2002 he led Salixs top rated gastrointestinal (GI) sales forces, the sales training department as well as many other sales operations functions. During Mr. Pleshas
tenure at Salix he was responsible for launching or growing product sales as well as optimizing and expanding the sales force to accommodate the multiple companies and products that Salix acquired. Prior to joining Salix, Mr. Plesha was a
Regional Sales Manager for the OClassen Dermatologics division of Watson Pharmaceuticals, Inc. Mr. Plesha began his pharmaceutical sales career with Solvay Pharmaceuticals where he was a field as well institutional sales representative.
Mr. Plesha received a Bachelor of Arts in Pre-Medical Studies from DePauw University.

Terry Coelho, age 57, has been our Chief Financial Officer since January 2019 and has more than 30 years of financial and operational
experience. Ms. Coelhos extensive experience includes serving in diverse leadership capacities across various industries for both private and public global companies. Prior to joining the company, Ms. Coelho served as Chief Financial
Officer and Treasurer at Balchem Corporation. Previously, she served as Chief Operating Office for Diversey, Inc., a multi-billion dollar global private equity carve-out from Sealed Air Corporation and held
senior finance positions at Diversey Care from 2014 through 2017. Ms. Coelho has also served in senior finance leadership roles at Novartis from 2007 to 2014. She spent the previous twenty years at Mars, Incorporated where she held roles of
increasing responsibility and encompassing leadership across all areas of finance and general management. Ms. Coelho earned an MBA in Finance from IBMEC in Brazil and a Bachelor of Arts degree in both Economics and International Relations,
summa cum laude, from The American University School of International Service.

Thomas B. Smith, M.D., age 58, has been Chief
Medical Officer since July 2018 and brings nearly thirty years of medical experience and expertise in the field of pain management. His extensive and wide-ranging roles include having served as Chief Medical Officer at various leading pain
companies, head of medical affairs at top tier pharma and CRO companies, as well as running his own private practice. Dr. Smith served as Chief Medical Officer at Charleston Labs, Inc., since 2017 and from 2014 to 2017, he served as the Chief
Medical Officer of Ameritox, Ltd. Dr. Smith previously served as Chief Medical Officer for Mallinckrodt Pharmaceuticals from 2012 to 2014 and held clinical leadership roles at Abbott Laboratories, Teva Pharmaceuticals, Kendle International,
Akros Pharma and Genzyme during 2001 to 2014. Dr. Smith earned a Doctor of Medicine degree from the Indiana University School of Medicine and a Bachelor of Science degree from Purdue University. He is a member of several medical societies and
organizations including the American Medical Association and the American Academy of Family Physicians. Dr. Smith is a highly published scientific author and has delivered more than 150 presentations in his field of expertise.

James Vollins, age 50, has been our General Counsel, Chief Compliance Officer and Corporate Secretary, and member of the Executive
Leadership Team since November 2018. Mr. Vollins has twenty-five years of legal experience with over ten years of in-house experience in the pharmaceutical industry, which includes work on several major
strategic transactions and a successful initial public offering. From 2014 to 2018, Mr. Vollins was General Counsel, Chief Compliance Officer and Corporate Secretary for Bio Products Laboratory Limited, a UK based manufacturer of plasma-derived
therapies, where he helped lead the transformation of the business from a government owned not-for-profit to a high-performing commercial enterprise that successfully
launched three new drugs in the U.S., expanded its sales force, and achieved significant revenue growth. Mr. Vollins has also worked for other industry-leading pharmaceutical companies, including Grifols Inc., Talecris Biotherapeutics, Inc. and
Pfizer Inc. Mr. Vollins received a Juris Doctor from Case Western Reserve University School of Law and a Bachelor of Arts from Wesleyan University.

Frank E. ODonnell, Jr., M.D., age 69, has served as a member of our Board of Directors since March 2002 and served as our
Chairman of the Board until May 2018. Dr. ODonnell has previously served as our President and Chief Executive Officer. In January 2005, he relinquished the title of President and in August 2005 he relinquished the title of Chief
Executive Officer. Until November 2016, Dr. ODonnell previously served as a Manager of The Hopkins Capital Group, an affiliation of limited liability companies which engage in private equity and venture capital investing in disruptive
technologies in healthcare. Dr. ODonnell is Chairman of Defender Pharmaceuticals, Inc., a privately-held company developing pharmaceuticals for national defense. Until November 2016, Dr. ODonnell was also Chairman of the
Board of Directors of Hedgepath Pharmaceuticals, Inc., which is developing oncology drugs for an orphan indication. Dr. ODonnell is qualified to serve on our board of directors because of his long history with our company and his
extensive experience in managing and investing in biopharmaceutical companies. Dr. ODonnell is a graduate of The Johns Hopkins School of Medicine and received his residency training at the Wilmer Ophthalmological Institute, Johns
Hopkins Hospital.

Dr. ODonnell is a former professor and Chairman of the Department of Ophthalmology, St. Louis University School of Medicine. He is a trustee of St. Louis University.

William Mark Watson, CPA, age 68, joined our board as an independent member in December 2017 and is Chairman of the Audit Committee of
our board of directors. Mr. Watson is a Certified Public Accountant with over 40 years of experience in public accounting and auditing, having spent his entire career from January 1973 to June 2013 at Deloitte Touche Tohmatsu and its
predecessor, most recently as Central Florida Marketplace Leader. Among other industries, he has a particular expertise in the health and life sciences sector, having played a significant role in the development of Deloittes audit approach for
health and life sciences companies and leading its national healthcare regulatory and compliance practice. He has served as lead audit partner and advisory partner on the accounts of many public companies ranging from middle market firms to Fortune
500 enterprises. Mr. Watson is a member of American Institute of Certified Public Accountants and the Florida Institute of Certified Public Accountants. Mr. Watson is a member of the board of directors and Chairman of the Audit Committee
of HedgePath Pharmaceuticals, Inc. (OTCQX:HPPI). Mr. Watson was elected to the Board of Directors of Sykes Enterprises Inc. in May 2018 and serves on its Audit Committee. Mr. Watson is qualified to serve on our board due to his expertise
in public accounting and his experience with pharmaceutical companies. He received his undergraduate degree in Accounting from Marquette University.

Todd C. Davis, age 58, has served as a member of our Board of Directors since May 2018. Mr. Davis is the Founder and Managing Partner
of RoyaltyRx Capital, a special opportunities investment firm. From 2006 until 2018, Mr. Davis was a Founder & Managing Partner of Cowen/HealthCare Royalty Partners, a global healthcare investment firm. He has almost thirty years of
experience in both operations and investing in the biopharmaceutical and life science industries. Mr. Davis has been involved in over $3 billion in healthcare financings including growth equity, public equity turnarounds, structured debt and
royalty acquisitions. He has also led, structured and closed over 40 additional intellectual property licenses, as well as hybrid royalty-debt deals. Previously, Mr. Davis was a partner at Paul Capital Partners, where he co-managed that
firms royalty investments as a member of the Royalty Management Committee. He also served as a partner responsible for biopharmaceutical growth equity investments at Apax Partners. Mr. Davis began his business career in sales at Abbott
Laboratories where he held several commercial roles of increasing responsibility. He subsequently held general management, business development, and licensing roles at Elan Pharmaceuticals. Mr. Davis is a navy veteran and holds a B.S. from the
U.S. Naval Academy and an M.B.A. from Harvard University. He currently serves on the board of Palvella Therapeutics Inc., and Ligand Pharmaceuticals. He is also a board member of the Harvard Business School Healthcare Alumni Association.

Kevin Kotler, age 47, has served as a member of our Board of Directors since May 2018. Mr. Kotler has over 25 years of experience
as an investor and analyst following the healthcare industry. He is the Founder and Managing Member of Broadfin Capital, which is the investment advisor for Broadfin Healthcare Master Fund, Ltd., a healthcare-focused investment fund that he launched
in 2005. Mr. Kotler serves as a Director of Avadel Pharmaceuticals since 2018 and as a director of InnerSpace Neuro Solutions, Inc., a privately-held medical device company, since 2014. He served as Director of Novelion Therapeutics Inc., from
2016 to 2018. Mr. Kotler earned a BS in Economics from the Wharton School at the University of Pennsylvania in 1993.

Key Employees

Below are the biographies of certain key non-executive officer employees of our company:

Ernest R. De Paolantonio, CPA, MBA, served as our Chief Financial Officer and Treasurer from October 2013 to January 2019.
Mr. De Paolantonio remains at our Company to allow for an orderly transition to the new CFO. Mr. De Paolantonio has over 35 years of varied financial and business experience in the pharmaceutical industry. Prior to joining the company, he
served as the Chief Financial Officer of CorePharma LLC, a private specialty generic company, and was directly involved in the financial and commercial strategy to establish Cores proprietary labeled portfolio of products. In addition, he
previously served in finance and controllership positions in roles of increasing responsibility at Colombia Laboratories, where he was also responsible for business development and logistics, including supply chain management for the companys
first commercial product launch. Mr. De Paolantonio has served in various financial positions in senior management at Taro Pharmaceuticals where he was the Corporate Controller, Watson Pharmaceuticals where he was Executive Director of Finance,
Group Controller and responsible for managing the Corporations supply chain of Active Pharmaceutical Ingredients, and GlaxoSmithKline where he began his career in finance and spent over 17 years in areas of increasing responsibility including;
Manufacturing, Corporate Finance, R&D and U.S. Pharmaceuticals where he was Group Controller. Mr. De Paolantonio received his Bachelor of Arts Degree from Lycoming College; his MBA in Finance at Saint Josephs University and is a
licensed CPA.

Joseph Lockhart was promoted to Senior Vice President of Operations for our company in January 2018 after having
served as our Vice President of Manufacturing and Supply Chain since joining the company in November 2015. Drawing upon over 30 years of experience in the pharmaceutical industry with specific focus in the areas of manufacturing, supply chain,
product development, CMC (Chemistry, Manufacturing, and Controls) and quality, Mr. Lockhart now provides senior-level management to our companys overall Operations, including Clinical, Quality, Regulatory, and Manufacturing/Supply Chain.
Prior to joining our company, Mr. Lockhart

served as Vice President, Pharmaceutical Development and Manufacturing at Salix Pharmaceuticals, where since 2001 he established the Pharmaceutical Development and Manufacturing team and
contributed to multiple NDA submissions, as well as multiple product acquisitions and launches. During Mr. Lockharts tenure at Salix he held positions of increasing responsibility and was responsible for managing Manufacturing, Technical
Operations, Formulation Development, and Clinical Trial Material Operations. From 1986 thru 2001 Mr. Lockhart served in various pharmaceutical CMC-related roles and responsibilities at both the Manager
and the Director levels of management. Mr. Lockhart received a Master of Business Administration degree from the University of North Carolina at Charlotte as well as a Bachelor of Arts degree in Chemistry from the University of North Carolina
at Chapel Hill.

Director Independence

We believe that Peter S. Greenleaf, William M. Watson, Todd C. Davis and Kevin Kotler qualify as independent directors for NASDAQ Stock Market
purposes. This means that our board of directors is composed of a majority of independent directors as required by NASDAQ Stock Market rules.

Meetings of the Board of Directors and Stockholders

Our board of directors met in person and telephonically six times during 2018 and also acted by unanimous written consent. Each member of our
board of directors was present at least 83% of the board of directors meetings held. It is our policy that all directors must attend all stockholder meetings, barring extenuating circumstances. All directors were present at the 2018 Annual
Meeting of Stockholders.

Board Committees

Our board of directors has established three standing committees: Audit, Compensation, and Nominating and Corporate Governance. Historically,
all independent directors have been members of each board committee. All standing committees operate under a charter that has been approved by the board. Our board of directors has also, from time to time, appointed
non-standing committees to assist the board in its duties to our company. The charters for each of our board committees are available at http://ir.bdsi.com/corporate-governance/governance-overview.

Audit Committee

Our
board of directors has an Audit Committee, composed of William M. Watson, Peter S. Greenleaf and Todd C. Davis, all of whom are independent directors as defined in accordance with section 3(a)(58)(A) of the Exchange Act and the rules of NASDAQ.
Mr. Watson serves as chairman of the committee. The board of directors has determined that Mr. Watson is an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation
S-K. The Audit Committee met four times during 2018. Each member of the Audit Committee was present at 100% of the Audit Committee meetings held during such directors tenure as a member of the Audit
Committee.

Our Audit Committee oversees our corporate accounting, financial reporting practices and the audits and reviews of financial
statements. For this purpose, the Audit Committee has a charter (which is reviewed annually). As summarized below, the Audit Committee:



evaluates the independence and performance of, and assesses the qualifications of, our independent auditor and
engages such independent auditor;



approves the plan and fees for the annual audit, quarterly reviews, tax and other audit-related services and
approves in advance any non-audit service and fees therefor to be provided by the independent auditor;



monitors the independence of the independent auditor and the rotation of partners of the independent auditor on
our engagement team as required by law;



reviews the financial statements to be included in our Annual Report on Form
10-K and Quarterly Reports on Form 10-Q and reviews with management and the independent auditors the results of the annual audit and reviews of our quarterly financial
statements;



oversees all aspects of our systems of internal accounting and financial reporting control; and



provides oversight in connection with legal, ethical and risk management compliance programs established by
management and the board, including compliance with requirements of Sarbanes-Oxley and makes recommendations to the board of directors regarding corporate governance issues and policy decisions.

Our board of directors has a Nominating and Corporate Governance Committee composed of Kevin Kotler, William M. Watson and Todd C. Davis. Kevin
Kotler serves as the chairman of the committee. The Nominating and Corporate Governance Committee is charged with the responsibility of reviewing our corporate governance policies and with proposing potential director nominees to the board of
directors for consideration. The Nominating and Corporate Governance Committee met three times in 2018 and has a charter which is reviewed annually. All members of the Nominating and Corporate Governance Committee are independent directors as
defined by the rules of the NASDAQ Stock Market. The Nominating and Corporate Governance Committee will consider director nominees recommended by security holders. To recommend a nominee please write to the Nominating and Corporate Governance
Committee c/o James Vollins, BioDelivery Sciences International, Inc, 4131 ParkLake Avenue. Suite #225, Raleigh, NC. 27612. The Nominating and Corporate Governance Committee has established nomination criteria by which board candidates are to
be evaluated. The Nominating and Corporate Governance Committee will assess all director nominees using the same criteria. During 2018, we did not pay any fees to any third parties to assist in the identification of nominees. In April 2018, the
Company received notice from Broadfin Capital, LLC of its intention to nominate certain individuals to stand for election to the Board at the 2018 annual meeting of the Companys stockholders, which notice was irrevocably withdrawn pursuant to
the Broadfin Agreement.

The Nominating and Corporate Governance Committee has adopted a set of criteria by which it will seek to evaluate
candidates to serve on our board of directors. The evaluation methodology includes a scored system based on criteria including items such as experience in the biotechnology sector, experience with public companies, executive managerial experience,
operations and commercial experience, fundraising experience and contacts in the investment banking industry, personal and skill set compatibility with current board members, industry reputation, knowledge of our company generally, independence and
ethnic and gender diversity. While diversity is considered as a board qualification criteria, it would not be weighted any more or less in an evaluation process than any other criteria. The established criteria do not distinguish board candidates
based on whether the candidate is recommended by a stockholder of our company.

Compensation Committee

Our board of directors also has a Compensation Committee, which reviews or recommends the compensation arrangements for our management and
employees and also assists the board of directors in reviewing and approving matters such as company benefit and insurance plans, including monitoring the performance thereof. The Compensation Committee has a charter (which is reviewed annually) and
is composed of three members: Todd C. Davis, Peter S. Greenleaf and Kevin Kotler. Todd C. Davis serves as chairman of this committee. The Compensation Committee met five times during 2018.

The Compensation Committee has the authority to directly engage, at our expense, any compensation consultants or other advisers as it deems
necessary to carry out its responsibilities in determining the amount and form of employee, executive and director compensation. In 2018, the Compensation Committee engaged Radford, an AON Consulting Company, to obtain market data against which
it has measured the competitiveness of our compensation programs. In determining the amount and form of employee, executive and director compensation, the Compensation Committee has reviewed and discussed historical salary information as well
as salaries for similar positions at comparable companies. We paid consultant fees to Radford of $0.1 million in 2018.

Section 16(a)
Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires that our
directors and executive officers and persons who beneficially own more than 10% of our common stock (referred to herein as the reporting persons) file with the SEC various reports as to their ownership of and activities relating to our
common stock. Such reporting persons are required by the SEC regulations to furnish us with copies of all Section 16(a) reports they file.

Based solely upon a review of copies of Section 16(a) reports and representations received by us from reporting persons, and without
conducting any independent investigation of our own, in fiscal year 2018, all Forms 3, 4 and 5 were timely filed with the SEC by such reporting persons, with the exception of Mark A. Sirgo, who filed a Form 4, which was due January 5, 2018 on
January 19, 2018, Scott Plesha, Ernest De Paolantonio and Francis E. ODonnell, who filed Form 4s, which were due on February 21, 2018 on February 23, 2018, Ernest De Paolantonio, who filed a Form 4, which was due on
April 5, 2018 on April 6, 2018, Mark A. Sirgo, who filed a Form 4, which was due April 10, 2018 on April 13, 2018, and Scott Plesha, who filed a Form 4, which was due October 19, 2018 on October 25, 2018.

Code of Ethics

We have adopted a
code of ethics that applies to all employees, as well as each member of our board. Our code of ethics is posted on our website, and we intend to satisfy any disclosure requirement under Item 5.05 of Form
8-K regarding an amendment to, or waiver from, a provision of our code of ethics by posting such information on our website, www.bdsi.com. A copy of our code of

ethics is also available in print, without charge, upon written request to 4131 ParkLake Avenue, Suite #225, Raleigh, NC 27612. Attn: James Vollins.

Involvement in Certain Legal Proceedings

None

Compensation Committee Report

The
Compensation Committee has reviewed and discussed the foregoing Compensation Discussion and Analysis with management. Based on this review and discussion, the Compensation Committee recommended to the Board that the Compensation Discussion and
Analysis be included in the Companys Annual Report on Form 10-K for the year ended December 31, 2018.

This Report was submitted by the following members of the Compensation Committee of the Board:

Todd C. Davis, Chairman

Peter C. Greenleaf

Kevin Kotler

The information contained in
the foregoing Compensation Committee Report shall not be deemed to be soliciting material or filed with the SEC, nor shall such information be incorporated by reference into a future filing under the Securities Act or the
Exchange Act, except to the extent BioDelivery Sciences International, Inc. specifically incorporates this Report by reference therein.

Compensation Discussion and Analysis

The Compensation Committee of our board of directors has the responsibility to review, determine and approve the compensation for our
executive officers. Further, the Compensation Committee oversees our overall compensation strategy, including compensation policies, plans and programs that cover all employees.

This Compensation Discussion and Analysis sets forth a discussion of the compensation for our NEOs as of December 31, 2018 as well as a
discussion of our philosophies underlying the compensation for our NEOs and our employees generally.

Objectives of Our Compensation Program

The Compensation Committees philosophy seeks to align the interests of our stockholders, officers and employees by tying compensation to
individual performance and the Companys performance, both short-term in the form of salary and annual cash bonus payments, and long-term in the form of incentive equity awards. The objectives of our compensation program enhance our ability to:



attract and retain qualified and talented individuals;



share the risks and rewards of our business with our NEOs and employees; and



provide reasonable and appropriate incentives to our team for building long-term value within our company, in
each case in a manner comparable to companies similar to ours.

In addition, we strive to be competitive with other
similarly-situated companies in our industry. The process of developing and commercializing pharmaceutical products is a long-term proposition and outcomes may not be measurable for several years. Therefore, to build long-term value for our
stockholders, and to achieve our business objectives, we believe that we must compensate our officers and employees in a competitive and fair manner that reflects our current activities but also reflects contributions to building long-term value.

We utilize the services of the Radford Group, an AON consulting company (which we refer to herein as Radford) to review compensation
programs of peer companies to assist the Compensation Committee in determining the compensation levels for our

NEOs, as well as for other employees of ours. Radford is a recognized independent consulting company and services clients throughout the United States.

The companies that comprise our peer group are selected and reviewed no less frequently than biennially. The current peer group used to
evaluate compensation for the fiscal year ended December 31, 2018 was approved by the Compensation Committee in September 2017 and includes the following companies:

Company

Location

AcelRx Pharmaceuticals, Inc.

Redwood City, CA

Adamis Pharmaceuticals

San Diego, CA

Alimera Sciences, Inc.

Alpharetta, GA

Antares Pharma, Inc.

Ewing, NJ

BioCryst Pharmaceuticals, Inc.

Durham, NC

Collegium Pharmaceutical

Stoughton, MA.

Corium

Menlo Park, CA.

CTI BioPharma Corp.

Seattle, WA

Cumberland Pharmaceuticals, Inc.

Nashville, TN

DURECT Corporation

Cupertino, CA

KemPharm

Coralville, IA.

Neos Therapeutics, Inc.

Grand Prairie, TX

Recro Pharma

Malvern, PA

Sorrento Therapeutics

San Diego, CA

Strongbridge BioPharma plc

Trevose, PA

Vivus, Inc.

Campbell, CA

With respect to our employees and non-senior management, we will also
take into consideration regional market data in determining appropriate compensation packages, and we have in the past relied on Radford to provide us with such data.

Elements of Our Compensation Program and Why We Chose Each

Main Compensation Components

Our company-wide compensation program, including for our NEOs, is broken down into three main components: base salary, performance cash bonuses
and potential long-term compensation in the form of stock options or restricted stock units (or RSUs). We believe these three components constitute the minimum essential elements of a competitive compensation package in our industry. We also have a
Performance Long Term Incentive Plan (which we refer to herein as the LTIP) for our NEOs and selected senior officers, which compensates such employees with RSUs based on our achievement of certain
pre-determined revenue performance goals.

Salary

Base salary is used to recognize the experience, skills, knowledge and responsibilities required of our NEOs as well as recognizing the
competitive nature of the biopharmaceutical industry. This is determined partially by evaluating our peer companies as well as the degree of responsibility and experience levels of our NEOs and their overall contributions to our company. Base salary
is one component of the compensation package for NEOs; the other components being cash bonuses, annual equity grants, a long-term incentive plan and our benefit programs. Base salary is determined in advance whereas the other components of
compensation are awarded in varying degrees following an assessment of the performance of a NEO. This approach to compensation reflects the philosophy of our board of directors and its Compensation Committee to emphasize and reward, on an
annual basis, performance levels achieved by our NEOs, and to provide appropriate retention incentives based on future performance.

Performance Cash Bonus Plan

We have a performance cash bonus plan under which bonuses are paid to our NEOs based on achievement of our performance goals and objectives
established by the Compensation Committee and/or our board of directors as well as on individual performance. The bonus program is discretionary and is intended to: (i) strengthen the connection between individual compensation and our
achievements; (ii) encourage teamwork among all disciplines within our company; (iii) reinforce our pay-for-performance philosophy by awarding higher bonuses
to higher performing employees; and (iv) help ensure that our cash compensation is competitive. Depending on our companys cash position, the Compensation Committee and our board of directors have the discretion after consulting with our
NEOs to not pay (or pay more limited) cash bonuses in order that we may conserve cash and support ongoing development programs and commercialization efforts. Regardless of our cash position, we consistently grant annual merit-based stock

options (and, more recently in the case of senior executives, RSUs) to continue incentivizing both our senior management and our employees.

Based on their employment agreements, each NEO is assigned a target payout under the performance cash bonus plan, expressed as a percentage of
base salary for the year. Actual payouts under the performance cash bonus plan are based on the achievement of corporate performance goals and an assessment of individual performance. For the NEOs, the corporate goals receive the highest weighting
to ensure that the bonus system for our management team is closely tied to our corporate performance. Each employee also has specific individual goals and objectives as well that are tied to the overall corporate goals. For employees, mid-year and end-of-year progress is reviewed with the employees managers.

Equity Incentive Compensation

We view long-term compensation, currently in the form of stock options and RSUs, which generally vest in annual increments over three years
(other than awards under our LTIP, which vest immediately if awarded, and performance based awards as described below), as a tool to align the interests of our NEOs and employees generally with the creation of stockholder value, to motivate our
employees to achieve and exceed corporate and individual objectives and to encourage them to remain employed by us. While cash compensation is a significant component of employees overall compensation, the Compensation Committee and our board
of directors (as well as our NEOs) believe that the driving force of any employee working in a growing pharmaceutical company should be strong equity participation. We believe that this not only creates the potential for substantial longer term
corporate value but also serves to motivate employees and retain their loyalty and commitment with appropriate personal compensation over a longer period of time. Our equity awards are granted under our 2011 Equity Incentive Plan (as the same may be
amended, supplemented or superseded from time to time, which we refer to herein as the Plan).

During 2018, we granted equity incentive
awards with two types of vesting: time-based and performance-based.

Time-based vesting. The Compensation Committee believes that
because time-vested stock options and RSUs have a three-year vesting schedule that begins one year after the date of the award, the equity grants constitute a significant retention incentive and a tool to foster continuity of management, an
important factor for a company with a relatively low number of employees.

Performance-based vesting. Based on the Compensation
Committees review in 2017 of market practices, pronouncements by corporate governance advisory services and discussions with our institutional investors, beginning with the annual equity awards granted to senior executives (including our NEOs)
in February 2017 and February 2018, one-half of the RSUs granted were performance-based and vest over a three-year period based on the level of achievement of specified predetermined net revenue and operating
income targets, with the remaining one-half being time-vested as described above.

On
January 31, 2019, the Compensation Committee determined that 1/3rd of the 2018 performance-based RSUs would vest at a rate of 100% according to the achievement of the aforementioned targets.
Such RSUs will vest on the first open window after the filing of our Annual Report on Form 10-K.

Performance Long Term Incentive Plan

In December 2012, in anticipation of the commencement of revenue generating operations by our company by means of product commercialization,
the Compensation Committee approved our LTIP. The LTIP is designed as an incentive for our senior management (including our NEOs) to generate revenue for us.

The LTIP consists of RSUs (which we refer to herein as Performance RSUs), which are rights to acquire shares of our common stock upon
satisfaction of performance-based goals. All Performance RSUs granted under the LTIP will be granted under the Plan as Performance Compensation Awards under such plan. The participants in the LTIP are either NEOs or senior officers of
ours.

The term of the LTIP began with our fiscal year ended December 31, 2012 and lasts through our fiscal year ended
December 31, 2019. The total number of Performance RSUs covered by the LTIP is 1,078,000, of which an aggregate of 978,000 were awarded in 2012 (and an aggregate of 35,000 in 2015). The Performance RSUs under the LTIP are subject to potential
vesting each year over the eight-year term of the LTIP depending on the achievement of revenue by us, as reported in our Annual Report on Form 10-K. During years 2013 through 2018, a cumulative total of
139,882 Performance RSUs vested. Performance RSUs will be valued on the day of issuance and will vest annually on the last day preceding the first open trading window after filing our Annual Report on Form
10-K based on the revenue achieved during the prior fiscal year as a proportion of the total cumulative revenue target for the entire term of the LTIP (which we call the Predefined Cumulative Revenue).
Predefined Cumulative Revenue is a predefined aggregate revenue target for the entire term of the LTIP that was determined by the

Compensation Committee in conjunction with our executive management. The Predefined Cumulative Revenue may be adjusted by the Compensation Committee upon the occurrence of extraordinary corporate
events during the term of the LTIP (such as acquisitions by us of revenue generating businesses or assets).

Other Compensation

In addition to the main components of compensation outlined above, we also provide contractual severance and/or change in control
benefits to the NEOs as well as to Terry Coelho, who was appointed as our Chief Financial Officer as of January 15, 2019, (see Appointment of Chief Financial Officer below), to Joseph Lockhart, our Senior Vice President Operations
and to Albert J. Medwar, our former Senior Vice President, Corporate and Business Development (who retired from our company on April 1, 2018 and received a retirement benefits package that included equity features). Ernest R. De Paolantonio,
our former Treasurer and Chief Financial Officer, executed a transitional service and separation agreement with us on January 23, 2019 and received contractual severance benefits as a condition of his retirement (see De Paolantonio
Retirement Agreement). The change in control benefits for all applicable persons has a double trigger. A double-trigger means that the executive officers will receive the change in control benefits described in the agreements only
if there is both (1) a Change in Control of our company (as defined in the agreements) and (2) a termination by us of the applicable persons employment without cause or a resignation by the applicable persons for
good reason (as defined in the agreements) within a specified time period prior to or following the Change in Control. We believe this double trigger requirement creates the potential to maximize stockholder value because it prevents an
unintended windfall to management as no benefits are triggered solely in the event of a Change in Control while providing appropriate incentives to act in furtherance of a change in control that may be in the best interests of the stockholders. We
believe these severance or change in control benefits are important elements of our compensation program that assist us in retaining talented individuals at the executive and senior management levels and that these arrangements help to promote
stability and continuity of our executives and senior management team. We also believe that the interests of our stockholders will be best served if the interests of these members of our management are aligned with theirs. Furthermore, we believe
that providing change in control benefits lessens or eliminates any potential reluctance of members of our management to pursue potential change in control transactions that may be in the best interests of the stockholders. Finally, we believe that
it is important to provide severance benefits to members of our management to promote stability and to focus on the job at hand.

We also
provide benefits to the executive officers that are generally available to all regular full-time employees of ours, including our medical and dental insurance, life insurance and a 401(k) match for all individuals who participate in the 401(k) plan.
Currently, we do not provide any perquisites to any of our NEOs. Further, we do not have pension arrangements or post-retirement health coverage for our executive officers or employees. We also do not have deferred compensation plans other than
allowing senior executive recipients of RSUs to defer payment of RSUs that may vest in future years, subject to compliance with Section 409A of the Internal Revenue Code (or the Code) and related rules.

All our employees not specifically under contract are at-will employees, which means that
their employment can be terminated at any time for any reason by either us or the employee. Our NEOs (as well as certain of our senior managers) have employment agreements that provide lump sum compensation in the event of their termination without
cause or, under certain circumstances, upon a Change of Control.

Determination of Compensation Amounts

Many factors impact the determination of compensation amounts for our NEOs, including the individuals role in our company and individual
performance, length of service with us, competition for talent, individual compensation package, assessments of internal pay equity and industry data. Stock price performance has generally not been a significant factor in determining annual
compensation because the price of our common stock is subject to a variety of factors outside of our control.

Industry Survey Data

In collaboration with our compensation advisor, our Compensation Committee establishes a list of peer companies to best ensure that we
are compensating our executives on a fair and reasonable basis, as set forth above under the heading Objectives of our Compensation Program. We also utilize data for below-executive level personnel, which data focuses on similarly-sized life science companies in the Southeastern region of the United States. The availability of peer data is used by the Compensation Committee strictly as a guide in determining compensation levels
regarding salaries, cash bonuses and annual equity grants to all employees. However, the availability of this data does not imply that the Compensation Committee is under any obligation to exactly follow peer companies in compensation matters.

As a guideline for NEO base salary, we perform formal benchmarking against respective comparable positions in our established peer group. Our
guideline is to set targeted NEO salary ranges between the 25th and 50th percentile for comparable positions within our peer group. We then adjust salaries based on our assessment of our NEOs levels of responsibility, experience, overall
compensation structure and individual performance. The Compensation Committee has the discretion if it believes circumstances warrant, to go above the 50th percentile of the peer group. The Compensation Committee is not obliged to raise salaries
purely on the availability of data. Merit-based increases to salaries of executive officers are based on our assessment of individual performance and the relationship to applicable salary ranges. Cost of living adjustments may also be a part of that
assessment. The Compensation Committee, in recent years, has tended to maintain cash compensation levels at or near the 50th percentile but to exceed that level in determining equity compensation. The emphasis on equity compensation reflects the
Committees objective, given that we have only recently engaged in revenue generating operations, to incentivize personnel and to preserve cash in a prudent manner and yet reward personnel for outstanding performance.

Performance Cash Bonus Plan

Concurrently with the beginning of each calendar year, preliminary corporate goals that reflect our business priorities for the coming year are
prepared by our NEOs with input from other officers. The draft goals are presented to the Compensation Committee and our full board at the beginning of each year and discussed, revised as necessary, and then approved by our board of directors. The
Compensation Committee then reviews the final goals to determine and confirm their appropriateness for use as performance measurements for purposes of the bonus program. The goals may be re-visited during the
year and potentially restated in the event of significant changes in corporate strategy or the occurrence of significant corporate events. Following the agreement of our board of directors on the corporate objectives, the goals are then shared
with all employees in a formal meeting(s) and are reviewed periodically throughout the year at monthly staff meetings and quarterly board of director meetings.

The performance cash bonus plan for our executive officers and employees in 2018 was adopted by the Compensation Committee in February 2018.
The plan sets forth target bonus opportunities, as a percentage of salary, based on the level of responsibility of the position, ranging up to 55% of salary for Herm Cukier, our CEO, up to 45% of salary for our NEOs and up to 30% of salary for
certain other officers. In setting these percentages, the Compensation Committee determined that the above percentages were reasonable and in line with our peer group. Each employee has the opportunity to achieve a targeted amount, depending on how
corporate goals and objectives are achieved, with variances on an employee by employee basis to be determined by our Compensation Committee in consultation with senior executives and employees direct reports.

Determination of Equity Incentive Compensation

To assist us in assessing the reasonableness of our equity grant amounts, historically we have reviewed information supplied by our
compensation consultant. Such information included equity data from a cross-section of the companies in the above-mentioned surveys. Initially, on-hire stock option grant amounts have generally been targeted
at the 25th to 50th percentile for that position or similar industry position, adjusted for internal equity, experience level of the individual and the individuals total mix of compensation and benefits provided in his or her offer package.
Initial on-hire grants typically vest over three years.

Beginning in January 2016, the
Compensation Committee expanded its criteria for equity awards, considering not only the financial value of awards, but also the burn rate (meaning the number of shares awarded as a percentage of total outstanding shares). These two
criteria (i.e. financial value and burn rate) often result in disparate computations when contrasted to peer group criteria. Accordingly, the Compensation Committee has attempted to equitably balance those two factors to achieve appropriate equity
awards.

In early 2017 and early 2018, with respect to equity awards to senior executives, including NEOs,
one-half of the RSUs were awarded in the form of time-based RSUs, as have been exclusively awarded to those executives in recent years, and for the first time, one-half
of the RSUs were in the form of performance-based RSUs as described above. In early 2019, the Compensation Committee further expanded upon its prior equity grant philosophy and decided to make award decisions that were more in line with current
industry standards.

For a discussion of equity awards made in early 2019, see Equity Awards in January 2019 under
Compensation Decisions For Performance in 2018 below.

Equity Grant Practices

All stock options and/or RSUs granted to the NEOs and other executives are approved by the Compensation Committee. Exercise prices for options
are set using a 30-day volume weighted average price method, which we define as the closing price of our common stock on the Nasdaq Capital Market on the trading day of the date of grant and the
30 trading days preceding that date. RSU grants are valued on the day of issuance and are vested (in the case of either time-based or performance-based vesting), if earned on

the last day preceding an open trading window after filing our Annual Report on Form 10-K. Grants are generally made: (i) on the employees start
date and (ii) at board of director meetings held each January or February and following annual performance reviews. However, grants have been made at other times during the year. The size of year-end
grants for each NEO is assessed against our internal equity guidelines. Current market conditions for grants for comparable positions and internal equity may also be assessed. Also, grants may be made relating to promotions or job-related changes in responsibilities. In addition, on occasion, the Compensation Committee may make special awards for extraordinary individual or our company performance.

Compensation Setting Process

At the first of the year, meetings of our board of directors and the Compensation Committee, overall corporate performance and relative
achievement of the corporate goals for the prior year are assessed. The relative achievement of each goal is assessed, and the summation of the individual components results in an overall corporate goal rating, expressed as a percentage.

Also, near the end of the year, the CEO evaluates the individual performance of each NEO (other than himself) and provides the Compensation
Committee with an assessment of the performance of such NEO. In determining the individual performance ratings of the NEOs, we assess performance against many factors, including each NEOs relative contributions to our corporate goals,
demonstrated career growth, level of performance in the face of available resources and other challenges, and the respective officers departments overall performance. This assessment is conducted in a holistic fashion, in contrast to the
summation of individual components as is done to arrive at the corporate goal rating.

Following a qualitative assessment of each
individual NEOs performance, our policies provide guidelines for translating this performance assessment into a numerical rating. Both the initial qualitative assessment and the translation into a numerical rating are made by the Compensation
Committee on a discretionary basis. We believe that conducting a discretionary assessment for the individual component of the NEOs performance provides for flexibility in the evaluation of our NEOs and their adaptability to addressing
potential changes in our priorities throughout the year.

The Compensation Committee looks to the CEOs performance assessments of
the other NEOs and his recommendations regarding a performance rating for each, as well as input from the other members of our board of directors. These recommendations may be adjusted by the Compensation Committee prior to finalization. For the
CEO, the Compensation Committee evaluates his performance, taking into consideration input from the other members of our board of directors, and considers the achievement of overall corporate objectives by both the CEO specifically and our company
generally. The CEO is not present during the Compensation Committees deliberations regarding his compensation.

The CEO may also
present any recommended changes to base salary and recommendations for annual equity grant amounts for NEOs and other senior executives.

The Compensation Committee has the authority to directly engage, at our expense, any compensation consultants or other advisors (such as
Radford) that it deems necessary to determine the amount and form of employee, executive and director compensation. In determining the amount and form of employee, executive and director compensation, the Compensation Committee has reviewed and
discussed historical salary information as well as salaries for similar positions at comparable companies. However, the availability of this data does not imply that the Compensation Committee is under any obligation to exactly follow peer
companies compensation practices.

We paid consultant fees to Radford of $0.1 million in 2018. NEOs may have indirect input in
the compensation results for other executive officers by virtue of their participation in the performance review and feedback process for the other executive officers.

Compensation Decisions for Performance in 2018

General Assessment of Management Performance in 2018

The Compensation Committee and our board of directors conducted the performance and compensation review for 2018 in January 2019. The
Compensation Committee compared performance as elaborated below.

The key corporate objectives for 2018 included the following:

(1) Key financial objectives including targeted revenue and cash on hand, (2) commercial objectives including BELBUCA sales and preferred
coverage, (3) organizational objectives including hiring of key NEOs and sales team expansions, (4) operational objectives including cost of goods reductions and improve production and inventory efficiencies, (5) medical objectives
including development of medical communication and data generation plans, and (6) legal objectives including continued success in ongoing and prospective litigation with respect to our intellectual property and patent portfolio.

The Compensation Committee determined that the Company had achieved all 2018 key objectives
as established and exceeded expectations of targeted performance measures.

2018 Cash Bonus Calculations

After reviewing the achievement of the corporate goals and objectives for 2018 as noted above, the Compensation Committee determined that all
NEOs should be awarded a cash bonus at 110% of their target, adjusting for time-served during 2018 for newly hired NEOs. A cash bonus pool, equal to 110% of the aggregate of individual bonus opportunities of all other employees, was established with
our executives having the authority to award individual bonuses from that pool with respect to these employees who reported to them. The cost of all such cash bonuses for 2018 performance (but paid in March 2019) was approximately $0.8 million
for NEOs and approximately $0.7 million for employees.

Equity Awards in January 2019

On January 31, 2019, the total amount of stock options awarded to our NEOs and senior executives was 1,120,000, which options vest
annually in one-third equal increments beginning one year after the date of grant and had an approximate Black Scholes value of $4.4 million.

The total amount of the RSUs awarded to our NEOs and senior executives was 190,250, having an approximate value on the date preceding the
grant of $0.9 million based on a share price of $4.50.

All RSUs and stock options awarded in January 2019 were granted pursuant to
the Plan, as amended.

Individual Compensation of Herm Cukier, our Chief Executive Officer

Mr. Cukier, who joined our Company May 2018, received a base salary of $570,000 in 2018.

Mr. Cukier was awarded a cash bonus for 2018 in the amount of $231,050, which is 110% of his target bonus of 55% of his base salary in
2018, after further adjustment for time served during 2018, a calculation consistent with our cash bonus policy. Mr. Cukier was also granted in January 2019, 540,000 stock options and 93,750 RSUs, which are subject to time-based vesting.

Mr. De Paolantonio was awarded a cash bonus for 2018 in the amount of $162,800, which is 110% of his target bonus of 40% of his base
salary in 2018, a calculation consistent with our cash bonus policy.

Mr. Plesha, who joined our Company in August 2015 and promoted to President in January 2018, received a base
salary of $365,000 in 2018.

Mr. Plesha was awarded a cash bonus for 2018 in the amount of $180,675, which is 110% of his target bonus
of 40% of his base salary in 2018, a calculation consistent with our cash bonus policy. Mr. Plesha was also granted in January 2019, 245,000 stock options and 40,000 RSUs, which are subject to time-based vesting.

Dr. Smith, who joined our Company in July 2018, received a base salary of $345,000 in 2018.

Dr. Smith was awarded a cash bonus for 2018 in the amount of $50,094, which is 110% of his target bonus of 40% of his base salary in 2018,
after further adjustment for time served during 2018, a calculation consistent with our cash bonus policy. Dr. Smith was also granted in January 2019, 130,000 stock options and 23,000 RSUs, which are subject to time-based vesting.

Mr. Vollins, who joined our Company in November 2018, received a base salary of $310,000 in 2018.

Mr. Vollins target bonus is 40% of his base salary in 2018, a calculation consistent with our cash bonus policy. Mr. Vollins
was also granted in January 2019, 65,000 stock options and 11,500 RSUs, which are subject to time-based vesting.

Ms. Coelho joined our Company in January 2019 and receives a base salary of $385,000. Ms. Coelhos target bonus is 45% of her
base salary for 2019, a calculation consistent with our cash bonus policy.

De Paolantonio Retirement Agreement

On January 23, 2019, we entered into a Transitional Service and Separation Agreement (the Separation Agreement) with
Mr. De Paolantonio, our former Chief Financial Officer and Treasurer. Unless Mr. De Paolantonio resigns, or his employment is terminated earlier, Mr. De Paolantonio will continue as a senior advisor to the Company until April 30,
2019, at which time his employment with us will end (the Retirement Date).

The Separation Agreement provides for, among other
things, Mr. De Paolantonio to (i) continue to receive his current base salary, (ii) remain eligible to participate in our group employee benefit plans as a regular full-time employee, and (iii) continue to vest in his outstanding
equity awards until his Retirement Date. At the termination of his employment with us, provided that, among other things, Mr. De Paolantonio is not terminated by us for cause, Mr. De Paolantonio will be entitled to receive
(a) a one-time cash payment of $0.36 million, subject to applicable deductions and withholdings, representing one full year of his current base salary, provided that Mr. De Paolantonio has not
breached any of his continuing obligations, including that he signs and does not revoke a general release of claims against us, (b) his target annual incentive compensation for 2018 (subject to determination by the board of directors of the
Company), and (c) a monthly cash payment for three months in an amount equal to the actual costs of continuation of Mr. De Paolantonios group health and dental insurance under the Consolidated Omnibus Reconciliation Act of 1985.

Additionally, the option exercise period for the vested incentive stock options granted to Mr. De Paolantonio on October 1, 2013
shall be extended through the remainder of the option period which ends on October 17, 2023. All time-based restricted stock units held by Mr. De Paolantonio that would have vested had Mr. De Paolantonio remained employed by us
through December 31, 2020 shall be deemed vested as of the Retirement Date, and all time-based restricted stock units held by Mr. De Paolantonio that by their terms vest after December 31, 2020 will be forfeited as of the Retirement
Date. Subject to Mr. De Paolantonios service through the Retirement Date, all performance-based restricted stock units shall remain outstanding and eligible to vest with respect to our performance through December 31, 2020 and any
performance-based restricted stock units that do not vest based upon performance through December 31, 2020 shall be forfeited.

Accounting and Tax Considerations

ASC 718. On January 1, 2006, we began accounting for share-based payments in accordance with the requirements of Accounting
Standards Codification 718 (ASC 718), Share-Based Payments. To date, the adoption of ASC 718 has not impacted our stock option granting practices.

Internal Revenue Code Section 162(m). Generally, Section 162(m) of the Code (Section 162(m)) disallows a
federal income tax deduction for public corporations of remuneration in excess of $1 million paid in any fiscal year to certain specified executive officers. For taxable years beginning before January 1, 2018 (i) these executive
officers consisted of a public corporations chief executive officer and up to three other executive officers (other than the chief financial officer) whose compensation is required to be disclosed to stockholders under the Exchange Act because
they are our most highly-compensated executive officers and (ii) qualifying performance-based compensation was not subject to this deduction limit if specified requirements are met.

Pursuant to the Tax Cuts and Jobs Act of 2017 (the Tax Act), for taxable years beginning after December 31, 2017, the
remuneration of a public corporations chief financial officer is also subject to the deduction limit. In addition, subject to certain transition rules (which apply to remuneration provided pursuant to written binding contracts which were in
effect on November 2, 2017 and which are not subsequently modified in any material respect), for taxable years beginning after December 31, 2017, the exemption from the deduction limit for performance-based compensation is no
longer available. Consequently, for fiscal years beginning after December 31, 2017, all remuneration in excess of $1 million paid to a specified executive will not be deductible. These changes will cause more of our compensation to be
non-deductible under Section 162(m) in the future and will eliminate the Companys ability to structure performance-based awards to be exempt from Section 162(m).

In designing our executive compensation program and determining the compensation of our executive officers, including our named executive
officers, our compensation committee considers a variety of factors, including the potential impact of the Section 162(m) deduction limit. However, our compensation committee will not necessarily limit executive compensation to that which is or
may be deductible under Section 162(m). The deductibility of some types of compensation depends upon the timing of an executive officers vesting or exercise of previously granted rights. Further, interpretations of and changes in the tax
laws, and other factors beyond our compensation committees control also affect the deductibility of compensation. Our compensation committee will consider various alternatives to preserving the deductibility of compensation payments and
benefits to the extent consistent with its compensation goals and will continue to monitor developments under Section 162(m).

To
maintain flexibility to compensate our executive officers in a manner designed to promote our short-term and long-term corporate goals, our compensation committee has not adopted a policy that all compensation must be deductible. Our compensation
committee believes that our stockholders interests are best served if its discretion and flexibility in awarding compensation is not restricted, even though some compensation awards may result in non-deductible compensation expense.

Section 409A. Section 409A of the Code generally changed the tax rules that affect most forms of deferred
compensation that were not earned and vested prior to 2005. Under Section 409A, deferred compensation is defined broadly and may potentially cover compensation arrangements such as severance or change in control pay outs and the extension of
the post-termination exercise periods of stock options. We take Code Section 409A into account, where applicable, in determining the timing of compensation paid to our executive officers in order to comply with, or be exempt from, its
requirements.

Item 11.

Executive Compensation.

The following table sets forth all compensation paid to our named executive officers at the end of the fiscal years ended December 31,
2018, 2017 and 2016. Individuals we refer to as our named executive officers include our Vice Chairman (formerly served as our Chief Executive Officer), our former Chief Financial Officer, our former Senior Vice President and Chief
Technology Officer and our most highly compensated executive officers whose salary and bonus for services rendered in all capacities exceeded $100,000 during the fiscal year ended December 31, 2018.

Mark A. Sirgo served as our President, Chief Executive Officer, Director and Vice Chairman until his retirement
date of January 2, 2018. Upon retirement, Dr. Sirgo now serves as a Director and Vice Chairman.

(2)

Includes compensation in the amount of $52,500 for serving as Vice Chairman and Director post-retirement.

(3)

Includes: Second and final gross, retirement payment in 2018 of $787,000, $131,625 of payments made through
consulting company post-retirement during 2018, $40,846 of accrued vacation paid in 2018, $5,528 of health insurance premiums paid and 401(k) matching of $13,250 paid in 2018.

(4)

Herm Cukier was hired as our Chief Executive Officer and Director on May 8, 2018. As such, the salary
compensation presented in this table has been annualized.

James Vollins was hired as our General Counsel, Chief Compliance Officer and Corporate Secretary on
November 5, 2018. As such, the salary compensation presented in this table reflects the salary earned for his partial year of employment.

(12)

Includes: $351 telephone reimbursement paid in 2018. As such, the salary compensation presented in this table
has been annualized.

(13)

Ernest De Paolantonio retired as our Chief Financial Officer and Treasurer on December 31, 2018 and
executed a transitional service and separation agreement with an effective date of retirement to be April 30, 2019.

As of each of the Retirement Dates, the stock awards disclosed in this item during 2018 related to one-half time-vesting and one-half performance-based RSUs issued to each of Dr. Sirgo and Dr. Vasisht pursuant to the Plan for 2017 performance, then terminated. In
lieu thereof, Dr. Sirgo and Dr. Vasisht each received a one-time issuance of fully vested shares of Common Stock under the Plan, the number of which was determined with reference to the time-vesting
RSUs by dividing (A) the Net Present Value of such time-vesting RSUs by (B) the 30-day VWAP as of the Retirement Date and with reference to the performance-based RSUs by multiplying the remaining
half by 66%. Dr. Sirgo deferred this stock award to March 2018.

(2)

The stock awards disclosed in this item consists of performance-based RSUs issued under our 2011 Equity
Incentive Plan with a FMV of $2.63, which vest under certain performance criteria beginning May 2019.

(3)

The stock awards disclosed in this item consists of half time-based RSUs and half performance based RSUs issued
under our 2011 Equity Incentive Plan with a FMV of $2.10, which vest ratably in thirds beginning March 2019.

(4)

The stock awards disclosed in this item consists of performance-based RSUs issued under our 2011 Equity
Incentive Plan with a FMV of $3.75, which vested under certain performance criteria in October 2018.

Except as set forth below, we currently have no written employment agreements with any of our officers, directors, or key employees. All
directors and officers have executed confidentiality and noncompetition agreements with us.

The following is a description of our current executive employment agreements:

Herm Cukier, Chief Executive Officer  Mr. Cukiers employment agreement, dated May 2, 2018 includes a base salary
of $570,000, target bonus of up to 55% of his base salary (which is subject to modification by our Compensation Committee), and other employee benefits. Under the terms of his agreement, Mr. Cukier also received in 2018 a sign-on bonus of $50,000.

We or Mr. Cukier may terminate his agreement for any reason or no reason
upon sixty (60) days prior written notice to the other. Solely in the case of an event of cause, we cannot terminate Mr. Cukier for cause unless we haves provided written notice to Mr. Cukier of the existence of the circumstances
providing grounds for termination for a cause capable of cure, and Mr. Cukier has had at least thirty (30) days from the date on which such notice is provided to cure such circumstances to the reasonable satisfaction of us.

Mr. Cukier cannot terminate his employment for Good Reason unless he has provided written notice to us of the existence of the
circumstances providing grounds for termination for good reason within sixty (60) days (thirty (30) days in the event of the grounds of the date Mr. Cukier learns of the initial existence of such grounds and we have had at least
thirty (30) days from the date on which such notice is provided to cure such circumstances.) If Mr. Cukier does not terminate his employment for good reason within ninety (90) days after the date Mr. Cukier learns of the first
occurrence of the applicable grounds, then Mr. Cukier will be deemed to have waived his right to terminate for good reason with respect to such grounds.

In the event of a termination by us for Cause or Mr. Cukiers resignation without good reason, we will pay Mr. Cukier
(i) the base salary earned and expenses reimbursable incurred through the date of Mr. Cukiers termination, (ii) the prior year bonus (if applicable), and (iii) all amounts otherwise required to be paid or provided by law
and shall thereafter have no further responsibility for termination or other payments to Mr. Cukier.

In the event of a termination
by us without Cause, resignation by Mr. Cukier for good reason, or a non-renewal by us: We shall pay Mr. Cukier a one-time cash severance payment equal to two
(2) times the amount of his then current annual base salary (or, in the event of a resignation by Mr. Cukier for good reason as a result of a reduction in Mr. Cukiers base salary, two (2) times the amount of his annual base
salary prior to the reduction that gave rise to grounds for good reason). We shall pay Mr. Cukier on the payment date his pro-rated bonus through the date of termination and his prior year bonus (if
applicable). In addition, all unvested option awards shall immediately become fully vested and exercisable and shall be exercisable over a period of three (3) years, and any performance-based equity awards shall continue to vest and
settled upon achievement of the applicable annual financing or performance objectives. Mr. Cukiers employment agreement will terminate prior to its scheduled expiration date in the event of Mr. Cukiers death or disability.

In the event that Mr. Cukiers employment with the Company is terminated by the Company or its successor without Cause, or by
Mr. Cukier for good reason, in any case in anticipation of, upon, or within twelve (12) months following the occurrence of a Change of Control (as defined in the employment agreement), Mr. Cukier will be entitled to
receive a one-time severance payment equal to two (2) times the sum of (i) his base salary plus (ii) his bonus for the applicable year (calculated at 100% of target). In addition, all unvested option awards shall immediately
become fully vested and exercisable and shall be exercisable over a period of three (3) years, and any performance-based equity awards shall continue to vest and settled upon achievement of the applicable annual financing or performance
objectives.

Mr. Cukiers employment agreement also includes 5-yearnon-competition and non-solicitation and confidentiality covenants. Under the terms of this agreement, he was also entitled to the following benefits: medical, dental, life,
disability and 401(k).

Scott M. Plesha, President  Mr. Plesha was promoted to the role as our President and his current
employment agreement, dated December 20, 2017 includes a base salary of $365,000, target bonus of up to 45% of his base salary (which is subject to modification by our Compensation Committee), and other employee benefits. Under the terms of his
agreement, Mr. Plesha received a bonus in 2018 of $83,138, which bonus was related to 2017 performance.

We may terminate
Mr. Pleshas employment agreement without cause and Mr. Plesha may resign without notice. We may immediately terminate Mr. Pleshas employment agreement for Good Cause (as defined in the agreement). Upon the termination of
Mr. Pleshas employment for any reason, Mr. Plesha will continue to receive payment of any base salary earned but unpaid through the date of termination and any other payment or benefit to which he is entitled under the applicable
terms of any applicable company arrangements. If Mr. Plesha is terminated during the term of the employment agreement other than for Good Cause (as defined in the employment agreement), or if Mr. Plesha terminates his employment for Good
Reason (as defined in the employment agreement), Mr. Plesha is entitled to a lump sum severance payment equal to 1 times the amount of his annual base salary. In the event that such termination is within six months following a Change of Control
(as defined in the employment agreement), the lump sum paid to Mr. Plesha will equal to one times the amount of his then current annual base salary. In the event of Mr. Pleshas death or disability, the amount owed to Mr. Plesha
will be a one-time cash severance payment equal to one times his then current base salary.

Mr. Pleshas employment agreement also includes 2-yearnon-competition and non-solicitation and confidentiality covenants. Under the terms of this agreement, he is also entitled to the following benefits: medical, dental,
life, disability and 401(k).

Thomas Smith, M.D., Chief Medical Officer- Dr. Smiths employment agreement, dated
July 30, 2018 includes a base salary of $345,000, target bonus of up to 40% of his base salary (which is subject to modification by our Compensation Committee), and other employee benefits. Under the terms of his agreement, Dr. Smith also
received in 2018 a sign-on bonus of $25,000.

We may terminate Dr. Smiths employment agreement without cause and Dr. Smith
may resign without notice. We may immediately terminate Dr. Smiths employment agreement for Cause (as defined in his agreement). Upon the termination of Dr. Smiths employment for any reason, Dr. Smith will continue to
receive payment of any base salary earned but unpaid through the date of termination and any other payment or benefit to which he is entitled under the applicable terms of any applicable company arrangements. If Dr. Smith is terminated during
the term of the employment agreement other than for Cause (as defined in the employment agreement) Dr. Smith is entitled to a lump sum severance payment equal to one times the amount of his annual base salary. In the event that such termination
is within six months following a Change of Control (as defined in the employment agreement), the lump sum paid to Dr. Smith will equal to one times the amount of his then current annual base salary.

In the event that Dr. Smiths employment with the Company is terminated by the Company or its successor without Cause within six
(6) months following the occurrence of a Change of Control (as defined in the employment agreement), Dr. Smith will be entitled to receive a one-time severance payment equal to a one-time cash severance payment equal to his then
current annual base salary. In addition, all unvested time-based options, RSUs or other equity securities to acquire shares of Company common stock shall immediately become fully vested and shall be exercisable to the extent provided for in the
Plan.

Dr. Smiths employment agreement also includes 2-yearnon-competition and non-solicitation and confidentiality covenants. Under the terms of this agreement, he is also entitled to the following benefits: medical, dental, life,
disability and 401(k).

James Vollins, General Counsel, Chief Compliance Officer and Corporate Secretary- Mr. Vollins
employment agreement, dated November 5, 2018 includes a base salary of $310,000, target bonus of up to 40% of his base salary (which is subject to modification by our Compensation Committee), and other employee benefits. Under the terms of his
agreement, Mr. Vollins also received in 2018 a sign-on bonus of $35,000.

We may terminate
Mr. Vollins employment agreement without cause and Mr. Vollins may resign without notice. We may immediately terminate Mr. Vollins employment agreement for Cause (as defined in his agreement). Upon the termination of
Mr. Vollins employment for any reason, Mr. Vollins will continue to receive payment of any base salary earned but unpaid through the date of termination and any other payment or benefit to which he is entitled under the applicable
terms of any applicable company arrangements. If Mr. Vollins is terminated during the term of the employment agreement other than for Cause (as defined in the employment agreement) Mr. Vollins is entitled to a lump sum severance payment
equal to one times the amount of his annual base salary. In the event that such termination is within six months following a Change of Control (as defined in the employment agreement), the lump sum paid to Mr. Vollins will equal to one times
the amount of his then current annual base salary.

In the event that Mr. Vollins employment with the Company is terminated by the
Company or its successor without Cause within six (6) months following the occurrence of a Change of Control (as defined in the employment agreement), Mr. Vollins will be entitled to receive a one-time severance payment equal to a
one-time cash severance payment equal to his then current annual base salary. In addition, all unvested time-based options, RSUs or other equity securities to acquire shares of Company common stock shall immediately become fully vested and shall be
exercisable to the extent provided for in the Plan.

Mr. Vollins employment agreement also includes 2-yearnon-competition and non-solicitation and confidentiality covenants. Under the terms of this agreement, he is also entitled to
the following benefits: medical, dental, life, disability and 401(k).

Ernest R. De Paolantonio, CPA, MBA, Chief Financial Officer,
Secretary and Treasurer  Mr. De Paolantonios prior employment agreement, dated October 1, 2013, included a base salary of $300,000, target bonus of up to 40% of his base salary (which was subject to modification by our
Compensation Committee), and other employee benefits. Under the terms of his agreement in 2018, Mr. De Paolantonio received a base salary of $370,000 and a bonus of $98,000, which bonus was related to 2017 performance.

On January 23, 2019, the Company entered into a transitional service and separation agreement with Mr. De Paolantonio. Unless
Mr. De Paolantonio resigns or his employment is terminated earlier, Mr. De Paolantonio will continue as a senior advisor to us until April 30, 2019, at which time his employment with us will end. (See Compensation Discussion and
Analysis for details on Mr. De Paolantonios separation agreement.)

Mr. De Paolantonios transitional service and
separation agreement also includes 2-yearnon-competition and non-solicitation and confidentiality covenants on terms identical
to the prior employment agreement. Under the terms of this agreement, he was also entitled to the following benefits: medical, dental, life, disability and 401(k).

Amended and Restated 2001 Incentive Plan

In July 2011, our original Amended and Restated 2001 Incentive Plan expired. Options to purchase 578,645 shares of common stock were
outstanding and exercisable as of December 31, 2018 under the Amended and Restated 2001 Incentive Plan. In April 2011, our board approved, and in July 2011, our stockholders approved a new 2011 Equity Incentive Plan, which is discussed below.

2011 Equity Incentive Plan

Our 2011 Equity Incentive Plan was originally comprised of 4,200,000 shares of our common stock. The purpose of the 2011 Equity Incentive Plan
is: (i) to align our interests and recipients of options under the plan by increasing the proprietary interest of such recipients in our growth and success, and (ii) to advance our interests by providing additional incentives to officers,
key employees and well-qualified non-employee directors and consultants who provide services to us, who are responsible for our management and growth, or otherwise contribute to the conduct and direction of
our business, operations and affairs. The Compensation Committee of our board of directors administers our incentive plan, selects the persons to whom options are granted and fixes the terms of such options. In July 2013, 2014, 2015 and in December
2017, our stockholders approved increases to our 2011 Equity Incentive Plan in the amounts of 2,600,000, 2,000,000, 2,250,000 and 7,100,000, respectively.

Options may be awarded during the ten-year term of the plan to our employees, directors, or
consultants who are not employees and our other affiliates. Our plan provides for the grant of options that qualify as incentive stock options, or Incentive Stock Options, under Section 422 of the Internal Revenue Code of 1986, as amended, and
options which are not Incentive Stock Options, or Non-Statutory Stock Options, as well as restricted stock and other awards. Only our employees may be granted Incentive Stock Options. Our affiliates or
consultants or others as may be permitted by our board of directors, may be granted Non-Statutory Stock Options.

Options to purchase 4,406,004 shares of our common stock at prices ranging from $1.78 to $16.47 are outstanding at December 31, 2018.

Options issued during 2018 to directors and employees under the 2011 Equity Incentive Plan totaled 2,549,177 shares, at exercise prices
ranging from $2.07 to $3.72.

Outstanding equity awards

The following table summarizes outstanding unexercised options, unvested stock and equity incentive plan awards held by each of our name
executive officers, as of December 31, 2018.

Unvested stock awards consist of Restricted Stock Units (RSUs) from our Long-Term Incentive Plan (as defined
under our 2011 Equity Incentive Plan, the 2011 EIP) and which we refer to as Performance RSUs, which are rights to acquire shares of our common stock.

(3)

Unvested stock awards consist of RSU (as defined under the 2011 EIP) which are rights to acquire shares of our
common stock. These performance-based RSUs provide for vesting if specified net revenue and operating income goals are achieved with respect to the annual fiscal years 2019 through 2021.

(4)

Unvested stock awards consist of RSUs (as defined under the 2011 EIP) which are rights to acquire shares of our
common stock. These unvested RSUs vest in thirds beginning March 2017.

(5)

Unvested stock awards consist of RSUs (as defined under the 2011 EIP) which are rights to acquire shares of our
common stock. One-half of which are time-based and one-half of which are performance-based, all of which vest over a three-year period beginning in March 2018. The
performance-based RSUs provide for vesting if specified net revenue and operating income goals are achieved with respect to the annual fiscal years 2017 through 2019.

(6)

Unvested stock awards consist of RSUs (as defined under the 2011 EIP) which are rights to acquire shares of our
common stock. One-half of which are time-based and one-half of which are performance-based, all of which vest over a three-year period beginning in March 2019. The
performance-based RSUs provide for vesting if specified net revenue and operating income goals are achieved with respect to the annual fiscal years 2018 through 2020.

Mark A. Sirgo served as our President, Chief Executive Officer, Director and Vice Chairman until his retirement
date of January 2, 2018. Upon retirement, Dr. Sirgo now serves as a Director and Vice Chairman.

(8)

Niraj Vasisht served as our Senior Vice President and Chief Technology Officer until his retirement date of
February 5, 2018.

Option Exercises and Stock Vested

The following information sets forth stock options exercised by the executive officers during the year ended December 31, 2018:

OPTION AWARDS

STOCK AWARDS

Name

Number ofSharesAcquired onExercise (#)

ValueRealized onExercise ($)

Number ofSharesAcquired onVesting (#)

ValueRealized onVesting ($)

Mark A. Sirgo, Pharm.D.





1,799,782

4,664,266

Herm Cukier









Scott Plesha





124,400

261,240

Thomas Smith, M.D.









James Vollins









Ernest R. De Paolantonio, CPA MBA





107,307

306,109

Niraj Vasisht, Ph.D.

61,908

31,043

622,586

1,874,667

Pension Benefits

None of our employees participate in or have account balances in qualified or non-qualified defined
benefit plans sponsored by us. Our Compensation Committee may elect to adopt qualified or non-qualified benefit plans in the future if it determines that doing so is in our companys best interests.

None of our employees participate in or have account balances in nonqualified defined contribution plans or other nonqualified deferred
compensation plans maintained by us. Our Compensation Committee may elect to provide our officers and other employees with non-qualified defined contribution or other nonqualified deferred compensation
benefits in the future if it determines that doing so is in our companys best interests.

The table below sets forth potential payments payable to our current executive officers in the event of a termination of employment under
various circumstances. For purposes of calculating the potential payments set forth in the table below, we have assumed that (i) the date of termination was December 31, 2018 and (ii) the stock price was $3.70, which was the closing
market price of our common stock on December 31, 2018, the last business day of the 2018 fiscal year.

Name

If Company TerminatesExecutive Without Causeor Executive Resignswith Good Reason($)

Termination Following aChange in Control withoutCause or Executive Resignswith Good Reason($)

Pursuant to retirement on January 2, 2018, Dr. Sirgo was not party to an employment agreement or
change of control benefits as of December 31, 2018.

(2)

Determined by taking the excess of the fair market value of our common stock on December 31, 2018, less
the exercise price of each accelerated option, multiplied by the number of unvested shares subject to outstanding options.

(3)

Determined by taking the fair market value of our common stock on December 31, 2018, multiplied by the
number of shares subject to invested RSUs.

(4)

Pursuant to retirement on April 4, 2018, Dr. Vasisht was not party to an employment agreement or
change of control benefits as of December 31, 2018.

For each of our executive officers, in their employment
agreements the term change of control means the occurrence of any one or more of the following events (it being agreed that, with respect to paragraphs (i) and (iii) of this definition below, a change of control
shall not be deemed to have occurred if the applicable third party acquiring party is an affiliate of our company within the meaning of Rule 405 promulgated under the Securities Act of 1933, as amended):

(i) An acquisition (whether directly from our company or otherwise) of any voting securities of our company by any person or entity,
immediately after which such person or entity has beneficial ownership of forty percent (40%) or more of the combined voting power of our then outstanding voting securities.

(ii) The individuals who, as of the date hereof, are members of our board of directors cease, by reason of a financing, merger,
combination, acquisition, takeover or other non-ordinary course transaction affecting our company, to constitute at least fifty-one percent (51%) of the members of
our board of directors; or

(iii) Approval by our board of directors and, if required, our stockholders of, or our execution of any
definitive agreement with respect to, or the consummation of (it being understood that the mere execution of a term sheet, memorandum of understanding or other non-binding document shall not constitute a
change of control):

(A) A merger, consolidation or reorganization involving our company, where either or both of the events described in
clauses (i) or (ii) above would be the result;

(B) A liquidation or dissolution of or appointment of a receiver, rehabilitator,
conservator or similar person for, or the filing by a third party of an involuntary bankruptcy against, our company; or

(C) An agreement
for the sale or other disposition of all or substantially all of the assets of our company to any person or entity (other than a transfer to a subsidiary of our company).

The cash component (as opposed to option accelerations) of any change of control payment would be structured as a one-time cash severance payment.

CEO Pay Ratio  21:1

We believe our executive compensation program must be consistent and internally equitable to motivate our employees to perform in ways that
enhance shareholder value. We are committed to internal pay equity, and the Compensation Committee monitors the relationship between the pay of our executive officers and the pay of our non-executive
employees. The Compensation Committee reviewed a comparison of Herm Cukiers, our Chief Executive Officer (which we refer to for these purposes as the CEO), annualized total compensation in fiscal year 2018 to that of the median annual
compensation of all other company employees for the same period. The calculation of annual total compensation of all employees was determined in the same manner as the Total Compensation shown for our CEO in the Summary
Compensation Table on page 65 of this Report. Pay elements that were included in the annual total compensation for each employee are:

We determined our median employee by: (i) calculating the annual total compensation described above for each of our employees,
(ii) ranking the annual total compensation of all employees except for the CEO from lowest to highest (a list of

157 employees), and (iii) since we have an odd number of employees when not including the CEO, we used ranked employee number 79 on the list as our (Median Employee). In 2018, we
experienced a substantial increase in our headcount. Accordingly, we determined it was appropriate to re-calculate our Median Employee for 2018.

The annualized total compensation for fiscal year 2018 for our CEO was $2,679,509 and for the Median Employee was $125,563. We estimate that
the resulting ratio of our CEOs pay to the pay of our Median Employee for fiscal year 2018 is 21 to 1.

Compensation of Directors Summary Table

DIRECTOR COMPENSATION

Name (a)

FeesEarnedor Paidin Cash($)

StockAwards($) (12)

OptionAwards($) (12)

Non-EquityIncentive PlanCompensation($)

Non-QualifiedDeferredCompensationEarnings ($)

All OtherCompensation($)

Total ($)

Peter S. Greenleaf ±

27,088

300,931

(1)

90,472

(2)







418,491

Frank E. ODonnell, Jr.

62,052

(3)

189,000

(4)







11,728(5)

262,780

William M. Watson

66,997

293,405

(6)

77,183

(7)







437,584

Todd C. Davis ±

28,022

257,941

(8)

67,854

(9)







353,817

Kevin Kotler ±

23,352

257,941

(8)

67,854

(9)







349,147

Samuel P. Sears, Jr. *

74,375

26,813

(10)

9,694

(12)







110,882

Thomas W. DAlonzo *

53,750

26,813

(10)

9,694

(12)







90,257

Barry I. Feinberg *

61,875

26,813

(10)

9,694

(12)







98,382

Timothy C. Tyson *

48,750

26,813

(10)

9,694

(12)







85,257

±

Newly elected directors as of May 17, 2018

*

Retiring directors as of May 17, 2018

(1)

The stock awards disclosed in this item consists of 112,288 RSUs issued in 2018 with a FMV of $2.68 for serving
on the board which vested ratably from 2018-2022. Mr. Greenleaf holds 108,644 shares of unvested RSUs which vest ratably from August 2019 to August 2022.

(2)

The stock options disclosed in this item consists of 64,164 options granted in 2018 with a FMV of $1.41 for
serving on the board which vest ratably from 2018-2022. Mr. Greenleaf holds options to purchase 2,082 shares of common stock, all of which are currently exercisable. Mr. Greenleaf also holds options to purchase 62,082 shares of common
stock, none of which are currently exercisable.

(3)

Compensation for serving as Chairman through May 2018. Dr. ODonnell now serves as Director.

(4)

The stock awards disclosed in this item consists of 90,000 RSUs issued as executive grants in 2018 with a FMV
of $2.10 which half vest in ratably in thirds beginning in 2019 and half vest pursuant to achievement of certain performance criteria. Dr. ODonnell holds options to purchase 107,500 shares of our common stock, all of which is currently
exercisable. Dr. ODonnell holds an aggregate of 216,000 shares of unvested RSUs which vest in thirds from March 2019 to March 2021. Does not include 170,000 shares of unvested RSUs potentially issuable in thirds if certain pre-determined company revenue targets are achieved. Dr. ODonnell also holds 164,022 shares of unvested RSUs potentially issuable under our LTIP if certain
pre-determined company revenue targets are achieved.

(5)

Includes $11,728 in health benefits paid in 2018.

(6)

The stock awards disclosed in this item consists of 109,479 RSUs issued in 2018 with a FMV of $2.68 for serving
on the board which vest ratably from 2018-2022. Mr. Watson holds 99,739 shares of unvested RSUs which vest ratably from August 2019 to August 2022.

(7)

The stock options disclosed in this item consists of 54,740 options granted in 2018 with a FMV of $1.41 for
serving on the board which vest ratably from 2018-2022. Mr. Watson holds options to purchase 4,870 shares of common stock, all of which are currently exercisable. Mr. Watson also holds options to purchase 49,870 shares of common stock, none of
which are currently exercisable.

(8)

The stock awards disclosed in this item consists of 96,247 RSUs issued in 2018 with a FMV of $2.68 for serving
on the board which vest ratably from 2018-2022. Mr. Kotler holds 93,123 shares of unvested RSUs which vest ratably from August 2019 to August 2022. Mr. Davis holds 93,123 shares of unvested RSUs which vest ratably from August 2019 to August 2022.

(9)

The stock options disclosed in this item consists of 48,123 options granted in 2018 with a FMV of $1.41 for
serving on the board which vest ratably from 2018-2022. Mr. Davis holds options to purchase 1,561 shares of common stock, all of which are currently exercisable. Mr. Davis also holds options to purchase 46,562 shares of common stock, none of
which are currently exercisable. Mr. Kotler holds options to purchase 1,561 shares of common stock, all of which are currently exercisable. Mr. Kotler also holds options to purchase 46,562 shares of common stock, none of which are currently
exercisable.

(10)

The stock awards disclosed in this item consists of 13,750 RSUs issued in 2018 with a FMV of $1.95 pursuant to
retirement from the board which half vested in 2018 and the remaining half vest in 2019.

(11)

The stock options disclosed in this item consists of 6,875 options granted in 2018 with a FMV of $1.41 pursuant
to retirement from the board which half vested in 2018 and the remaining half vest in 2019.

30,000 restricted stock units of our common stock per year, to each director.



5,000 additional restricted stock units of our common stock per year to the Lead Director.



15,000 stock options of our common stock per year, to each director.



5,000 additional stock options of our common stock per year to the Lead Director.



New directors will earn a pro-rated portion (based on months to be served
in the fiscal year in which they join) of cash and restricted stock units.

In August 2018, we granted our directors
upfront awards of options and restricted stock units to cover the options and restricted stock units they would be entitled to receive over the next four years, subject to vesting over such four-year period. Options granted to directors expire in 10
years and are outstanding for the life of the option, as long as service criteria is met. Director options qualify as Non-Statutory Stock Options. The total number of options granted to members of our board of
directors during the year ended December 31, 2018 was 242,650, which vests ratably during the first open window upon issuance in August 2018 to August 2022.

The total number of RSUs granted to members of our board of directors during the year ended December 31, 2018 was 469,261 which vests
ratably during the first open window upon issuance in August 2018 to August 2022.

None of our executive officers serves as a member of the Compensation Committee of our board of directors, or other committee serving an
equivalent function. None of the members of our Compensation Committee has ever been our employee or one of our officers.

The following table sets forth, as of March 14, 2019, by: (i) each of our directors, (ii) all persons
who, to our knowledge, are the beneficial owners of more than 5% of the outstanding shares of common stock, (iii) each of the executive officers, and (iv) all of our directors and executive officers, as a group. Each person named in this
table has sole investment power and sole voting power with respect to the shares of common stock set forth opposite such persons name, except as otherwise indicated. Unless otherwise indicated, the address for each person listed below is in
care of BioDelivery Sciences International, Inc., 4131 ParkLake Avenue, Suite #225, Raleigh, NC 27612.

Name and Address of Beneficial Owner

Amount and Nature ofBeneficial Ownership

Percentage of Class as ofMarch 14, 2019(1)

venBio Select Advisor LLC (2)

4,725,700

6.67

%

Broadfin Capital, LLC (3)

4,375,066

6.18

%

Stonepine Capital
Management (4)

3,981,867

5.62

%

Herm Cukier (5)

0

*

Scott M. Plesha (6)

224,004

*

Mary Theresa Coelho (7)

0

*

Thomas Smith, M.D. (8)

0

*

James Vollins (9)

0

*

Peter S. Greenleaf(10)

5,726

*

Mark A. Sirgo, Pharm.D. (11)

2,699,259

3.80

%

Frank E. ODonnell, Jr.,
M.D.(12)

628,687

*

William M. Watson (13)

16,110

*

Todd C. Davis (14)

421,352

*

Kevin Kotler (15)

4,379,751

6.19

%

All Directors and Officers as a group (11 persons)

8,047,598

11.75

%

*

Less than 1%

(1)

Based on 70,953,944 shares of Common Stock outstanding as of March 14, 2019 and shares beneficially
owned by the referenced parties as described below.

(2)

Based on 13G filed by venBio Select Advisor LLC with the SEC on February 14, 2019 for the year ended
December 31, 2018. Does not include 3,888,888 shares of Common Stock issuable upon conversion of 700 shares of Series B Preferred Stock beneficially owned by venBio Select Advisor LLC.

(3)

Based on 13F filed by Broadfin Capital, LLC with the SEC on February 14, 2019 for the year ended
December 31, 2018. Does not include 12,222,223 shares of Common Stock issuable upon conversion of 2,200 shares of Series B Preferred Stock beneficially owned by Broadfin Capital LLC.

(4)

Based on 13G/A filed by Stonepine Capital Management with the SEC on February 13, 2019 for the year ended
December 31, 2018.

(5)

Mr. Cukier is our Chief Executive Officer and a director. Does not include 200,000 shares of unvested RSUs
potentially issuable in thirds if certain pre-determined company revenue targets are achieved. Also, does not include 93,750 shares of unvested RSUs which vest in thirds from January 2020 to January 2022. Does
not include options to purchase 1,340,000 shares of common stock, none of which are currently exercisable.

(6)

Mr. Plesha is our President. This number is 224,004 shares owned by Mr. Plesha. Does not include an
aggregate of 119,167 shares of unvested RSUs which vest from March 2019 to January 2022. Also, does not include 79,167 shares of unvested RSUs potentially issuable if certain pre-determined company revenue
targets are achieved, which vest from March 2019 to March 2021. Does not include options to purchase 245,000 shares of common stock, none of which are currently exercisable.

Ms. Coelho became our Chief Financial Officer on January 15, 2019. Does not include 55,000 shares of
unvested RSUs which vest in thirds from January 2020 to January 2022. Does not include options to purchase 107,109 shares of common stock, none of which are currently exercisable.

(8)

Dr. Smith became our Chief Medical Officer on July 30, 2018. Does not include 23,000 shares of
unvested RSUs which vest in thirds from January 2020 to January 2022. Does not include options to purchase 247,691 shares of common stock, none of which are currently exercisable.

(9)

Mr. Vollins became our General Counsel, Chief Compliance Officer and Corporate Secretary on
November 5, 2018. Does not include 11,500 shares of unvested RSUs which vest in thirds from January 2020 to January 2022. Does not include options to purchase 154,476 shares of common stock, none of which are currently exercisable.

(10)

Mr. Greenleaf became our Chairman of the Board and a director in May 2018. Includes 3,644 shares owned by
Mr. Greenleaf. Includes options to purchase 2,082 shares of common stock, all of which are currently exercisable. Does not include 108,644 shares of unvested RSUs which vest ratably from August 2019 to August 2022.Does not include options to
purchase 62,082 shares of common stock, none of which are currently exercisable.

(11)

Includes 2,489,542 shares owned by Dr. Sirgo, our Vice Chairman. Includes options to purchase 209,717
shares of common stock, all of which are currently exercisable. Does not include 327,170 unvested RSUs potentially issuable under our LTIP if certain pre-determined company revenue targets are achieved.

(12)

Dr. ODonnell is a director. Excludes 167,500 shares owned by The Francis E. ODonnell, Jr.
Irrevocable Trust #1, of which Dr. ODonnells sister, Kathleen ODonnell, is trustee, and as to which Dr. ODonnell disclaims beneficial interest. This number includes 521,187 shares owned by Dr. ODonnell
and options to purchase 107,500 shares of our common stock, all of which is currently exercisable. Does not include an aggregate of 170,000 shares of unvested RSUs which vest in thirds from March 2019 to March 2021. Does not include 170,000 shares
of unvested RSUs potentially issuable in thirds if certain pre-determined company revenue targets are achieved. Also, does not include 170,828 shares of unvested RSUs potentially issuable under our LTIP if
certain pre-determined company revenue targets are achieved.

(13)

Mr. Watson is a director. Includes 11,240 shares owned. Includes options to purchase 4,870 shares of
common stock, all of which are currently exercisable. Does not include 99,739 shares of unvested RSUs which vest ratably from August 2019 to August 2022. Does not include options to purchase 49,870 shares of common stock, none of which are currently
exercisable.

(14)

Mr. Davis became a director in May 2018. Includes 419,791 shares owned. Includes options to purchase 1,561
shares of common stock, all of which are currently exercisable. Does not include 93,123 shares of unvested RSUs which vest ratably from August 2019 to August 2022. Does not include options to purchase 46,562 shares of common stock, none of which are
currently exercisable.

(15)

Mr. Kotler became a director in May 2018. Includes 3,124 shares owned by Mr. Kotler. Does not include
12,222,223 shares of Series B Non-Voting Convertible Stock which are held in the account of Broadfin Healthcare Master Fund, Ltd., a private investment fund managed by Broadfin Capital, LLC, and may be deemed
to be beneficially owned by Mr. Kotler, managing member of Broadfin Capital, LLC. Includes 4,375,066 shares owned by Broadfin, Capital LLC. Includes options to purchase 1,561 shares of common stock, all of which are currently exercisable. Does
not include 93,123 shares of unvested RSUs which vest ratably from August 2019 to August 2022. Does not include options to purchase 46,562 shares of common stock, none of which are currently exercisable.

Securities Authorized for Issuance Under Equity Compensation Plans

The following table indicates shares of common stock authorized for issuance under our 2011 Equity Incentive Plan as of December 31, 2018:

Plan category

Number of securities tobe issued upon exerciseof outstandingoptions,warrants and rights (1)

Includes 578,645 shares of common stock underlying options previously granted under our Amended and Restated
2001 Incentive Plan, which are still exercisable despite the fact that such plan expired July 2011.

(2)

Weighted average exercise price does not include restricted stock units.

As of December 31, 2001, our board of directors appointed an audit committee consisting of independent directors. This committee, among
other duties, is charged to review, and if appropriate, ratify all agreements and transactions which had been entered into with related parties, as well as review and ratify all future related party transactions. The audit committee and/or our
independent directors independently reviewed, ratified and/or approved, as the case may be, the agreements described below. From time to time, after compliance with our internal policies and procedures, we have entered into related party contracts,
some of which were amended subsequently in accordance with the same policies and procedures.

We are currently not a party to any related
party transactions.

As a matter of corporate governance policy, we have not and will not make loans to officers or loan guarantees
available to promoters as that term is commonly understood by the SEC and state securities authorities.

All future
transactions between us and our officers, directors or five percent stockholders, and respective affiliates will be on terms no less favorable than could be obtained from unaffiliated third parties and will be approved by a majority of our
independent directors who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.

To the best of our knowledge, other than as set forth above, there were no material transactions, or series of similar transactions, or any
currently proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds $120,000, and in which any director or executive officer, or any security holder who is known by us to
own of record or beneficially more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, has an interest.

Item 14.

Principal Accountant Fees and Services.

Audit Fees. The aggregate fees billed by Cherry Bekaert LLP for professional services rendered for the audit of our annual financial
statements, review of the financial information included in our Forms 10-Q for the respective periods and other required filings with the SEC for the years ended December 31, 2018 and 2017 totaled
$216,000 and $188,500, respectively. The above amounts include interim procedures and audit fees, as well as attendance at audit committee meetings.

Audit-Related Fees. The aggregate fees billed by Cherry Bekaert LLP for audit-related fees for the years ended December 31,
2018 and 2017 were $131,776 and $149,839, respectively. The fees were provided in consideration of services consisting of review and update procedures associated with registration statements and other SEC filings.

Tax Fees. The aggregate fees billed by Cherry Bekaert LLP for professional services rendered for tax compliance for the years ended
December 31, 2018 and 2017 were $34,600 and $42,460, respectively. The fees were provided in consideration of services consisting of preparation of tax returns and related tax advice.

All Other Fees. None

The
Audit Committee of our board of directors has established its pre-approval policies and procedures, pursuant to which the Audit Committee approved the foregoing audit and
non-audit services provided by Cherry Bekaert LLP in 2018. Consistent with the Audit Committees responsibility for engaging our independent auditors, all audit and permitted non-audit services require pre-approval by the Audit Committee. The full Audit Committee approves proposed services and fee estimates for these services. The Audit Committee
chairperson has been designated by the Audit Committee to approve any audit-related services arising during the year that were not pre-approved by the Audit Committee. Any
non-audit service must be approved by the full Audit Committee. Services approved by the Audit Committee chairperson are communicated to the full Audit Committee at its next regular meeting and the Audit
Committee reviews services and fees for the fiscal year at each such meeting. Pursuant to these procedures, the Audit Committee approved the foregoing services provided by Cherry Bekaert LLP.

Confidential treatment has been granted for certain portions of this exhibit pursuant to 17 C.F.R. Sections
200.8(b)(4) and 240.24b-2.

#

A signed original of this written statement required by Section 906 has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.



Confidential treatment extension of confidential treatment previously granted for certain portions of this
exhibit pursuant to 17 C.F.R. Sections 200.8(b)(4) and 240.24b-2 is currently pending with the Securities and Exchange Commission.

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of BioDelivery Sciences International, Inc. and Subsidiaries (the Company) as of
December 31, 2018 and 2017, and the related consolidated statements of operations, stockholders equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2018, the related notes, and Schedule
II  Valuation and Qualifying Accounts and Reserves (the financial statements). We also have audited the Companys internal control over financial reporting as of December 31, 2018, based on criteria established in
Internal ControlIntegrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of
December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of
America. Also, in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established in Internal ControlIntegrated Framework
(2013) issued by COSO.

Basis for Opinion

The Companys management is responsible for these financial statements, for maintaining effective internal control over financial reporting, and for its
assessment of the effectiveness of internal control over financial reporting included in the accompanying Managements Report of Internal Control over Financial Reporting included in Item 9A  Controls and Procedures in the Companys
2018 Annual Report on Form 10-K. Our responsibility is to express an opinion on the Companys financial statements and an opinion on the Companys internal control over financial reporting based on
our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance
with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud, and whether
effective internal control over financial reporting was maintained in all material respects.

Our audits of the financial statements included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the
amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our
audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

Definition and Limitations of Internal Control over Financial Reporting

A companys internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A companys internal control over financial reporting includes those policies and procedures that
(1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors
of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the companys assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Common Stock, $.001 par value; 125,000,000 and 75,000,000 shares authorized at December 31,
2018 and December 31, 2017, respectively; 70,793,725 and 55,904,072 shares issued;70,778,234 and 55,888,581 shares outstanding at September 30, 2018 and December 31, 2017, respectively.